Research funding: Genetech, Adaptive Biotechnologies, Celgene,

Pharmacyclics, Seattle Genetics, and Astra Zeneca

376 |A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐

99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN

PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN

LYMPHOMAS

J.‐M. Michot

, C. Carpio

, L. Nastoupil

, J. Chavez

, T. Feldman

, S.

Ferrari

, D. Morillo

, E. Bachy

, A. Pinto

, J. Kuruvilla

, T. J.

Buchholz

, S. Kasibhatla

, S. Carrancio

, C. Guarinos

, F. Wu

, S.

, P. Patah

, M. Pourdehnad

Gustave Roussy Institute of Cancer, Département d'Innovation

Thérapeutique et d'Essais Précoces (DITEP), Villejuif, France,

Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall

d'Hebron, University Autònoma of Barcelona (UAB), Department of

Hematology, Barcelona, Spain,

MD Anderson Cancer Center,

University of Texas, Department of Lymphoma & Myeloma, Houston,

Texas, USA,

Mofﬁtt Cancer Center, University of South Florida,

Department of Malignant Hematology, Tampa, Florida, USA,

Hackensack Meridian Health, Lymphoma Division, Edison, New

Jersey, USA,

Papa Giovanni XXIII Hospital, Dipartimento di

Ematologia, Bergamo, Italy,

Hospital Fundación Jiménez Díaz,

Department of Hematology, Madrid, Spain,

Hospices Civils de Lyon,

Department of Hematology, Lyon, France,

National Cancer Institute,

Fondazione G. Pascale, IRCCS, Hematology‐Oncology & Stem Cell

Transplantation Unit, Napoli, Italy,

Princess Margaret Cancer

Centre, Cancer Clinical Research Unit, Division of Medical Oncology

and Hematology, Toronto, Canada,

Bristol Myers Squibb, Early

Clinical Development, Oncology, Princeton, New Jersey, USA,

Bristol

Myers Squibb, Translational Biology, Oncogenesis Therapeutic

Research Center, Princeton, New Jersey, USA,

Bristol Myers Squibb,

ONC‐TRC CITRE, Princeton, New Jersey, USA,

Bristol Myers Squibb,

Clinical Pharmacology, Early Clinical Development, Princeton, New

Jersey, USA,

Bristol Myers Squibb, Global Biometric Sciences,

Princeton, New Jersey, USA,

Bristol Myers Squibb, Early Clinical

Development, Hematology/Oncology and Cell Therapy, Princeton, New

Jersey, USA

Background: CC‐99282 is a novel, oral cereblon (CRBN) E3 ligase

modulator (CELMoD) agent that co‐opts CRBN to induce potent

and targeted degradation of Ikaros and Aiolos, transcription factors

that are known to be important for the normal differentiation and

function of multiple types of hematopoietic cells. Non‐Hodgkin

lymphomas (NHL) comprise diverse lymphoma subtypes with

varying genomic alterations and clinical outcomes. Despite treat-

ment advances, management of aggressive relapsed or refractory

(R/R) NHL remains challenging. The ability of CC‐99282 to spe-

ciﬁcally target Ikaros and Aiolos for degradation provides a strong

biological rationale for studying it for the treatment of patients

with R/R B‐cell NHL, both as a single agent and in combination

with rituximab, an approved humanized anti‐CD20 monoclonal

antibody. CC‐99282‐NHL‐001 (NCT03930953) is an ongoing,

phase 1, multicenter, open‐label, ﬁrst‐in‐human study evaluating

the safety, tolerability, and preliminary clinical activity of CC‐99282

alone and in combination with rituximab in patients with R/R B‐cell

NHL.

Methods: Eligible patients include those with R/R NHL, including

diffuse large B‐cell lymphoma (DLBCL), follicular lymphoma (FL),

mantle cell lymphoma, or primary central nervous system lym-

phoma (PCNSL), who have relapsed on or are refractory to ≥2

lines of therapy (or who have received ≥1 prior line of standard

therapy and are not eligible for any other therapy). This study is

conducted in 2 parts: dose escalation (Part A) and dose expan-

sion (Part B). Part A evaluates the safety and tolerability of

escalating CC‐99282 doses to determine the maximum tolerated

dose (MTD)/recommended phase 2 dose (RP2D) of CC‐99282

monotherapy. In Part A, patients with R/R DLBCL or R/R FL

receive oral CC‐99282 once daily on intermittent schedules per

28‐day cycle. Following the evaluation of the Bayesian logistic

regression model recommendation as well as the safety and

pharmacokinetic/pharmacodynamic data that are monitored

continually, decisions on dose escalations are made by the safety

review committee until the MTD/RP2D is reached. Part B will

evaluate the safety and efﬁcacy of CC‐99282 administered at the

RP2D alone or in combination with rituximab to conﬁrm the

RP2D of CC‐99282. Treatment efﬁcacy is assessed according to

the Lugano Classiﬁcation for NHL and the modiﬁed International

PCNSL Collaborative Group criteria. Correlations between various

biomarkers and clinical outcomes of treatment with CC‐99282,

alone or in combination with rituximab, will also be explored.

Adverse events are monitored until 28 days following the ﬁnal

dose. Study treatments may be continued for up to 2 years, or

until signiﬁcant disease progression, unacceptable toxicity, or

withdrawal.

The research was funded by: Bristol Myers Squibb

Keywords: Molecular Targeted Therapies, Ongoing Trials

Conﬂicts of interests pertinent to the abstract

Jean‐M. Michot

Consultant or advisory role: ASTEX, AstraZeneca, Bristol Myers

Squibb

Other remuneration: Investigator of clinical studies with Abbvie,

Agios, ARGENX, Bristol Myers Squibb, Forma, Genentech, Janssen,

Lilly, Roche, Sanoﬁ, Xencor

C. Carpio

Consultant or advisory role: Novartis, Takeda, Regeneron

Educational grants: Bristol Myers Squibb, Novartis, Gilead, Takeda

L. Nastoupil

Consultant or advisory role: ADC Therapeutics, Bristol Myers Squibb,

Genentech, Janssen, Novartis

462

SUPPLEMENT ABSTRACTS

Honoraria: Bayer, Epizyme, Kite/Gilead, Pﬁzer, TG Therapeutics

Research funding: Bayer, Bristol Myers Squibb, Epizyme, Genentech,

Janssen, Novartis, TG Therapeutics

J. Chavez

Consultant or advisory role: Kite/Gilead, Novartis, Kymera, Kar-

yopharma, Abbvie, Janssen, ADC Therapeutics, Pﬁzer, TeneBio

Other remuneration: Speakers Bureau: Beigene, Morphosys, Epizyme

T. Feldman

Consultant or advisory role: AstraZeneca, ADC Therapeutics, Jans-

sen, Karyopharm, Kite, MorphoSys, AbbVie, Daiichi Sakyo

Honoraria: AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers

Squibb, Daiichi Sakyo, Janssen, Karyopharm, Kite, MorphoSys,

Pharmacyclics, Seattle Genetics, Takeda

Other remuneration: Speakers Bureau: AbbVie, Bristol Myers Squibb,

Janssen, Pharmacyclics, Seattle Genetics, Takeda

D. Morillo

Honoraria: AbbVie, Takeda, Janssen

Educational grants: AbbVie, Takeda, Janssen, Kite

E. Bachy

Consultant or advisory role: Roche, Bristol Myers Squibb

Honoraria: Roche, Gilead, Novartis, Sanoﬁ, Amgen

Educational grants: AbbVie, Gilead, Sanoﬁ

Other remuneration: Provision of Writing Assistance: Roche

A. Pinto

Honoraria: Roche, Servier, Takeda, Bristol Myers Squibb, MSD

J. Kuruvilla

Consultant or advisory role: AbbVie, Bristol Myers Squibb, Gilead,

Karyopharm, Merck, Roche, Seattle Genetics

Honoraria: Amgen, Antengene, AstraZeneca, Bristol Myers Squibb,

Gilead, Incyte, Janssen, Karyopharm, Merck, Novartis, Pﬁzer, Roche,

Seattle Genetics, TG Therapeutics

Research funding: Canadian Cancer Society, Leukemia and Lym-

phoma Society Canada, Princess Margaret Cancer Foundation,

Janssen, Roche, AstraZeneca

Other remuneration: Karyopharm (DSMB)

T. J Buchholz

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

S. Kasibhatla

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

S. Carrancio

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

C. Guarinos

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

F. Wu

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

S. Li

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

P. Patah

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

M. Pourdehnad

Employment or leadership position: Bristol Myers Squibb

Stock ownership: Bristol Myers Squibb

FIGURE 1 A) Activation signature and B) fold increase in PF of tab‐lots after EBV‐speciﬁc activation. C) Representative alluvial plot

illustrates the clonal expansion of TCRs associated with the‐cel manufacturing process and that the clonal expansion of TCRs associated with

the tab‐cel manufacturing process and that the TCR repertoire of tab‐cel is conserved within the functionally activated T‐cell population

SUPPLEMENT ABSTRACTS

463

Other remuneration: Patents, Royalties, or Other Intellectual Prop-

erty: Bristol Myers Squibb

CAR‐T CELL THERAPY

377 |COMPREHENSIVE ACTIVATION PROFILING OF

TABELECLEUCEL, AN OFF‐THE‐SHELF, Allogeneic EBV‐SPECIFIC

T‐CELL IMMUNOTHERAPY

F. Ruiz

, T. Jehng

, T. Spindler

, D. Munson

, J. Karlen

, V. Thota

A. Wang

, J. Chuan

, M. Yedwabnick

, J. Dubovsky

, B. T. Aftab

Atara Biotherapeutics, Thousand Oaks, California, USA

Background: Tabelecleucel (tab‐cel) is an investigational off‐the‐

shelf, allogeneic Epstein‐Barr virus (EBV)‐speciﬁc T‐cell immuno-

therapy. Tab‐cel has shown clinical activity in patients with EBV

post‐transplant lymphoproliferative disease and other EBV‐

associated diseases. We aim to comprehensively proﬁle tab‐cel

through high‐content immunophenotyping (IPT), T‐cell receptor

(TCR) repertoire, cytokine polyfunctionality (PF), and differential

gene expression patterns (GEP) using resting and EBV‐antigen

stimulation states to model intrinsic effector responses associated

with engagement of EBV

disease. Using this approach, we aim to

identify corollaries associated with clinical outcomes.

Methods: IPT was performed using targeted ﬂow cytometry activa-

tion proﬁling (CD25/CD69), and 40‐plex mass cytometry by time‐of‐

ﬂight (CyTOF). PF response and cytokine proﬁles were evaluated us-

ing the IsoLight single‐cell PF strength assay. TCR repertoires were

assessed using TCRβimmunoSEQ and GEP were evaluated using a

custom Nanostring panel consisting of 333 T‐cell lineage gene targets.

Results: Analyses for a subset of tab‐cel lots has been completed and

are described here. This subset of tab‐cel lots varied in their CD4/CD8

composition, with the majority having proportionally higher CD8+T

cells (>70%). Baseline control expression of activation markers of

8.5 ±2.1% increased to 65 ±3.9% post‐activation with EBV

targets

(Figure 1A). Baseline control PF was 0.58 ±0.21%, and upon activation

tab‐cel demonstrated a 25.3‐fold average induction of PF (Figure 1B).

The resultant activated cytokine proﬁles are primarily comprised of

effector and chemoattractive cytokines including IFNγand MIP1β.

The tab‐cel manufacturing process effectively ampliﬁed and enriched

for EBV‐speciﬁc TCRs that correspond back to a starting frequency of

0.52 ±0.8% of the initial donor TCR repertoire (Figure 1C). Notably,

cross comparison of tab‐cel enriched TCRs against publicly available

databases (VDJdb, McPas‐TCR) identiﬁed previously curated EBV‐

speciﬁc TCRβsequences as a component of the expanded reper-

toire. We are currently assessing the degree of convergence for TCR

sequences against common antigen motifs across donors and corre-

lation of IPT to post‐activation PF. Analysis of post‐activation GEP and

extended IPT by CyTOF are currently underway and will be reported

at the time of presentation.

Conclusions: The process for generating tab‐cel from unre-

lated donors enriches for known EBV‐speciﬁc clones and results

in a net ampliﬁcation of EBV‐targeted T‐cell clonality. Upon acti-

vation, tab‐cel exhibits a multi‐factorial activation proﬁle

and demonstrates PF associated with secretion of effector

and chemoattractive cytokines. Altogether this multi‐omics

proﬁling will facilitate corollaries associated with clinical

outcomes.

EA – previously submitted to regional or national meetings (up to

1000 attendees) and EBMT 2021.

The research was funded by: Atara Biotherapeutics

Keywords: Genomics, Epigenomics, and Other ‐Omics, Cellular

therapies, Immunotherapy

Conﬂicts of interests pertinent to the abstract

F. Ruiz

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

T. Jehng

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

T. Spindler

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

D. Munson

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

J. Karlen

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

V. Thota

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

A. Wang

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

J. Chuan

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

M. Yedwabnick

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

464

SUPPLEMENT ABSTRACTS

J. Dubovsky

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

B. T. Aftab

Employment or leadership position: Atara Biotherapeutics

Stock ownership: Atara Biotherapeutics

378 |CLINICAL AND RADIOGRAPHIC FACTORS PRIOR TO CAR

T‐CELL THERAPY ACCURATELY IDENTIFY RELAPSED/

REFRACTORY LYMPHOMA PATIENTS AT HIGH RISK FOR

PROGRESSION AND POOR SURVIVAL

G. Jodon

, M. D. Colton

, A. R. Cai

, B. Haverkos

, R. Morgan

M. Kamdar

TABLE 1Clinical and Radiographic Characteristics at Baseline

SUPPLEMENT ABSTRACTS

465

University of Colorado Anschutz Medical Campus, Hematology/

Oncology, Aurora, Colorado, USA,

University of Colorado Anschutz

Medical Campus, Internal Medicine, Aurora, Colorado, USA,

University of

Colorado Anschutz Medical Campus, Radiology, Aurora, Colorado, USA

Introduction: Although chimeric antigen receptor (CAR) T‐cell

therapy has drastically improved outcomes for relapsed/refractory

(R/R) lymphomas, a subset of patients will not respond to treatment

or will relapse quickly following an initial response. The identiﬁca-

tion of predictive factors to identify which patients will beneﬁt most

from this therapy is crucial to improve patient selection. The pur-

pose of this study is to further elucidate patient clinical and

radiographic variables that could be predictive of a response to

CAR‐T therapy.

Methods: We conducted a single‐center retrospective review of all

R/R lymphoma patients who received infusion of CAR T‐cells from

2017‐2020 and had one PET scan post‐treatment for response

evaluation. Clinicopathological and radiographic parameters were

identiﬁed a‐priori and collected through chart review. PET param-

eters included standardized uptake value (SUVmax) at baseline,

total metabolic tumor volume (TMTV), total lesion glycolysis (TLG),

and change in SUVmax from baseline to 9 months. For continuous

parameters without established cutoffs, variables were dichoto-

mized separately for time to progression and time to death using

the Contal and O'Quigley method. Risk factors for progression and

death were identiﬁed by constructing a Cox proportional hazards

model.

Results: Sixty‐four patients with R/R lymphoma were included in

the study. Median age at treatment was 65, 65% were males, and

87% DLBCL. Baseline characteristics are summarized in Table 1.

With a median follow up of 10.7 months, 36 patients (56.2%)

progressed, and 38 patients (59.4%) remain alive. Median

progression free survival (PFS) was 9.6 months and median overall

survival (OS) was 19.9 months. Univariate analysis for PFS iden-

tiﬁed stage III/IV (HR 3.59, p =0.016) and elevated CRP >11 (HR

3.32, p <0.001) as risk factors for disease progression, with trends

for elevated LDH (HR 1.87, p =0.066), tocilizumab administration

(1.83, p =0.079), and TMTV >10 (HR 1.97, p =0.093) as risk

factors. Univariate analysis for OS identiﬁed CNS involvement (HR

6.66, p =0.005) and elevated ferritin (HR 2.75, p =0.014) as risk

factors, with trends for stage III/IV (HR 3.29, p =0.053), elevated

ALC (HR 2.11, p =0.058), and elevated CRP (HR 2.18, p =0.054)

as risk factors. Multivariate analysis for PFS identiﬁed stage III/IV

(HR 3.02, p =0.04), elevated CRP (HR 3.32, p <0.001) and delta

SUV max >‐1 (HR 3.4, p = <0.001) as risk factors for disease

progression. Multivariate analysis for OS identiﬁed CNS involve-

ment (HR 3.9, p =0.04), elevated ferritin (HR 2.8, p =0.014) and

delta SUV max >‐6 (HR 2.5, p =0.02) as risk factors for death

following CAR‐T therapy.

Conclusions: Both clinical (advanced stage, elevated CRP and ferritin,

CNS involvement) and radiographic variables (delta SUVmax) identify

R/R lymphoma patients who are at high risk for progression and/or

poor overall survival after CAR T‐cell therapy.

Keywords: Diagnostic and Prognostic Biomarkers, PET‐CT, Aggres-

sive B‐cell non‐Hodgkin lymphoma

Conﬂicts of interests pertinent to the abstract

M. Kamdar

Consultant or advisory role: AbbVie, KaryoPharm, Kite, AstraZeneca,

Celgene/ Bristol‐Myers Squibb, Adaptive Biotechnologies, Curio

Science

Research funding: TG Therapeutics, Genentech

Other remuneration: Speaker's Bureau: SeaGen

466

SUPPLEMENT ABSTRACTS

379 |LIFE AFTER CAR‐T CELLS: A PROSPECTIVE STUDY

EVALUATING THE PERSONAL, SOCIAL AND PROFESSIONAL

OUTCOMES AFTER CAR‐T CELL THERAPY IN LYMPHOMA

PATIENTS

A. Moignet

, A. Anota

, F. Colin

, L. Cherel

, B. Lorne

, T. Lamy

, S. De

Guibert

, L. Ysebaert

, R. Houot

University Hospital Rennes Pontchaillou, Hematology, Rennes, France,

IUCT Oncopole, Oncopole, Toulouse, France,

University Hospital Rennes

Pontchaillou, Hematology, Rennes, France,

IUCT Oncopole, Hematology,

Toulouse, France

Introduction: CD19 CAR‐T cells have been approved for the treat-

ment of relapse/refractory (R/R) diffuse large B‐cell lymphoma

(DLBCL). With these adoptive immunotherapies, about 30‐40% of

patients achieve prolonged remissions, most of whom are likely to be

cured. However, little is known about life after CAR‐T cells. Thus, we

initiated a prospective study to evaluate the personal, social

and professional outcomes after CAR‐T cell therapy in lymphoma

patients.

Methods: This is a prospective, observational, multicenter study,

conducted at the University Hospitals of Rennes and Toulouse

(France). All adult patients treated with CAR‐T cells (Yescarta

Kymriah

) for R/R DLBCL are eligible. Primary objective is to

describe health‐related quality of life (HRQoL) changes during the

ﬁrst year after CAR‐T cell therapy using the EORTC QLQ‐C30 and

FACT‐Lym questionnaires. Secondary objectives are to describe the

dynamic changes of other personal, social, and professional pa-

rameters including anxiety and depression (HAD scale), cognitive

state (FACT‐Cog), fatigue (FACT‐Fatigue), sexuality (SqoL), post‐

traumatic stress disorder (PTSD), social and professional reinte-

gration, supportive care measures. These outcomes are correlated

with baseline characteristics of the patients and his disease, as well

as with response to therapy, adverse events, and biological

parameters.

Patients ﬁll the questionnaires before leukapheresis, immedi-

ately before CAR‐T infusion, and then 3 months, 6 months and one

year after CAR‐T infusion. Adverse events are prospectively

collected by dedicated nurses who call patients daily until day 21,

twice a week until day 28, once a week until month 2, every other

week until month 3, once a month until month 6, and once every 3

months until month 12.

Results: This ﬁrst patient was enrolled in November 2020. To date,

30 patients were included in the study: 19 male and 11 female,

median age is 65 years (range, 19‐75) and median number of prior

lines is 2 (range, 2‐5). Median follow up is 3.2 months (range, 0‐12)

for the entire cohort. Six patients have completed their 6 months

follow‐up. Among the 5 patients with available HRQoL at 6 months, 3

patients (60%) presented a clinically signiﬁcant improvement of their

global HRQoL level.

Conclusions: This prospective study will provide a better under-

standing of the personal, social, and professional outcomes of pa-

tients who have been treated with CAR‐T cells. These data will be of

importance to better inform patients who undergo CAR‐T cell ther-

apy, identify needs for improvement in quality of life after CAR‐T cell

therapy, and better appreciate the social and economic impact of

these treatments.

Our preliminary data suggest that HRQoL is improved in most

patients. These results will be updated at the meeting.

Keywords: Late Effects in Lymphoma Survivors

No conﬂicts of interests pertinent to the abstract.

380 |THE PATIENT AND CARER EXPERIENCE OF CHIMERIC

ANTIGEN RECEPTOR T‐CELL THERAPY FOR RELAPSED/

REFRACTORY B‐CELL LYMPHOMA AT A UK REGIONAL CENTRE

C. Stenson

, T. Menne

, W. Osborne

, A. Publicover

, H. Kennedy

, J.

Shaw

, F. Dewhurst

, R. Stocker

, J. Vidrine

Freeman Hospital, Clinical Haematology, Newcastle upon Tyne, UK,

Newcastle University, Faculty of Medical Sciences, Newcastle upon Tyne,

Introduction: Chimeric Antigen Receptor T‐cell therapy (CAR‐T) is

a potentially life‐saving treatment for refractory haematological

malignancies. Many UK CAR‐T services are in their infancy. Patient

perspectives on service delivery, treatment toxicity and impact on

health related quality of life (HRQoL) are lacking. This qualitative

evaluation aimed to explore the patient and carer experience of

CAR‐T and identify areas for service improvement.

Methods: Patients who received CAR‐T between April 2019 and

March 2021 at the Freeman Hospital, Newcastle‐upon‐Tyne, who

attended primary or follow‐up appointments between December

2020 and March 2021 were asked if they wanted to take part in the

evaluation. 16 semi‐structured qualitative interviews were carried

out with 10 patients and 4 carers at speciﬁc time points in the patient

journey: hospital admission prior to CAR T‐cell infusion, day 28 post‐

infusion and routine follow‐up appointments after treatment (8, 9, 12

and 18 months). Five patients completed 2 interviews (pre‐infusion

and day 28).

Results: The mean age of the patients was 54 and 60% were female.

Nine patients had diffuse large B‐cell lymphoma and one had pri-

mary mediastinal B‐cell lymphoma. Inductive thematic analysis

identiﬁed three main themes. The importance of the CAR‐T nurse

specialist as a point of contact was consistently identiﬁed by pa-

tients and carers as vital to navigating the treatment process. The

continuity of care and approachability associated with this role were

linked to patient satisfaction and perceived level of support

received. Reported treatment toxicity centred on fatigue, poor

SUPPLEMENT ABSTRACTS

467

appetite/weight loss and problems with memory and cognition.

Patients and carers were well prepared for side effects in the acute

treatment phase but some felt less prepared for prolonged impact

on physical function and cognition after discharge. CAR‐T therapy

was viewed as a ‘lifeline,' but the uncertainty of treatment outcome

caused signiﬁcant anxiety, disruption to employment and family life,

and made it difﬁcult to make future plans. Many responses were

framed by the COVID‐19 pandemic which increased feelings of

isolation and vulnerability and had a signiﬁcant, negative impact on

HRQoL.

Conclusions: To our knowledge this is the ﬁrst qualitative work

exploring the views of CAR‐T patients and carers at multiple points in

the patient journey, including perspectives on long‐term treatment

impact. Considerations for service creation and development na-

tionally and internationally include: the importance of a dedicated

nurse specialist, preparing patients for and supporting them with

prolonged treatment side effects, and the psychological challenges

associated with prognostic uncertainty. Expanding indications of

CAR‐T therapy mean there is an urgent need for multi‐centre studies

incorporating patient‐reported outcome data to inform patient cen-

tred care and service delivery.

Keywords: Cellular therapies, Aggressive B‐cell non‐Hodgkin

lymphoma

No conﬂicts of interests pertinent to the abstract.

IMAGING

381 |SURVIVAL INDEPENDENT PREDICTIVE VALUE OF

INTERIM FDG

‐PET IN NEWLY DIAGNOSED DIFFUSE LARGE B

CELL LYMPHOMA

S. Duarte

, C. Afonso

, B. Marques

, C. Barros Lima

, D. Neves

, A. C.

Lai

, M. J. Julião

, A. Roque

, L. Ruzickova

, J. Carda

, M. Gomes

, A.

Cipriano

, A. Espadana

Centro Hospitalar e Universitário de Coimbra, Clinical Hematology

Department, Coimbra, Portugal,

Centro Hospitalar e Universitário de

Coimbra, Pathology Department, Coimbra, Portugal

Introduction: Interim response evaluation by PET (iPET) in diffuse

large B cell lymphoma (DLBCL) is encouraged to rule out disease

progression and has been suggested to be predictive of survival.

FIGURE 1 Image A, B, C: PFS according to baseline SUVmax in relationship to FLIPI risk categories. Image D: PFS according to baseline

SUVmax and presence of at least 2 risk factors (bone marrow involvement, elevated LDH, elevated b2‐microglobulin, extra‐nodal disease,

bulky disease and B‐symptoms)

468

SUPPLEMENT ABSTRACTS

However, treatment guidance by iPET is not yet recommended for

DLBCL in clinical practice. We aimed to assess the predictive value of

iPET in progression free survival (PFS) and overall survival (OS) in

DLBCL patients (pts).

Methods: Single centre retrospective analysis of pts diagnosed with

DLBCL from 2010 to 2019, uniformly treated with R‐CHOP/R‐

CHOP‐like protocols (6‐8 cycles) and submitted to iPET assessment

after 3‐4 cycles of treatment. Negative iPET (iPET‐) was deﬁned by

Lugano classiﬁcation. Cox regression model was used to estimate PFS

and OS. Risk factors with p <0.1 in the univariate analysis were

included in the multivariate model.

Results: A total of 335 pts were diagnosed with DLBCL. Forty‐one

percent (n =138) underwent iPET, 52% males, median age of 63

years old (24‐86). At diagnosis, 12% of the pts had an ECOG per-

formance status (PS) >1, 69% presented with advanced stage dis-

ease (AdS) and 47% with B symptoms (BS). About 44% of the pts

had intermediate/high risk International Prognostic Index (IPI)

score.

Considering early response evaluation by iPET, 73% (n =101) of

the pts had iPET‐and 27% (n =37) iPET+. ECOG‐PS >1 (OR 4.97,

p=0.001), AdS (OR 3.86, p =0.007), BS (OR 3.32, p =0.005),

elevated lactate dehydrogenase (OR 5.67, p <0.001), increased β2‐

microglobulin (OR 4.44, p =0.01), extranodal involvement (OR 3.14;

p=0.04) and IPI >2 (OR 5.32, p <0.001) were associated with higher

proportion of iPET+pts.

Primary refractory DLBCL (PrR) rate, deﬁned as having a positive

post‐treatment evaluation by PET (fPET), was 17%. iPET sensitivity

and speciﬁcity to predict PrR was 70% and 82%, respectively, for

positive and negative predictive values of 43% and 93%. fPET

demonstrated a signiﬁcant frequency of positivity in pts who had

iPET+(OR 10.2, p <0.001).

For a median follow‐up of 54 months, median PFS was not

reached (NR) and was higher in iPET‐(NR versus 10.9 months; HR

4.60, p <0.001), and iPET remains signiﬁcant after multivariate

analysis (HR 5.17, p <0.001).

Median OS was NR and was superior in the iPET‐group (NR and

54.2 months; HR 4.15, p <0.001), also remaining signiﬁcant after

applying a multivariate model (HR 4.85, p <0.001).

Conclusion: Our results showed iPET positivity is an independent

predictor of poorer PFS and OS in DLBCL, even after adjusting

for prognostic factors such as age, AdS and intermediate/

high IPI score. In addition, iPET showed a higher speciﬁcity

and negative predictive value, supporting iPET as a valuable tool for

early assessment of response in DLBCL, particularly of PrR.

Keywords: Diagnostic and Prognostic Biomarkers, PET‐CT, Aggres-

sive B‐cell non‐Hodgkin lymphoma

No conﬂicts of interests pertinent to the abstract.

382 |FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL

MAXIMAL STANDARDIZED UPTAKE VALUE IN FOLLICULAR

LYMPHOMA

G. M. Assanto

, G. Ciotti

, M. Brescini

, R. Agrippino

, G. Lapietra

, M.

L. De Luca

, G. Annechini

, G. M. D'Elia

, A. Chiaravalloti

, I. Del

Giudice

, A. Pulsoni

Haematology, Department of Translational and Precision Medicine,

Sapienza University of Rome, Rome, Italy,

Nuclear medicine, Department

of Biomedicine and Prevention, Nuclear Medicine, University Tor Vergata,

Rome, Italy

SUPPLEMENT ABSTRACTS

469

Introduction: Follicular Lymphoma (FL) is an indolent disease: despite

the efﬁcacy of treatment strategies in inducing remission, high risk

patients relapse within two years and others relapse on long term.

Despite encouraging studies on the prognostic role of Total Meta-

bolic Tumor Volume (TMTV) the role of SUVmax at baseline PET/CT

needs to be better deﬁned.

Methods: Retrospective observational monocentric cohort study

performed at Sapienza University of Rome. All patients affected by FL

who underwent a basal staging PET/CT were included. Patients who

fulﬁlled GELF criteria received different treatment, according to

guidelines and clinical judgment. Patients were stratiﬁed according to

the SUVmax assessed at the onset. Two subgroups were identiﬁed and

compared in terms of PFS and OS: A) Basal SUVmax <6; B) Basal

SUVmax >6.

Results: Ninety‐four patients were included, 34 in group A (36,2%) and

60 in group B (63,8%). Five‐year PFS in the whole cohort was 87,5%,

74,5% for group A and 95% for group B (p 0.005). Nevertheless, PFS at

two years was comparable in the two groups (97%). A correlation be-

tween PFS and baseline SUVmax was observed in patients in different

FLIPI risk categories. In low‐risk FLIPI patients (48.3%) a signiﬁcantly

superior long term PFS was observed in group B compared to A, PFS at

follow‐up was 92% and 66,7% respectively (p 0.012) (Figure 1A‐B). No

signiﬁcant association between PFS and baseline SUVmax was

observed in the subgroup of intermediate (p 0.180) and high‐risk FLIPI

(p 0.317). Multivariate analysis of all the parameters assessed,

conﬁrmed the presence of a basal SUVmax >6 as an independent

favorable prognostic factor for PSF (OR 0.234; 95% IC 0.58‐0.934; p

0.04) as well as a correlation between a BM involvement at diagnosis

and unfavorable PFS (odds ratio [OR] 5.98; 95% IC 1.5‐23.3; p 0.011).

Was ﬁnally explored the PFS of groups A and B based on the presence

of at least two baseline features considered as an indicator of

aggressive disease (bone marrow involvement, elevated LDH, elevated

β2‐microglobulin, extra‐nodal disease, bulky disease, presence of B‐

symptoms) (Figure 1D).

Conclusion: Our data demonstrate the independent prognostic role

of baseline SUVmax as a PFS predictor, especially in patients with

low‐risk FL. Even without other risk factors, patients with low tumor

metabolic activity exhibit a higher long‐term relapse probability.

Baseline SUVmax evaluation, with its simple assessment, could help

identifying patients at risk for late relapse, requiring strict follow‐up

and, potentially, MRD monitoring.

Keywords: Diagnostic and Prognostic Biomarkers, PET‐CT, Indolent

non‐Hodgkin lymphoma

No conﬂicts of interests pertinent to the abstract.

383 |FDG‐PET/CT‐GUIDED REBIOPSY MAY FIND CLINICALLY

UNSUSPICIOUS TRANSFORMATION OF AN INDOLENT

LYMPHOMA AT THE POINT OF DIAGNOSIS OR RELAPSE

A. Rajamäki

, K. Sunela

, H. Kuitunen

, M. Sorigue

, O. Kuittinen

Central Finland Central Hospital, Department of Oncology, Jyväskylä,

Finland,

Tampere University Hospital, Department of Oncology,

Tampere, Finland,

Oulu University Hospital, Department of Oncology,

Oulu, Finland,

ICO‐Hospital Germans Trias i Pujol, Department of He-

matology, Badalona, Spain,

Kuopio University Hospital, Department of

Oncology, Kuopio, Finland

Introduction: Histologic transformation (HT) to an aggressive lym-

phoma is a well‐described event in the clinical course of indolent

lymphomas. When HT occurs, it is common to ﬁnd both low grade

and high grade lymphoma in different areas of the body. Purpose of

the study was to evaluate the beneﬁt of a diagnostic FDG‐PET/CT‐

guided rebiopsy from the maximum standardized uptake value

(SUVmax) site in indolent lymphomas, to reveal HT not detected in

ﬁrst biopsy.

Methods: 85 patients with indolent lymphoma (follicular lymphoma,

marginal zone B‐cell lymphoma, or nodular lymphocyte‐predominant

Hodgkin's lymphoma) who had undergone a diagnostic FDG‐PET/CT,

were identiﬁed in Oulu university hospital in Finland. Principally,

FDG‐PET/CT was made to all patients who were referred to

hospital with a diagnosis of an indolent lymphoma or its

relapse. SUVmax 10 was mainly considered a limit for a new biopsy,

and rebiopsy was performed in the accessible site of highest

SUVmax.

Results: Median follow‐up was 41 months (range: 1–407 months).

During the follow‐up, 8 of 85 (9.4%) patients experienced a biopsy‐

conﬁrmed HT which was detected with a diagnostic FDG‐PET/CT.

One of these patients had also a clinical suspicion of HT, 2 had

minor symptoms which might be suggestive, but ﬁrst biopsy showed

indolent histology, and 5 presented clinically with an indolent dis-

ease. Median SUVmax in patients with HT vs. without HT was

27.1 (range, 10.5‐34.9) vs. 9.0 (range, 1.8‐24.9). 21.6% of patients

with SUVmax >10, and 66.7% of patients with SUVmax >20, had

a HT.

Conclusions: Our results suggest that a rebiopsy based on a high

SUVmax in a diagnostic FDG‐PET/CT is valuable in detecting HT

after the diagnosis or relapse of an indolent lymphoma.

Keywords: PET‐CT, Indolent non‐Hodgkin lymphoma

No conﬂicts of interests pertinent to the abstract.

384 |PROSPECTIVE VALIDATION OF RECIL RESPONSE

CRITERIA: RESULTS OF OBINUTUZUMAB‐GDP AS SALVAGE

PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IN

AGGRESSIVE B CELL LYMPHOMA

E. Lebel

, M. D. Jain

, A. Prica

, V. Kukreti

, R. Kridel

, R. C. Laister

L. Meng

, J. Delabie

, J. Weiss

, T. Panzarella

, M. Crump

, J.

Kuruvilla

Princess Margaret Cancer Centre, Division of Medical Oncology and

Hematology, Toronto, Canada,

Mofﬁtt Cancer Center, Department of

Blood and Marrow Transplant and Cellular Immunotherapy, Tampa,

Florida, USA

470

SUPPLEMENT ABSTRACTS

TABLE 1Responses to second line O‐GDP by Lugano and RECIL criteria

SUPPLEMENT ABSTRACTS

471

Introduction: Obinutuzumab plus gemcitabine, dexamethasone

and cisplatin (O‐GDP) is a feasible outpatient salvage regimen

that enables autologous stem cell transplant (ASCT) in patients with

relapsed/refractory aggressive B cell lymphomas (NCT02750670;

Jain, ASH 2019, 4610). The RECIL criteria have been developed for

lymphoma (aligned with RECIST criteria for solid tumors) and are

based on unidimensional measurements of no more than 3 lesions for

response assessment (Younes, Ann. Oncol. 2017). We prospectively

evaluated responses to O‐GDP by RECIL criteria.

Methods: following 2 cycles of O‐GDP, patients (pts) were evalu-

ated for response by both Lugano criteria (Cheson, JCO 2014;

primary study endpoint) and RECIL criteria (predeﬁned secondary

endpoint). Responsive pts by Lugano criteria proceeded to pe-

ripheral blood stem cell (PBSC) collection using the 3

cycle of

O‐GDP as mobilizing chemotherapy, and subsequently had end of

salvage assessment by PET‐CT. Responsive pts by PET‐CT pro-

ceeded to ASCT.

Results: Of 30 pts treated with 2 cycles of O‐GDP, 18 (60%)

responded by Lugano criteria (all with partial response (PR)), 8 had

stable disease (SD) and 4 had progressive disease (PD). 25/29 pts

(86%) had a concordant response by RECIL criteria (table 1). Three

pts were responsive by RECIL and were SD by Lugano (pts 1,13,16); 2

of them (1,13) proceeded to transplant but developed PD. In 1 pt,

response was downgraded (Lugano PR, RECIL MR; 26), he is now

post ASCT in remission.

Conclusions: We prospectively show that RECIL criteria offer

easier response assessment and appear concordant to Lugano

criteria for most pts. Reﬁnement of these criteria and deﬁning

their utility in decision making requires further prospective

assessment.

Keywords: Imaging and Early Detection – Other, Aggressive B‐cell

non‐Hodgkin lymphoma, Chemotherapy

Conﬂicts of interests pertinent to the abstract

M. D. Jain

Consultant or advisory role: kite/Gilead, Novartis, BMS and Takeda

A. Prica

Honoraria: Astra‐Zeneca, Gilead

R. Kridel

Research funding: Gilead Sciences and Roche

M. Crump

Honoraria: Novartis and Kite Gilead

Research funding: Roche

J. Kuruvilla

Consultant or advisory role: Abbvie, BMS, Gilead, Karyopharm,

Merck, Roche, Seattle Genetics

Honoraria: Amgen, Antengene, Astra Zeneca, BMS, Gilead, Incyte,

Janssen, Karyopharm, Merck, Novartis, Pﬁzer, Roche, Seattle Ge-

netics, TG Therapeutics

Research funding: Canadian Cancer Society, Leukemia and Lym-

phoma Society Canada, Princess Margaret Cancer Foundation,

Janssen, Roche, Astra Zeneca

Other remuneration: Karyopharm (DSMB)

385 |SPLENIC INCREASED 18F‐FDG UPTAKE IN PET SCAN

PERFORMED FOLLOWING TREATMENT WITH PEG‐GCSF

LIPEFILGASTRIM

A. Fe'

, M. Cimminiello

, A. Nicoletti

, A. Matturro

, G. Coralluzzo

, S.

P. Pascale

, R. Nuccorini

, L. Fabio

, S. Mancino

, T. Cavallo

AOR San Carlo, SIC di Medicina Nucleare, Potenza, Italy,

AOR San

Carlo, UOC Ematologia, Potenza, Italy,

AOR San Carlo, UOC Radiologia,

Potenza, Italy,

AOR San Carlo‐PO Villa d'Agri, SSD Radiologia, Villa

d'Agri, Italy

Introduction: Lipegﬁlgrastim, is once‐per‐cycle, a pegylated recom-

binant G‐CSF approved by the EMA in July 2013 for reducing the

duration of Chemotherapy‐induced neutropenia which can lead to

febrile neutropenia in cancer patients (pts) receiving chemotherapy.

Methods: We retrospectively analyzed 18FDG PET TC scan at the

initial staging (sPET), interim time (iPET) and at end of therapy (ePET)

in 16 consecutive pts (9 DLBCL and 7 HL). None of these pts had

focal or diffuse splenic involvement at sPET. All patients were treated

with consolidated chemoteraphy scheme associated with a Lipegﬁl-

gastrim, once‐per‐cycle. The time elapsed between Lipegﬁlgastrim

administration and iPET was on average 15 days.

Results: The 18FDG iPET did not show any pathological uptake in all

pts but showed a splenic diffuse,homogeneous increased uptake of

18FDG, greater than epatic 18FDG uptake in all pts,determining an

inversion of the hepatosplenic ratio uptake. The 18FDG ePET, per-

formed one month after the end of therapy, did not show any

pathological ﬁndings: normal spleen uptake lower than liver and

phisiological hepatosplenic ratio uptake.

Even if it is consolidated to perform an interim PET in HL and NHL

and it is consolidated to treat these pts with G‐CSF, we found a

diffuse, homogeneous increased splenic uptake of 18FDG greater

than epatic 18FDG uptake in all 16 pts treated with a Lipegﬁlgastrim,

once‐per‐cycle.

In literature, some authors did not observe larger variations in

bone marrow and spleen uptake in the group of pts having received

lipegﬁlgastrim compared to ﬁlgastrim and lenogastrim group, despite

its longer half‐life due to its PEGylated nature. The major determi-

nant for the occurrence of a bone or spleen hypermetabolism on

iPET/CT was the time‐lapse between the chemotherapy and the PET/

CT examination, which should be maintained greater than 15 days.

In our group of pts we did not observe any difference in the

increase of bone marrow uptake of 18FDG at the iPET compared

with pts received ﬁlgastrim or lenogastrim. The 18F‐FDG PET scan

performed at the end of therapy showed no pathological ﬁndings,

with a normal 18F‐FDG uptake in the spleen and bone marrow,

determining the benign and reactive nature of the splenic and bone

marrow 18F‐FDG increased uptake found in the previous iPET.

Conclusion: it is important to know that in pts who received

aggressive chemoteraphy protocol like HL and NHL associated with a

Lipegﬁlgastrim can have therapeutic‐related reactive splenic uptake

concurrent with bone marrow uptake secondary to administration of

G‐CSF for myelosuppression without inﬂuencing on the Deauville

score determination.

472

SUPPLEMENT ABSTRACTS

We think that the type of G‐CSF used, the time elapsed between

its last injection and interim PET/CT and the time‐lapse between the

chemotherapy and the PET/ CT examination must be evaluated when

performing a 18F‐FDG PET scan, to avoid false‐positive results.

Keywords: PET‐CT, Aggressive B‐cell non‐Hodgkin lymphoma,

Hodgkin lymphoma

No conﬂicts of interests pertinent to the abstract.

386 |PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH

RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE

TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPY

G. Fouquet

, M. Wartski

, A. Dechmi

, L. Willems

, B. Deau‐Fischer

P. Franchi

, J. Descroocq

, P. Deschamps

, J. Clerc

, D. Bouscary

S. Barreau

, N. Chapuis

, M. Vignon

, A.‐S. Cottereau

Cochin Hospital APHP, Paris, France, Hematology, Paris, France,

Cochin

Hospital, APHP, Paris, Nuclear Medicine, Paris, France,

Hôpital Cochin,

APHP, Service d'hématologie biologique, Paris, France

Introduction: Although immunotherapy with monoclonal antiCD38

antibody has improved prognosis of relapse/refractory multiple

myeloma (RRMM), some patients experience early relapse with a

dismal outcome. 18F‐FDG PET/CT is now recommended for the

visualization of disease activity in both newly diagnosed and

RRMM patients. It has also been used for the prediction of sur-

vival outcome in patients treated with allogeneic stem cell trans-

plant. This study evaluated the predictive impact of

PET parameters in RRMM patients before initiating antiCD38

therapy.

FIGURE 1 Kaplan Meier estimates of progression free survival

(PFS) and overall survival (OS) according to the presence of more

than 3 local lesions (FLs) or less/equal than 3 focal lesions

TABLE 1Patient characteristics and results

SUPPLEMENT ABSTRACTS

473

Methods: Consecutive RRMM patients who underwent baseline 18F‐

FDG PET /CT before anti‐CD38 based immunotherapy (Dar-

atumumab, Isatuximab) in our centre between June 2019 and

December 2020, were included. A focal lesions (FL) was deﬁned as

focally increased FDG uptake greater than the physiologic bone

marrow uptake, with or without any underlying lesion. Extra-

medullary disease (EMD) was deﬁned as FDG‐avid soft tissue not

contiguous to bone. High‐risk (HR) cytogenetics was deﬁned as del

(17p), t(4;14), and t(14;16). Survival functions were calculated using

Kaplan Meier estimates, comparisons between categories were made

with the log‐rank test. Mann‐Whitney U test was used to compare

PET variables in relation to beta2microglobuline (B2M).

Results: Thirty‐eight patients (female n =19) with a median age at

relapse of 73 (range 58 ‐87) were included. Median prior line of

treatment before antiCD38 immunotherapy was 3 (range 2‐9) and

47% (n =18) had underwent autologous stem cell transplantation.

The ISS initial stage 1, 2 and 3 comprised 42% (n =16), 37% (n =14)

and 21% (n =8) respectively. 24% (n =8/33) had HR cytogenetic.

Before starting CD38 targeted therapy, 65% of the patients (n =25)

had at least one FL with a median SUVmax of 7.8, 49% (n =19) had

more than 3 FLs with a median SUVmax of 10.7. EMD was present in

19% (n =7) of all patients. Median PFS and OS for the entire cohort

were 12,5 months and 15,8 months. The presence of >3 FLs was

associated with signiﬁcantly inferior PFS (p =0.0036) and OS

(p =0.025). A high SUV max ≥11.5 (n =8) was a predictor of PFS

(p =0.036) and OS (p =0.031). A median serum B2M level was

signiﬁcantly higher in patients with >3 FLs compared with 1‐3 FLs

(p =0.015). The initial ISS score was signiﬁcantly associated with

both PFS (p =0.0045) and OS (p =0.0081). EMD and HR cytogenetic

did not signiﬁcantly correlate with the PFS or the OS. In multivariable

analysis, ISS score and >3FLs were independent prognosticators for

PFS (p =0.010, p =0.025 respectively). Blood ﬂow cytometry, per-

formed in 15 patients, detected 4 patients with abnormal plasma cells

among 3 had FLs >3 and one had a single bone lesion with EMD.

Conclusion: Presence of >3 FLs on PET/CT is a predictor of survival

outcomes in patients with relapse/refractory MM treated with CD38

targeted therapy and correlates with tumour burden biomarker.

Keywords: Immunotherapy, PET‐CT, Multiple Myeloma

No conﬂicts of interests pertinent to the abstract.

MISCELLANEOUS

387 |STEM CELL MOBILIZATION AFTER TREATMENT WITH

BENDAMUSTINE IN PATIENTS WITH HODGKIN AND B‐CELL

NON‐HODGKIN LYMPHOMAS. RESULTS AT DONOSTIA

UNIVERSITY HOSPITAL, SPAIN

B. Mendibil Esquisabel

, J. J. Ferreiro Martinez

, I. Zeberio

Etxetxipia

, A. Altuna Mongelos

, J. Iriondo Alzola

, A. Zumalde

Murua

, A. Arambarri Oyarzabal

, N. F. Rois Pego

, A. Alkorta

Eizagirre

Hospital Universitario Donostia, Hematology Department, Donostia,

Spain

Introduction: Salvage chemotherapy followed by an autologous

stem‐cell transplantation (ASCT) is the standard of care for patients

with either relapsed or refractory Hodgkin lymphomas (HL) or B‐cell

non‐Hodgkin lymphomas (NHL). In the last decades treatment regi-

mens including bendamustine have shown efﬁcacy in patients with B‐

cell NHL, both as frontline treatment or in subsequent lines, and in

patients with relapsed or refractory HL. Bendamustine is an alky-

lating agent that shares structural properties with purine analogs like

ﬂudarabine, which are known to have a negative effect on peripheral

blood stem cell (PBSC) mobilization. This fact raised concern as to the

impact bendamustine could have on stem cell mobilization. Lately, a

retrospective multicenter study performed by Fondazione Italiana

Linfomi has shown that prior treatment with bendamustine does not

affect PBSC mobilization

Methods: We conducted a retrospective analysis of PBSC mobiliza-

tion in 31 patients with HL or NHL who had received treatment with

bendamustine, either in the same or previous lines, in our center.

Results: Patient characteristics and results are shown in Table 1. 31

patients underwent PBSC mobilization after treatment with bend-

amustine: 16 patients with follicular lymphoma, 14 patients with HL

and 1 patient with small lymphocytic lymphoma. Median age was 52

years. 27 patients received combinations with bendamustine as

second‐line treatment and 4 patients received it as part of the ﬁrst‐

line treatment. Median time from treatment with bendamustine to

PBSC mobilization was 2 months. All patients underwent mobiliza-

tion with G‐CSF and 14 required the use of plerixafor per protocol.

90% of the patients succeeded to mobilize in the ﬁrst attempt. 27

patients obtained ≥2 x 10

CD34+/kg of body weight in the ﬁrst

mobilization attempt and 1 patient required a second mobilization to

collect the CD34+target. 3 patients presented a mobilization failure,

2 of which underwent a second mobilization with G‐CSF with success

3 and 10 months later, respectively. Both patients were able to

collect the CD34+target. 11 patients required a second harvest to

achieve the CD34+target and only one patient required three har-

vests. The median number of CD34+obtained in each mobilization

was 3.06 x 10

/kg. 27 patients underwent ASCT with successful

engraftment.

Conclusions:

1. Consistent with previously published studies, our experience

shows that bendamustine does not impair PBSC mobilization.

2. Mobilization with G‐CSF alone has shown to be a successful

mobilization strategy in this subset of patients. No increased use of

plerixafor has been observed when compared to the usual rates in

our center.

REFERENCES:

1. Merli M, Luminari S, Farina L, Cocito F, Defrancesco I, Gini

G, et al. Stem cell mobilization after bendamustine in indolent

lymphomas: a multicenter study on behalf of the Fondazione

Italiana Linfomi. Bone Marrow Transplant. 2020 Dec;55

474

SUPPLEMENT ABSTRACTS

(12):2350‐2353. doi: 10.1038/s41409-020-0967-5. Epub 2020

Jun 15.

Keywords: Hodgkin lymphoma, Indolent non‐Hodgkin lymphoma,

Stem Cell Transplant

No conﬂicts of interests pertinent to the abstract.

388 |COMPARATIVE EVALUATION OF RADIATION THERAPY

TECHNIQUES FOR MEDIASTINUM IRRADIATION IN LYMPHOMA

PATIENTS USING IMRT, B‐VMAT, 3DCRT

M. Fomintseva

, Y. Vinogradova

, N. Ilyin

, I. Shenderova

, L.

Storozhenko

, A. Vasilieva

A.M. Granov Russian Research Centre for Radiology and Surgical

Technologies, Department of Radiation and Combined Therapy, Saint‐

Petersburg, Russian Federation

Introduction: Radiation therapy is effective in treating mediastinal

lymphomas, but the question of its long‐term radiation effects, such

as induced breast cancer, lung cancer, and heart disease, has been

increasingly raised in recent years. The aim of our work was to

compare the radiation doses that receive heart, lungs, and mammary

glands (MG) during irradiation of mediastinal lymphomas by 3

different techniques: IMRT, B‐VMAT, 3DCRT.

Methods:A radiation therapy plan was calculated for each of the

indicated techniques for 7 mediastinal lymphoma patients. Photon

energy: 6 MV, target dose: 30 Gy/15 fractions, planned target volume

(PTV) coverage: 98% PTV covered by at least 95% isodose. IMRT and

B‐VMAT plans were calculated by inverse planning, and 3DCRT by

direct planning using the Monte Carlo algorithm.

Each IMRT plan consists of 7 coplanar ﬁelds almost equally spaced

around a patient, using the ability not to pass through MG. B‐VMAT

plan is a composition of 3 non‐coplanar VMAT arcs, couch 0°

G330°÷G30°, couch 0° G150°÷G180° +G181°÷G210° and couch 270°

G330°÷G30°. 3DCRT plan is a couple of AP‐PA ﬁelds with an addition

of small portion of posterior oblique ﬁelds that lead to maximum dose

outside PTV avoidance without adding any signiﬁcant dose to lungs.

An extra sub‐volume “heart inside PTV” was created for inverse

optimization in order to keep its dose theraputical and avoid any

possible maximum inside the heart.

Results:With a probability of p <0.05, the following parameters

were estimated. Average volumes of PTV (620 ±170) cc, MG (710 ±

660) cc, total lung (2950±420) cc and heart (590 ±90) cc. Dose‐

Volume relations are given in following table

Normal Structure parameter IMRT B‐VMAT 3DCRT

Mammary Gland, % 22±10 12±13 20±19

Lungs, % 25±3 21±4 24±4

mean dose to Lungs, Gy 14,5±7,6 13,0±8 10±1,5

Heart, % 44±24 55±24 46±24

(Continues)

(Continued)

Normal Structure parameter IMRT B‐VMAT 3DCRT

Heart, % 25±12 25±12 34±20

mean Heart dose, Gy 10,9±6 12,4±5 12,6±6

max Heart dose, Gy 31,8±0,4 32,0±1,2 32,8±0,6

Conclusions: With the stated above PTV coverage, the IMRT tech-

nique can signiﬁcantly increase the conformity index of the plan and

lead to the lowest dose to the heart in all studied parameters, but

showed the highest dose to the lungs ‐both mean dose and V

The B‐VMAT technique can signiﬁcantly reduce V

MG while

maintaining minimum V

heart and V

lungs. At the same time,

despite the low mean dose to the heart‐inside‐PTV, the mean dose to

the whole heart with this technique is higher compared to the IMRT

technique due to the increase in V

heart.

The standard 3DCRT technique achieves the lowest average

dose to the lungs, but has not shown any advantages in the rest of

considered critical organs. The scatter of the data is due to the large

variability of the physiological parameters of the patients, in order to

specify the obtained data the study is proceeded.

EA – previously submitted to regional or national meetings (up to

1000 attendees).

Keywords: Late Effects in Lymphoma Survivors, Radiation Therapy

No conﬂicts of interests pertinent to the abstract.

389 |A NEW OPTION IN PAIN PREVENTION WITH BLISS©, A

DIGITAL THERAPEUTIC SOLUTION LEVERAGING VIRTUAL

REALITY: RESULTS OF A FRENCH OPEN‐LABEL MULTICENTER

RANDOMIZED PHASE III STUDY (REVEH TRIAL)

A.‐L. Septans

, K. Le Dû

, F. Maloisel

, H. Vanquaethem

, A. Schmitt

M. Le Goff

, M.‐P. Moles

, M. Zinger

, H. Bourgeois

, M. Peron

F. Denis

, S. Bouchard

ILC Jean Bernard, Onco‐hematology, Le Mans, France,

Conﬂuent Pri-

vate Hospital, Hematology, Nantes, France,

Clinique Saint‐Anne, Hema-

tology, Strasbourg, France,

Hôpital dInstruction des Armées Bégin,

Médecin interne, Saint Mande, France,

Institut Bergonié, Hematology,

Bordeaux, France,

ILC Jean Bernard, Hematology, Le Mans, France,

CHU, Hematology, Angers, France,

ILC Jean Bernard, Onco‐

hematoloogy, Le Mans, France,

Effet Papillon, Quality of Life, Laval,

France,

Université du Québec en Outaouais, Psychoeducation and

Psychology, Gatineau, Canada

Introduction: The prevention of care‐induced pain is a central concern

for healthcare teams in hematology units. Use of MEOPA (Oxygen

+Nitrous Oxide) is today a standard of care for relaxation procedure.

Distraction through immersion in virtual reality (VR) has already

documented its analgesic effects in several phase II trials but com-

parison with standard treatments in a large randomized study is

needed.

SUPPLEMENT ABSTRACTS

475

Methods: We conducted an open‐label multicenter randomized

phase III trial (ClinicalTrials.gov identiﬁer: NCT03483194). We

assessed the safety and efﬁcacy of Bliss© in prevention of pain and

anxiety before performing and during a bone marrow biopsy. Bliss©

is a new Digital Therapeutic/Virtual Reality solution with four

imaginary interactive environments in three dimensions (image and

sound) augmented by binaural sound. Efﬁcacy was evaluated by pain

intensity with visual analog scale (score from 0 to 10) immediately

after the biopsy and anxiety by 2 questionnaires (fear of pain before

the biopsy and revised STAI questionnaire before and after the

biopsy). The primary end point was patient‐assessed pain intensity

after the bone marrow procedure.

Results: A total of 126 patients were enrolled with previously

untreated malignant hemopathy between September 6, 2018 and

May 18, 2020. They were randomly assigned in a 1:1 ratio to receive

prevention pain with MEOPA (n =63) or Bliss© (n =63). All patients

received a local anesthesia with lidocaïne before the biopsy. Median

age of the study population was 65.5 years old (range 18 to 87) and

54.2% were men. The average pain intensity was 3.5 (standard de-

viation 2.6) for the MEOPA group and 3.0 (SD 2.4) for the VR group

(p =0.26) without any signiﬁcant difference according to age, gender

ord hemopathy. Concerning anxiety, 67.5% of patients were afraid

before the biopsy and anxiety scores were moderate to very high in

26.3% of patients before the biopsy (STAI questionnaire) and 9.0%

after the biopsy for all patients (17.3% of reduction in anxiety for the

MEOPA group and 17.2% for the VR group, p =0.83). Immersion in

VR was well tolerated in 100% of patients included in the VR group.

Physicians were very satisﬁed by the relaxation procedure in

64.9% of cases (52.5% in the MEOPA group and 77.6% in the

VR group, p =0.01) and recommended re‐use of the technique

in 54.2% in the MEOPA group and 79.1% in the VR group (p =0.02).

Conclusion: The intensity of pain did not signiﬁcantly differ in both

arms. Bliss©‐based relaxation method was well tolerated and the

satisfaction of patients and physicians was very high. This study vali-

dates the use of immersion in VR with Bliss© as a new Digital Thera-

peutic and support the integration of software in the panel of

supportive care.

EA – previously submitted to ASCO and EHA 2021.

The research was funded by: Roche, Elsan group and France

Lymphome Espoir Association

Keywords: Therapeutics and Clinical Trials in Lymphoma ‐Other

Conﬂicts of interests pertinent to the abstract

K. Le Dû

Consultant or advisory role: Incyte, Abbvie

Research funding: Roche

Educational grants: Janssen, Roche

F. Maloisel

Honoraria: Pﬁzer, Agmen, Incyte, Abbvie

S. Bouchard

Other remuneration: president and part owner of In Virtuo, a com-

pany that distributes virtual reality environments

390 |NEGATIVE SYNERGISM BETWENN THE COMBINATION

OF STEROID AND LOW MOLECULAR WEIGHT HEPARIN (LMWH)

ON BONE METABOLISM, IN PATIENTS TREATED FOR LYMPHOMA

L. Pezzullo

, M. D'Addona

, C. Martorelli

, L. Mettivier

, V. Giudice

R. Fontana

, I. Ferrara

, S. Luponio

, R. Guariglia

, B. Serio

, C. Selleri

476

SUPPLEMENT ABSTRACTS

Salerno University, Hematology Division, Salerno, Italy

Low molecular weight heparins (LMWH) are widely used in throm-

bosis prophylaxis in treated lymphoma patients with central periph-

eral venous device (PVD). The negative effect of heparin on

osteogenesis is known, it is not clear how anticoagulants vit K in-

hibitors act while the role of LMWH is controversial. The negative

effect of steroids on osteogenesis is also documented but there are

no data on negative synergy related to the simultaneous intake of

steroids and LMWH.

The aim of our study is to evaluate the bone events (bone

fractures) observed retrospectively in a consecutive cohort of lym-

phoma patients treated with chemotherapy (with or without ste-

roids) from January 2014 to January 2021 with at least 6 months of

follow‐up.

From January 2014 to January 2021 we observed 197 pa-

tients with a median follow‐up of 38 months (range 6‐85 months);

90 with NHL treated with CHOP or similar 34 f and 56 m with a

median age of 59 years (range 23‐77 years); 53 with NHL treated

with bendamustine based therapy; 23 f and 30 m with median

age of 65 years (range 42‐81 years) and 54 with HD treated

with ABVD or similar; 26 f and 28 m with a median age of 34

years (range 16‐75 years). All patients with PVD and all treated

in prophylaxis with LMWH (enoxaparin or nadroparin) 4000 U /

day.

In the NHL group treated with steroids and LMWH the

observed bone events (bone fractures) were 13 (14.5% of patients).

All patients had vertebral involvement and in 2 patients in addi-

tion to the vertebral problem, an event in the femur was docu-

mented. In the NHL group treated with LMWH but not steroids, the

observed bone events were 2 (3.8% of patients) while in the

HD group there were 2 (3.8% of patients), all with vertebral

involvement.

These data show a higher incidence of bone events in patients

receiving steroid and LMWH therapy. This evidence suggests a

negative synergism between the association of steroids and LMWH

on bone metabolism and also probably conﬁrms that vitamin D

metabolism in patients with aggressive NHL may be implicated in the

prognosis of these lymphomas.

This evidence suggests the need to integrate vit D with or

without calcifying into the therapy of patients with aggressive NHL

and to evaluate the possibility of proposing prophylaxis for throm-

bosis not with LMWH but with the new oral anticoagulants.

A prospective study is needed which also includes the study of

calcium metabolism and bone mineralization both at diagnosis and

over time in the various subtypes of NHL and which supportive

treatments they have received.

EA – previously submitted to EHA 2021.

Keywords: Late Effects in Lymphoma Survivors

No conﬂicts of interests pertinent to the abstract.

391 |RISK OF HEMOLYMPHOPOIETIC NEOPLASM BEFORE

AND AFTER THYROID CANCER. A POPULATION‐BASED STUDY

IN ITALY, 1998‐2012

V. Mattioli

, E. Crocetti

, L. Dal Maso

, C. Buzzoni

, S. Franceschi

D. Serraino

, S. Vaccarella

, S. Ferretti

, S. Busco

, U. Fedeli

M. Varvarà

, F. Falcini

, M. Zorzi

, G. Carrozzi

, W. Mazzucco

C. Gasparotti

, S. Iacovacci

, F. Toffolutti

, R. Cavallo

, F. Stracci

A. G. Russo

, A. Caldarella

, S. Rosso

, A. Musolino

L. Mangone

, C. Casella

, M. Fusco

, G. Tagliabue

, D. Piras

R. Tumino

, L. Guarda

, Y. M. Dinaro

, S. Piffer

, P. Pinna

G. Mazzoleni

, A. C. Fanetti

CRO Aviano, Cancer Epidemiology, Aviano, Italy,

AIRTUM Database,

Italy,

International Agency for Research on Cancer, Section of Cancer

Surveillance, Lyon, France,

IRCCS Istituto Romagnolo per lo Studio dei

Tumori (IRST) “Dino Amadori”, Meldola, Italy‐Azienda Usl della Romagna,

Romagna Cancer Registry, Forlì, Italy,

ASL Latina, Cancer Registry of

Latina Province, Latina, Italy,

Azienda Zero, Epidemiological Department,

Padua, Italy,

Università degli Studi di Catania, Registro Tumori Integrato

Catania‐Messina‐Siracusa‐Enna, Catania, Italy,

Istituto Scientiﬁco

Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Romagna

Cancer Registry, Meldola, Italy,

Veneto Region, Veneto Tumor Registry,

Padua, Italy,

Modena Cancer Registry, AUSL Modena, Public Health

Department, Modena, Italy,

Palermo and Province Cancer Registry,

Azienda Ospedaliera Universitaria Policlinico “Paolo Giaccone”, University

of Palermo, Clinical Epidemiology Unit with Cancer Registry, Palermo, Italy,

Brescia Health Protection Agency, Epidemiology Unit, Brescia Cancer

Registry, Brescia, Italy,

ASL Salerno, Cancer Registry, Salerno, Ita-

University of Perugia, Public Health Section ‐Dept. of Medicine and

Surgery, Perugia, Italy,

Agency for Health Protection of Milan, Cancer

Registry of Milan, Epidemiology Unit, Milan, Italy,

Institute for Cancer

Research, Prevention and Clinical Network (ISPRO), Tuscany Cancer Reg-

istry, Clinical Epidemiology Unit, Florence, Italy,

Azienda Ospedaliera‐

Universitaria Città della Salute e della Scienza di Torino, Piedmont Cancer

Registry, Torino, Italy,

Azienda Ospedaliera Universitaria di Parma,

Parma Cancer Registry, Oncology Unit, Parma, Italy,

AUSL ASMN‐IRCCS,

Azienda USL di Reggio Emilia, Reggio Emilia Cancer Registry, Epidemiology

Unit, Reggio Emilia, Italy,

IRCCS Ospedale Policlinico San Martino,

Liguria Cancer Registry, Clinical Epidemiology, Genova, Italy,

ASL Napoli

3 Sud, Cancer Registry, Napoli, Italy,

Fondazione IRCCS Istituto Nazio-

nale dei Tumori, Lombardy Cancer Registry, Varese Province, Cancer

Registry Unit, Department of Research, Milan, Italy,

Azienda Regionale

per la Tutela della Salute, North Sardinia Cancer Registry, Sassari, Italy,

Provincial Health Authority (ASP 7), Cancer Registry and Histopathology

Department, Ragusa, Italy,

Agenzia di Tutela della Salute (ATS) della Val

Padana, Mantova Cancer Registry, Epidemilogy Unit, Mantova, Italy,

Siracusa Cancer Registry, Health Unit of Siracusa, Siracusa, Italy,

Trento Province Cancer Registry, Unit of Clinical Epidemiology, Trento,

Italy,

ASSL Nuoro/ATS Sardegna, Nuoro Cancer Registry, RT Nuoro,

Nuoro, Italy,

Southtyrol Cancer Registry, Bolzano, Italy,

Health Pro-

tection Agency, Sondrio Cancer Registry, Sondrio, Italy

SUPPLEMENT ABSTRACTS

477

Introduction: The number of patients living after a cancer diagnosis is

increasing, especially after hemolymphopoietic and thyroid cancer

(TC). This study aims at evaluating both the risk of a second hemo-

lymphopoietic cancer in TC patients and the risk of TC as a second

cancer.

Methods: Two population‐based cohorts of cancer patients aged up

to 84 years were identiﬁed from 28 Italian cancer registries in the

1998–2012. The ﬁrst included TC patients and the second hemo-

lymphopoietic cancers patients with cancers. Standardized incidence

ratios (SIR) of SPC were stratiﬁed by sex, age, and time since ﬁrst

cancer. SPC diagnosed within 2 months since ﬁrst are not included in

the computation of cancer‐speciﬁc SIRs.

Results: 38,535 TC patients and 154,820 patients with hemolym-

phopoietic cancers were included. Overall SIR for hemolympho-

poietic cancer in TC patients was signiﬁcantly increased (SIR=1.5 in

women and 1.3 in men), as well as for most of the hemolymphopoietic

subtypes (SIR=2.7 for acute lymphoid leukemia, 1.6 for follicular non‐

Hodgkin lymphomas, 1.5 for chronic lymphoid leukemia, and 1.4 for

myelomas for both sexes). The overall SIR for hemolymphopoietic

cancer in TC patients was signiﬁcantly higher in all three age groups

(0‐34 years: 2.0, 35‐54: 1.4 and 55+: 1.4 for both sexes). The risk of

TC cancer was signiﬁcantly increased after Acute Lymphoid Leuke-

mia (10 cases, SIR=6.1), Hodgkin lymphomas (38, 2.8), and all

hemolymphopoietic neoplasms (183, 1.8). The risk of TC after any

hemolymphopoietic cancer was particularly higher for the age groups

0‐34 and 35‐54 (SIR 4.3 and 1.8 respectively).

Conclusions: TC patients have both an increased risk of developing a

second hemolymphopoietic cancer as TC to be a second cancer. An

elevated risk of second primary tumors from the use of radioactive

iodine (RAI) therapy in TC patients, in particular in pediatric and

young adult patients, may explain the elevated incidence of acute

lymphoid leukaemias and hemolymphoiectic neoplasms overall. The

present ﬁnding may help in designing surveillance programs for

hemolymphopoietic cancers in TC patients and vice versa keeping

into consideration the possibility of overdiagnosis of TC.

Keywords: Prevention and Cancer Interception

No conﬂicts of interests pertinent to the abstract.

392 |LATE TOXICITIES AND LONG‐TERM MONITORING IN

CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL

LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS

OF THE FONDAZIONE ITALIANA LINFOMI

C. Minoia

, C. Gerardi

, E. Allocati

, V. De Sanctis

, S. Franceschetti

S. Viviani

, M. A. Annunziata

, A. Bari

, T. Skrypets

, S. Oliva

, A.

Puzzovivo

, S. Di Molfetta

, V. Caccavari

, A. Di Russo

, G.

Loseto

, A. Daniele

, L. Nassi

, G. Gini

, A. Guarini

IRCCS Istituto Tumori “Giovanni Paolo II”, Hematology Unit, Bari, Italy,

Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Centro

Politiche Regolatorie in Sanità, Milan, Italy,

Faculty of Medicina e

Psicologia, Sant'Andrea Hospital, University of Rome "La Sapienza",

Department of Radiation Oncology, Rome, Italy,

ASST Ovest Milanese, U.

O.C. Ematologia, Legnano, Italy,

IEO European Institute of Oncology,

IRCCS, Division of Hemato‐Oncology, Milan, Italy,

Centro di Riferimento

Oncologico di Aviano (CRO), IRCCS, Unit of Oncological Psychology,

Aviano, Italy,

Università di Modena e Reggio Emilia, UO Terapie Mirate in

Oncoematologia ed Osteoncologia, Dipartimento di Scienze Mediche e

Chirurgiche Materno‐Infantili e dell'Adulto, Modena, Italy,

IRCCS Istituto

Tumori "Giovanni Paolo II", Cardiology Unit, Bari, Italy,

IRCCS Istituto

Tumori "Giovanni Paolo II, Cardiology Unit, Bari, Italy,

University of Bari

"Aldo Moro", Department of Emergency and Organ Transplantation,

Section of Internal Medicine, Endocrinology, Andrology and Metabolic

Diseases, Bari, Italy,

Istituto Clinico Città Studi, Assisted Reproduction

Unit, Milan, Italy,

Fondazione IRCCS Istituto Nazionale dei Tumori,

Radiotherapy Unit, Milan, Italy,

IRCCS Istituto Tumori "Giovanni Paolo

II", Experimental Oncology and Biobank Management Unit, Bari, Italy,

Careggi Hospital and University of Florence, Lymphoma Unit, Hema-

tology Department, Florence, Italy,

AOU Ospedali Riuniti Ancona‐Uni-

versità Politecnica delle Marche, Clinic of Hematology, Ancona, Italy

Background: In the current years it is estimated that cancer survivors

are more than 16 million and it is predicted to reach 22 million by

2030. Up today there is a paucity of data on late toxicities affecting

lymphoma survivors, thus we still need more data from literature to

follow late sequelae of these patients and to set up an organized and

evidence based follow‐up strategy.

Aim: Researchers belonging to the Fondazione Italiana Linfomi

drawn a series of systematic reviews with the aim to :i) evaluate

available data and develop homogeneous indications for lymphoma

survivors' monitoring using a systematic approach; ii) ﬁnd a balance

between the unmet medical need and the sustainability of health-

care system.

Methods: The research work was carried out by a multi‐disciplinary

team of 16 researchers of the Fondazione Italiana Linfomi under

the methodological supervision of 3 Researchers of the Istituto di

Ricerche Farmacologiche “Mario Negri”, in Milan. The systematic

reviews focused on six topics: cardiotoxicity, secondary cancers,

endocrine‐metabolic sequelae, fertility and neurological/ cognitive

toxicities, healthy lifestyles. The following speciﬁc questions were

analyzed, considering the population of classical Hodgkin lymphoma

(cHL) and Diffuse large B‐cell lymphoma (DLBCL) survivors treated

at adult age (≥18 years old): i) incidence of the long‐term toxicity;

ii) comparison with more recent therapies (e.i. modern radiation

therapy); iii) best monitoringof long‐term sequelae. The search was

conducted on 3 bibliographic databases (PubMed, Embase and the

Cochrane Library) with also hand searching up to December, 2020.

Selection process and data extraction were conducted according to

the Preferred Reporting Items for Systematic reviews and Meta‐

analyses (PRISMA) guidelines.

Results: Six independent systematic reviews were conducted accord-

ing to the topics of research. A global number of 170 full text papers

resulted eligible for data extraction and were included in the ﬁnal

sample. They concerned: cardiotoxicity (n =22), secondary cancers

(n =21), endocrine‐metabolic sequelae (n =9), fertility (n =46),

478

SUPPLEMENT ABSTRACTS

neurologic and cognitive toxicity (n =62), healthy lifestyles (n =10).

The optimal detection and monitoring was found out for: i) early left

ventricular ejection fraction dysfunction, coronary artery disease,

valvular heart disease; ii) secondary acute myeloid leukemias/ myelo-

displastic syndromes and solid tumors; iii) metabolic syndrome, thy-

roid, gonadal, and mineral bone disorders; iv) peripheral neuropathy,

fatigue, cognitive impairment, anxiety and depression. Fertility pres-

ervation and correction of unhealthy lifestyles were also examined.

Conclusion: The ﬁnal documents could be a reasonable bridge from

evidence to decision in order to improve the clinical practice and

customize the general follow‐up approach of cHL and DLBCL

survivors.

EA – previously submitted to EHA 2021.

Keywords: Late Effects in Lymphoma Survivors

No conﬂicts of interests pertinent to the abstract.

393 |HEALTHCARE RESOURCE UTILIZATION IN PATIENTS

WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC

LEUKEMIA USING REAL‐WORLD DATA FROM FIVE COUNTRIES

C. Cool

, C. Feng

, S. Wade

, R. Rau

, K. Ching

, L. Nyamutswa

H. Viswanathan

, B. Kharabi

, A. Duvall

Precision Value & Health, PRECISIONheor, New York, New York, USA,

Kite Pharma, A Gilead Company, Global Health Economics and

Outcomes Research, Santa Monica, California, USA,

Wade Outcomes

Research and Consulting, Health Economics, Salt Lake City, Utah, USA,

University of Chicago, Department of Medicine, Section of Hematology/

Oncology, Chicago, Illinois, USA

Introduction: About half of acute lymphoblastic leukemia (ALL) pa-

tients relapse, and outcomes are poor in relapsed or refractory (R/R)

ALL patients with the current standard of care. Healthcare resource

utilization (HRU) by line of therapy (LoT) in R/R ALL patients is not

well studied. This study aims to assess their HRU by LoT.

Methods: A retrospective review of R/R ALL patient charts by 243

oncologists in the United Kingdom, France, Germany, Italy, and Spain

was conducted. Patients were treated at second‐line (2L) or third‐line

(3L) between January 2015 and December 2018. HRU including hos-

pitalizations, length of stay (LoS), Intensive Care Unit (ICU) days, and

Emergency Room (ER) visits was assessed and stratiﬁed by patients' R/

R status [primary refractory, relapsed without Stem Cell Transplant

(SCT), or relapsed post SCT] and LoT. Baseline characteristics and in-

duction regimens were summarized. HRU for induction or SCT was

excluded.

Results: Data on 725 and 309 R/R ALL patients who started 2L and 3L

respectively were analyzed (Table 1). Sample size varied by outcome.

Median ages were 53 years (2L) and 50 years (3L). The majority were

male (2L: 72.1%; 3L: 64.1%), and about a quarter were Philadelphia‐

positive (2L: 25.2%; 3L: 25.6%). 34.5% (2L) and 47.6% (3L) of pa-

tients were treated with new regimens (blinatumomab or inotuzu-

mab). Over the duration of therapy (DoT) (2L: 7.7 months, 3L: 7.4

months), the percent of patients hospitalized ranged over varying R/R

status from 27.1% to 39.7% (2L) and 27.4% to 47.6% (3L). For both 2L

and 3L, relapsed patients post SCT had higher hospital and ER use

compared to primary refractory and relapsed patients without SCT.

Conclusions: HRU is substantial for R/R ALL. Relapsed patients post

SCT had more hospitalizations and ER visits compared to other R/R

ALL patients. There is a need for more effective therapies with po-

tential to reduce HRU for R/R ALL.

The research was funded by: Kite Pharma, A Gilead Company

Keywords: Cancer Health Disparities, Molecular Targeted Therapies,

Combination Therapies

Conﬂicts of interests pertinent to the abstract

C. Cool

Employment or leadership position: PRECISIONheor

C. Feng

Employment or leadership position: Kite Pharma, Boston Scientiﬁc

Stock ownership: Kite Pharma/Gilead, Boston Scientiﬁc, Sanoﬁ, Pﬁzer

TABLE 1HRU of R/R ALL by R/R status and LoT

SUPPLEMENT ABSTRACTS

479

Educational grants: Kite Pharma/Gilead; Boston Scientiﬁc

S. Wade

Consultant or advisory role: Kite Pharma

R. Rau

Employment or leadership position: PRECISIONheor

K. Ching

Employment or leadership position: PRECISIONheor

L. Nyamutswa

Employment or leadership position: Kite Pharma

Stock ownership: Kite Pharma/Gilead

H. Viswanathan

Employment or leadership position: PRECISIONheor

B. Kharabi

Employment or leadership position: Kite Pharma

Stock ownership: Kite Pharma, GSK, Immatics, Novartis, BMS, Roche

Educational grants: Kite Pharma

TABLE 1Subtypes of malignant lymphomas in Ukraine, according to 2016 WHO classiﬁcation

480

SUPPLEMENT ABSTRACTS

394 |BURDEN OF MULTIPLE MYELOMA IN CHINA: AN

ANALYSIS OF THE GLOBAL BURDEN OF DISEASE, INJURIES, AND

RISK FACTORS STUDY 2019

W. Liu

, J. Liu

, L. Mi

, C. Cai

, T. Gong

, J. Ma

, L. Wang

Peking University Cancer Hospital & Institute, Department of

Lymphoma, Beijing, China,

National Center for Chronic and

Noncommunicable Disease Control and Prevention, Chinese Center for

Disease Control and Prevention, National Center for Chronic and

Noncommunicable Disease Control and Prevention, Beijing, China,

Beijing Institute of Survey and Mapping, Beijing Municipal Key

Laboratory of Urban Spatial Information Engineering, Beijing Institute

of Survey and Mapping, Beijing, China,

Harbin Institute of

Hematology & Oncology, Harbin Institute of Hematology & Oncology,

Harbin, China

Background: The burden of multiple myeloma (MM) is increasing

over time in China. However, there is limited data to evaluate

comprehensively the epidemiological characteristics of MM.

Methods: Following the general analytical strategy used in Global

Burden of Disease, Injuries, and Risk Factors Study 2019, we ana-

lysed the burden of MM including incidence, mortality, prevalence

and disability‐adjusted life years (DALYs) with 95% uncertainty in-

terval (UI) in China. Trends in burden of MM from 1990 to 2019 were

evaluated.

Results: There were an estimated 347.45 thousands DALYs with an

age‐standardized DALYs rate of 17.05 (95% UI, 12.31‐20.77) per

100,000 population in 2019. The estimated incidence case and

deaths of MM were 18.79 thousands and 13.42 thousands, with age‐

standardized incidence and mortality rates of 0.93 (95%UI, 0.67‐

1.15) and 0.67 (95%UI, 0.50‐0.82) per 100 000 population. The age‐

speciﬁc DALYs rates per 100,000 population increased more than 10

at age group 40‐44 and reached a peak (93.82) at age group 70‐74.

Males had higher burden than females with about 1.5‐2 folds sexual

differences in age‐speciﬁc DALYs rates in all age groups. From 1990

to 2019, the DALYs number of MM increased by 134% with changing

from 148.48 thousands in 1990 to 347.45 thousands in 2019.

Conclusion: The burden of MM increased doubly during the past 3

decades, which highlighted the need of establishment of effective

disease prevention and control strategies in both national and pro-

vincial levels.

Keywords: Multiple Myeloma

No conﬂicts of interests pertinent to the abstract.

395 |SUBTYPES OF MALIGNANT LYMPHOMAS IN UKRAINE,

ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY

REPORT OF THE UKRAINIAN LYMPHOMA REGISTRY

T. Skrypets

, Y. Stepanishyna

, G. R. Galli

, M. Manni

, A. Hubareva

I. Tytorenko

, A. Martynchyk

, O. Aleksik

, N. Shudrak

Y. Pastushenko

, O. Novosad

, K. Filonenko

, T. Kadnikova

Y. Kushchevyi

, M. Federico

, I. Kriachok

University of Modena and Reggio Emilia, PhD Program in Clinical and

Experimental Medicine, Modena, Italy,

National Cancer Institute,

Department of Oncohematology, Kyiv, Ukraine,

Associazione Angela

Serra, Associazione Angela Serra for Cancer Research, Lecce, Italy,

University of Modena and Reggio Emilia, CHIMOMO, Modena, Italy,

Ukrainian Lymphoma Study Group, Ukrainian Lymphoma Study Group,

Kyiv, Ukraine

Introduction: According to the Ukrainian National Cancer Registry,

Malignant Lymphoma (ML) represent the 9th most frequent type of

cancer, with age‐standardized rates of 8.4 for males and 6.6 for fe-

males. Unfortunately, no data on subtypes of ML are reported

neither by WHO2008 nor the updated WHO2016 classiﬁcation.

There is a lack of information on real incidence, clinical presentation,

outcome of different subtypes, and performances of the healthcare

system in Ukraine. In 2019, the Ukrainian lymphoma registry (ULR)

was established and here we report the preliminary analysis of the

ﬁrst 432 cases registered, based on local histological diagnosis.

Methods: The ULR prospectively collects information on baseline

clinical and disease characteristics, ﬁrst‐line treatment, and response

evaluation of new cases of ML classiﬁed according to the most recent

WHO2016 classiﬁcation. Registration was performed on‐line on a

secured dedicated database. Electronic Case Report Forms were

reviewed and veriﬁed by the ULR team.

Results: ULR was launched in October, 2019. So far, 432 patients

with newly diagnosed ML were registered. The median age is 45.9

years (range 17‐99), 40,6% were male, and 59,4% ‐female. By age

distribution, 20,6% of patients were under 30 years old, 37,8% be-

tween 30 ‐49, 22,7% in 50‐64, while 18,9% were over 65. Overall,

64% of the population is affected by mature B‐cell neoplasms, 32%

by Hodgkin lymphoma and 4% by mature T and NK‐cell neoplasms.

As reported in Table 1, DLBCL (24.7% of cases) represents the most

frequent subtype of B‐cell malignancies, followed by CLL/SLL (7.7%)

and FL (7.6%). A high incidence of PMBCL (7.0%) and PCNSL (4.6%),

was observed. With respect to mature T and NK‐cell lymphomas,

ATLL and AITL resulted the most frequent sub‐types.

Conclusions: Our preliminary ULR data provides the ﬁrst compre-

hensive analysis on the distribution pattern of ML in Ukraine, clas-

siﬁed according to the recent WHO classiﬁcation. As expected

considering the Ukrainian population age structure, a high percent-

age of ML are represented by HL, while a limited number of FL have

been found, suggesting a possible different genetic predisposition to

this subtype in the Ukrainian population. In conclusion, regardless its

very young age, ULR is recruiting very well and may help to better

investigate the outcome of patients with ML outside clinical trials, in

the real world.

The research was funded by: Associazione Angela Serra for

Cancer Research, Italy

Keywords: Pathology and Classiﬁcation of Lymphomas

SUPPLEMENT ABSTRACTS

481

No conﬂicts of interests pertinent to the abstract.

396 |THE SURVIVAL OF 2852 PATIENTS WITH LYMPHOMA: A

SINGLE CENTER STUDY FROM CHINA

L. Zhang

, Z. Sun

, X. Fu

, W. Wan

, J. Ge

, Y. Xia

, D. Xu

, F. Nan

, H.

, M. Zhang

, L. Li

, X. Li

, Z. Li

, X. Wang

, Y. Chang

, J. Yan

, X.

, Z. Zhou

The First Afﬁliated Hospital of Zhengzhou University, Department of

Oncology, Zhengzhou, China

Background: Hospital type can also affect the treatment outcome

and prognosis of patients with lymphoma. This study was to describe

the survival of lymphoma patients admitted to an academic center in

China over the past decade.

Methods: The survival and prognosis of 2852 patients with lym-

phoma admitted to an academic center in China in the past decade

were retrospectively analyzed.

Results: The 5‐year OS for 269 patients with Hodgkin lymphoma

(HL) were 91.3%. In 1744 patients with mature BCL, the patients

with follicular lymphoma (FL) had the highest 5‐year OS rate (75.3%),

followed by Burkitt lymphoma (71.2%), diffuse large B‐cell lymphoma

(62.0%), small lymphocytic lymphoma/chronic lymphocytic leukemia

(60.5%), and mantle cell lymphoma (50.7%). In 712 patients with

mature T and NK cell lymphomas, the 5‐year OS rate was highest in

ALK+anaplastic large cell lymphoma (68.6%), followed by natural

killer/T‐cell lymphoma (61.4%), ALK−anaplastic large cell lymphoma

(43.0%), peripheral T‐cell lymphoma not otherwise speciﬁed (40.4%)

and angioimmunoblastic T‐cell lymphoma (37.1%). In 127 patients

with lymphoblastic lymphoma, the 5‐year OS rate were 36.3% and

32.1% in B cell lymphoblastic lymphoma and T cell lymphoblastic

lymphoma, respectively.

Conclusion: The survival rate of patients with natural killer/T‐cell

lymphoma or HL in our center are numerically higher than that of

other domestic and foreign centers (currently reported). The sur-

vival rate of patients with mature BCL is similar with other

centers.

The research was funded by: National Natural Science Founda-

tion of China(Grant No. 81970184)

Keywords: Lymphoid Cancers ‐Other

No conﬂicts of interests pertinent to the abstract.

397 |COCHRANE HAEMATOLOGY REVIEWS TO INFORM

WORLD HEALTH ORGANIZATION'S LIST OF ESSENTIAL

MEDICINES ON CLINICAL VALUE OF HIGH‐PRIORITY CANCER

MEDICINES

V. Piechotta

, C. Hirsch

, M. Ernst

, M. Goldkuhle

, L. Moja

, N.

Skoetz

University of Cologne, Cochrane Haematology, Department I of

Internal Medicine, Center for Integrated Oncology Aachen Bonn

Cologne Duesseldorf, Faculty of Medicine and University Hospital,

Cologne, Germany,

World Health Organization, Department of

Essential Medicines and Health Products, Geneva, Switzerland,

University of Cologne, Cochrane Cancer, Department I of Internal

Medicine, Center for Integrated Oncology Aachen Bonn Cologne

Duesseldorf, Faculty of Medicine and University Hospital, Cologne,

Germany

Introduction: Essential medicines aim to satisfy the priority health

needs of a population. In 2019, cancer medicines made up 12% of

all listed medicines in the World Health Organization's Essential

Medicines List (EML). Every other year, scientists and stakeholders

worldwide are invited to prepare evidence‐based applications for

the inclusion of novel medicines, and changes to or deletion of

currently listed medicines in order to reﬁne and update the EML.

Our aim is to illustrate the value of Cochrane Haematology sys-

tematic reviews for the revision of antineoplastic therapeutics listed

in the EML.

Methods: As part of a prioritisation within Cochrane Haematology

and the EML cancer medicines working group,we identiﬁed a need

to systematically review multiple antineoplastic therapeutics for

the treatment of multiple myeloma and B‐cell lymphomas. We

prepared ﬁve Cochrane reviews according to standard Cochrane

methodology to review the efﬁcacy and safety of the treatments in

question, and integrated the results as evidence body into three

EML applications.

Results: Based on the results of the Cochrane reviews, we prepared

EML applications for the inclusion of four individual medicines

(bortezomib, daratumumab, lenalidomide, and thalidomide) for the

treatment of multiple myeloma. A ﬁfth review contributed to the

work of the EML Committee providing information on the beneﬁts,

harms, production, and access to CAR‐T therapies, suggesting to

monitor these treatments over time. A potential candidature of CAR‐

T cell therapies for diffuse large B‐cell lymphoma might be possible in

the near future.

Bortezomib, lenalidomide, and thalidomide were included in the

21st EML that was published in 2019. Proposals on daratumumab

and CAR‐T cells are available for public review on the WHO website

and will be discussed during the 23rd WHO Expert Committee on the

Selection and Use of Essential Medicine in June 2021.

Conclusions: Using Cochrane Haematology reviews to inform the

EML allows to adequately consider potential biases and un-

certainties in the available evidence in order to identify essential

treatment options in haemato‐oncology. The EML process is also

an opportunity for Cochrane to expand on dimensions such as

medicine development, logistics and purchase and procurement

agreements.

EA – previously submitted to EHA 2021.

Keywords: Cancer Health Disparities

No conﬂicts of interests pertinent to the abstract.

482

SUPPLEMENT ABSTRACTS

398 |PRIORITISATION OF RELEVANT COCHRANE REVIEW

TOPICS IN THE FIELD OF HAEMATOLOGY

C. Hirsch

, T. Jakob

, E. Tomlinson

, L. Estcourt

, S. Theurich

, S.

Ocheni

, N. Skoetz

, V. Piechotta

Cochrane Haematology, Department I of Internal Medicine, Center

for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty

of Medicine and University Hospital, University of Cologne, Cologne,

Germany,

Cochrane Cancer Network, Royal United Hospital, Bath, UK,

Cochrane Haematology, Haematology/Transfusion Medicine, NHS

Blood and Transplant, Oxford, UK,

Department of Medicine III,

University Hospital LMU, Ludwig‐Maximilians‐Universität München,

Munich, Germany,

Department of Haematology & Immunology,

University of Nigeria, Ituku‐Ozalla Campus, Enugu, Nigeria,

Cochrane Cancer, Department I of Internal Medicine, Center for

Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of

Medicine and University Hospital, University of Cologne, Cologne,

Germany

Background: Cochrane Haematology produces, publishes and

maintains systematic reviews in the ﬁeld of haematology. The group

wants to ensure that their limited resources and efforts are being

used to produce Cochrane reviews addressing topics that are of

utmost importance to their end‐users. According to one of

Cochrane's key principle ‘striving for relevance' the group initialised

their ﬁrst priority setting exercise engaging stakeholders worldwide

to identify the top priority topics for Cochrane Haematology re-

views. The aim was to identify the top ten priority topics for review

updates and the top ﬁve priority topics for new Cochrane Haema-

tology reviews as part of Cochrane Haematology's priority setting

exercise.

Methods: The priority setting exercise consisted of two phases. In

phase one, potential priority topics were generated by identifying

trends (analysing review metrics) and gaps (screening for priority

topics of the American Society of Hematology (ASH), the Euro-

pean Hematology Association (EHA), the German Society for

Hematology and Oncology (DGHO) and the James Lind Alliance

(JLA) in the ﬁeld of hematology) in the current review portfolio.

In the second phase, the identiﬁed topics were then prioritised

by various stakeholders in an online survey. Respondents were

asked to select the topics they deemed to be of high priority and

rank them afterwards from highest to lowest priority. An average

score was then calculated for each ranked topic. Topics with the

highest average score were identiﬁed as being the top priority

topics.

Results: The online survey was open between July 6th 2020 to

August 28th 2020. A total of 160 responses were collected, of which

63 respondents (39%) provided complete responses. Most of the

respondents identiﬁed themselves as physician (34%), someone who

is or has been affected by haematological disease (31%), or researcher

(24%) and were distributed across 21 countries. The highest number

of respondents resided in the United Kingdom (n =72), Germany (n =

20) and Canada (n =11). The top ten priority topics for reviews that

need updating were related to interventions in multiple myeloma,

hodgkin lymphoma and topics from the areas of stem cell trans-

plantation and supportive care for haematological diseases. The top

ﬁve priority topics for new reviews addressed mainly myelodysplastic

syndrome (MDS), relapse of disease post‐haematopoietic stem cell

transplant and long‐term survival in cancer.

Conclusion: The priority setting process engaged various stake-

holders and identiﬁed the most relevant review topics, published on

Cochrane Haematology's website. These topics, some of them are

open to new authors, will now guide the group's future scope of work

and ensure that the most important reviews are updated. New pri-

ority reviews will close gaps within the review portfolio of Cochrane

Haematology.

EA – previously submitted to regional or national meetings (up to

1000 attendees) and EHA 2021.

Keywords: Cancer Health Disparities, Lymphoid Cancers ‐Other

No conﬂicts of interests pertinent to the abstract.

399 |CLINICAL, LABORATORY, IMAGING FINDINGS AND

TREATMENT OF 60 CASES WITH CASTLEMAN'S Disease

Q. Siyu

, Z. Xudong

The First Afﬁliated Hospital of Zhengzhou University, Oncology

Department, Zhengzhou, China

Purpose: Castleman disease is a rare lymphoproliferative disorder

with low prevalence, the clinical study of CD is mainly among case

reports and small series trials. We want to provide more detailed

clinical information of this rare disease to offer some insight for the

management and treatment of CD patients.

Methods: We retrospectively collected the clinical information of 60

CD patients diagnosed in the First Afﬁliated Hospital of Zhengzhou

University with unbridged follow‐up data.

Results: We analyzed the detailed information of 60 patients (19

with UCD and 41 with MCD). The most common pathology type of

UCD is HV, whereas PC and Mix much expresses for MCD.

Asymptomatic and lymphadenopathy are more common in UCD,

whereas fever is more common in MCD. MCD patients were more

likely to show anemia, hypoproteinemia, abnormal A/G, abnormal

platelet count, as well as elevation of LDH and urinary protein

than UCD patients according to laboratory test information. In

addition, EBV and cytomegalovirus were found positive in

approximately 87.0% of the tested patients with MCD more than

UCD (75.0%). The most common region of lymphadenopathy in

MCD patients is neck (80.5%), the UCD patients (65.0%) as well.

SUVmax of PET‐CT was signiﬁcantly higher in MCD than in the

UCD group (6.8±4.2 and 2.8±0.7, respectively). Thrombocytopenia,

splenomegaly and elevated β2‐MG were deﬁned as the

SUPPLEMENT ABSTRACTS

483

independent poor prognosis factor of CD. Surgical resection is the

ﬁrst choice for the treatment of UCD, and there is no standard

treatment for MCD.

Conclusions: The present work increase understanding on the dif-

ference between UCD and MCD from clinical various aspects which

provide a comprehensive evaluation of CD patients for better diag-

nosis and treatment.

The research was funded by: The paper is supported by National

Natural Science Foundation of China (Grant No.82070209) and

(Grant N0.82070210).

Keywords: Diagnostic and Prognostic Biomarkers, PET‐CT, Pathology

and Classiﬁcation of Lymphomas

No conﬂicts of interests pertinent to the abstract.

484

SUPPLEMENT ABSTRACTS

DOI: 10.1002/hon.2882

SUPPLEMENT ABSTRACT

INDUSTRY PROGRAM – SATELLITE SYMPOSIUM AGENDA

Friday, June 18

Time Channel Session Article/ abstract nr.

12:00 – 13:30 Channel 1 Janssen Oncology Pharmaceutical Companies of Johnson & Johnson

PRECISION MEDICINE IN LYMPHOMA: WHAT DOES IT MEAN?

Chair: John Gribben, London (UK)

The power of precision medicine lies in its ability to guide health care decisions toward the

most effective treatment strategy for a given patient, and thus, improve the quality of

patient care. In this symposium, the expert faculty will evaluate what precision

medicine means for the management of patients with B‐cell lymphomas. Professor John

Gribben will lead a structured roundtable discussion with Professor Steven le Gouill,

Professor Steve Treon and Professor Catherine Thieblemont to consider how aspects

of precision medicine can be applied in different lymphomas to improve patient care

and clinical outcomes. EM‐61522

Welcome and introduction

John Gribben, London (UK)

Structured roundtable discussion: What does precision medicine mean for the

management of lymphoma now and in the future?

Steven Le Gouill, Nantes (France)

Catherine Thieblemont, Paris (France)

Steve Treon, Boston (USA)

All faculty, moderated by John Gribben, London (UK)

Q&A live session

All faculty, moderated by John Gribben, London (UK)

Closing remarks

John Gribben, London (UK)

12:00 – 13:30 Channel 2 AstraZeneca

EVOLVING STRATEGIES USING BTK INHIBITORS IN CLL: A SELECTIVE APPROACH TO

IMPROVE PATIENT OUTCOMES

Chair: Paolo Ghia, Milan (Italy)

In this CME‐certiﬁed, live webinar on 18 June 2021 at 12.00 CEST, Drs. Paolo Ghia, George

A. Follows, and Veronique Leblond will discuss the evolving global strategies around

using BTK inhibitors in CLL, including the current role of BTKi in CLL, safety concerns,

and a discussion of patient cases. Attendees will have the opportunity to have questions

answered by these experts, enhancing the interactivity of this webinar.

(Continues)

All session times for the 16‐ICML Virtual edition follow the Central European Summer Time (CEST)

Hematological Oncology. 2021;39(S2):485–493. wileyonlinelibrary.com/journal/hon

485

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

The Current Role of BTK Inhibitors in CLL

Paolo Ghia, Milan (Italy)

A Focus on Safety of BTK inhibitors in the Management of CLL

George Follows, Cambridge (UK)

Practical Case Discussions: Selecting BTK inhibitor Therapy in CLL

Véronique Leblond, Paris (France)

12:00 – 13:15 Channel 3 MSD

EXPLORING THE UTILITY OF NOVEL TARGETS IN LYMPHOMAS

Chair: Ulrich Jaeger, Vienna (Austria)

Educational Objectives

Review the most recent data and the actual treatment landscape in cHL

Review the treatment options with BTK inhibitors in CLL and NHL

12:00 ‐12:10 Welcome and introduction

Ulrich Jaeger, Vienna (Austria)

12:10 – 12:35 Current treatment landscape in Classical Hodgkin‘s Lymphoma

Jane Winter (USA)

12:35 – 13:00 Bruton‘s Tyrosine Kinase (BTK) inhibition: past, present, future

Paolo Ghia (Italy)

13:00 – 13:10 Q&A Live Panel Discussion

All faculty

13:10 – 13:15 Closing remarks

Ulrich Jaeger, Vienna (Austria)

12:00 – 13:30 Channel 4 ADC Therapeutics

ELEVATE YOUR KNOWLEDGE ON NOVEL ANTIBODY‐BASED THERAPIES TO TREAT

R/R DLBCL

Chair: Carmelo Carlo‐Stella, Milan (Italy)

Although ﬁrst‐line chemoimmunotherapy for diffuse large B‐cell lymphoma (DLBCL) is

highly effective, a substantial proportion of patients develop relapsed or refractory

(R/R) disease, which is associated with poor survival outcomes. While current salvage

treatments can provide effective disease control in eligible patients with R/R DLBCL,

treatment options are limited, and many patients still experience disease progression.

Join this year’s ADC Therapeutics Satellite Symposium where a panel of experts,

chaired by Prof. Carmelo Carlo‐Stella, discuss the evolving treatment landscape in R/R

DLBCL and the role novel antibody‐based therapies might have in meeting this urgent

unmet need.

12:00 Welcome and Introduction

Carmelo Carlo‐Stella, Milan (Italy)

12:01 – 12:20 Aiming to meet the unmet need in R/R DLBCL with novel antibody‐based therapies

Sonali Smith, Chicago, IL (USA)

12:20 – 12:45 CD19 as a target in DLBCL

Weiyun Z. Ai, San Francisco, CA (USA)

12:45 – 13:10 Clinical data on CD19‐targeted antibody‐based therapies in R/R DLBCL

486

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

Carmelo Carlo‐Stella, Milan (Italy)

13:10 – 13:30 Live Q&A Discussion and Closing Remarks

14:00 – 15:30 Channel 1 Bristol Myers Squibb

ARE WE GOING TOWARDS A NEW CARE PARADIGM IN FL AND CLL?

Chair: Stefano Luminari, Reggio Emilia (Italy)

Please join this Bristol Myers Squibb supported Satellite Symposium on the changing

treatment landscape of Follicular Lymphoma (FL) and Chronic Lymphocytic Leukemia

(CLL) at the 16th ICML Virtual Edition. During the Symposium, Prof. Luminari and Dr.

Kittai will address the parameters to deﬁne the treatment goals in patients with FL and

CLL respectively and discuss the current treatment options including chemotherapy

free approaches in FL and CLL. In addition, the question whether chemotherapy‐free

regimens will replace chemotherapy at least for some subgroups of patients will also be

addressed. After the presentations, you are encouraged to join the discussion with the

expert speakers during the live Q&A session.

14:00 – 14:05 Welcome and Introduction

Stefano Luminari, Reggio Emilia (Italy)

14:05 – 14:30 Follicular Lymphoma: re‐setting the treatment goals and is chemotherapy here to stay in

FL?

Stefano Luminari, Reggio Emilia (Italy)

14:30 – 14:55 Chronic Lymphocytic Leukemia: re‐setting the treatment goals and is chemotherapy here

to stay in CLL?

Adam S. Kittai, Columbus, OH (USA)

14:55 – 15:30 Q&A and discussion

All faculty, moderated by Stefano Luminari

Closing remarks

Stefano Luminari, Reggio Emilia (Italy)

14:00 – 15:30 Channel 2 Medscape (supported by an independent educational grant from Takeda)

SPOTLIGHT ON LYMPHOMA: ADDRESSING REAL WORLD CLINICAL CHALLENGES

FOR HL AND PTCL

Chair: Timothy Illidge, Manchester (UK)

In this live virtual symposium, three expert faculty will navigate the changing landscape for

the treatment of HL and PTCL. The faculty will explore factors to consider when

choosing among the available treatment options for both frontline and relapsed/

refractory HL, with an emphasis on how to best sequence these treatments. The faculty

will also discuss newly available therapies for the frontline treatment of PTCL, including

how to manage adverse effects related to their use. Patient cases will be presented to

illustrate these concepts, and the faculty panel will discuss evidence‐based

management of these challenging cases.

14:00 – 14:05 Welcome and Introductions

Timothy Illidge, Manchester (UK)

14:05 – 14:40 Spotlight on the Treatment of HL: Which Regimen, for Which Patient?

Martin Hutchings, Copenhagen (Denmark) and Anna Sureda, Barcelona (Spain)

14:40 – 15:10 Spotlight on the Treatment of Newly Diagnosed PTCL: Incorporating New Therapies Into

the Treatment Paradigm

Timothy Illidge, Manchester (UK)

(Continues)

487

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

15:10 – 15:30 Shifting Focus: What Do You and the Experts Think?

Q&A Live Session

Timothy Illidge, Manchester (UK), Martin Hutchings, Copenhagen (Denmark) and Anna

Sureda, Barcelona (Spain)

Adjourn

14:00 – 15:30 Channel 3 AbbVie

NOT ALL BISPECIFIC ANTIBODIES ARE CREATED EQUAL

Chair: Gilles Salles, New York, NY (USA)

We will consider how bispeciﬁc antibodies offer a novel approach and treatment paradigm

for patients with non‐Hodgkin lymphoma (NHL). The science and rationale for bispeciﬁc

antibodies in NHL will be discussed as we take a look at the mechanistic differences in

the bispeciﬁc CD3xCD20 class. We will then review the latest preclinical and early

phase data, consider where bispeciﬁc antibodies ﬁt into the future treatment algorithm,

and ﬁnish by opening the ﬂoor for questions from the audience.

Welcome and Introduction

Gilles Salles, New York, NY (USA)

Bispeciﬁc antibodies: a mechanistic review of the pipeline

John Gribben, London (UK)

Emerging clinical data for bispeciﬁc antibodies in NHL

Sarit Assouline, Montreal, Quebec (Canada)

Future perspectives on bispeciﬁc antibodies in NHL

Gilles Salles, New York, NY (USA)

Live Q&A session and closing remarks

All speakers

14:00 – 15:30 Channel 4 Pﬁzer Oncology

COVID‐19 IN CLL AND B CELL MALIGNANCIES

Chair: Toby Eyre, Oxford (UK)

Introductory remarks on COVID 19 ‐Perspective on hematological malignancies patients

and clinical research in the era of COVID‐19

Toby Eyre, Oxford (UK)

Clinical outcomes of CL patients with COVID‐19

Lindsey Roeker, New York, NY (USA)

Clinical outcomes of B cell lymphoma patients with COVID‐19

Toby Eyre, Oxford (UK)

Vaccine efﬁcacy in patients with B cell malignancies and impact of anti CD20 antibodies

and other targeted therapies on humoral immunity

David Knorr, New York, NY (USA)

16:00 ‐17:30 Channel 1 Kite, a Gilead Company

BUILDING ON SURVIVAL IN CELL THERAPY: FOCUS ON THE FUTURE

Chair: John Gribben, London (UK)

CAR T‐cell therapy continues to reshape the R/R NHL landscape, with multiple CAR T‐cell

products now licensed in Europe and the US. Despite successes, questions remain on

the future of CAR T‐cell therapy. During this interactive symposium, our faculty will

discuss how we deﬁne survival in lymphoma, examine the impact of CAR T product on

survival and share insights into patient management optimisation. Finally, they will

488

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

explore future directions and advances in cell therapy. We encourage you to take the

opportunity to participate in the voting questions and live Q&A, where the faculty will

discuss questions submitted by the audience.

Welcome and introduction: We have come so far…

John Gribben, London (UK)

How is CAR T reshaping survival in lymphoma?

Armando López‐Guillermo, Barcelona (Spain)

What is the impact of the CAR T product on achieving survival?

Frederick Locke, Tampa, FL (USA)

How can we optimise patient management?

John Gribben, London (UK) and Marion Subklewe, Munich (Germany)

New directions: What does the future hold?

Caron Jacobson, Boston, MA (USA)

Live audience Q&A

All faculty

16:00 ‐17:30 Channel 2 Incyte

PEARLS OF KNOWLEDGE: EXPERT PERSPECTIVES IN THE TREATMENT OF R/R DLBCL

Patients with relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who are

transplant‐ineligible tend to have very poor outcomes. There is no standard of care, and

the currently available treatments generally result in responses that are not durable. In

this symposium, we address key unmet needs for these patients with a series of short

videos from DLBCL experts outlining various aspects of how they treat their patients

with R/R DLBCL.

What is your goal for second‐line treatment and further for patients with transplant‐

ineligible R/R DLBCL?

Pier Luigi Zinzani, Bologna (Italy)

What is the role of chemo‐free regimens for the treatment of R/R DLBCL?

Marco Ladetto, Alessandria (Italy)

How do you decide which treatment option to use for patients with transplant‐ineligible

R/R DLBCL? What is the role of new molecules with targets other than CD20?

Georg Lenz, Münster (Germany)

What are your expectations of median PFS and DoR for patients with non‐transplant

eligible R/R DLBCL with the current treatment options? What would you consider to be

a good response? When would you consider a patient to be cured?

Johannes Düll, Würzburg (Germany)

Which therapies would you consider (will be considering) for patients with transplant‐

ineligible R/R DLBCL with CNS involvement?

Martin Dreyling, Munich (Germany)

What is your approach to the treatment of patients with double‐or triple‐hit R/R DLBCL?

Guillaume Cartron, Montpellier (France)

In your experience, are most transplant‐ineligible patients also ineligible for CAR T‐cell

therapy?

Roch Houot, Rennes (France)

(Continues)

489

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

What challenges have you experienced with the early identiﬁcation of patients eligible for

CAR T‐cell therapy?

Eva González Barca, Barcelona (Spain)

Which adverse events are of concern to you when treating patients with transplant‐

ineligible R/R DLBCL?

Christopher Fox, Nottingham (UK)

In what way does your approach to treatment differ for patients with transplant‐ineligible

R/R DLBCL who relapse early compared with those who relapse at a later stage?

Armando López‐Guillermo, Barcelona (Spain)

16:00 ‐17:30 Channel 3 Regeneron

EVOLVING TREATMENT PARADIGM FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐

CELL LYMPHOMA

Chair: Pier Luigi Zinzani, Bologna (Italy)

The treatment landscape for patients with relapsed/refractory (R/R) diffuse large B‐cell

lymphoma DLBCL has expanded with therapeutic advances involving novel targets and

modalities. New agents under investigation for R/R DLBCL include bispeciﬁc antibodies,

which are designed to facilitate T‐cell activation against tumor cells by binding targets

on T cells and tumor cells simultaneously. This symposium will highlight considerations

for treating patients with R/R DLBCL using newly available therapies, and discuss the

potential impact of emerging bispeciﬁc agents on the treatment paradigm in DLBCL. A

question‐and‐answer session will provide the opportunity for participants to engage

with faculty experts.

Current Landscape and Recent Therapeutic Advances in the Management of R/R DLBCL

Pier Luigi Zinzani, Bologna (Italy)

Considerations for Evaluating Treatment Options for Patients with R/R DLBCL

John Kuruvilla, Toronto (Canada)

Understanding Emerging Bispeciﬁc Therapies

Jeremy Abramson, Boston, MA (USA)

Panel Discussion: Exploring the Potential Impact of Bispeciﬁc Therapies on the DLBCL

Treatment Paradigm

Pier Luigi Zinzani, Bologna (Italy)

John Kuruvilla, Toronto (Canada)

Jeremy Abramson, Boston, MA (USA)

17:15 – 17:30 Live Q&A session

John Kuruvilla, Toronto (Canada) and Jeremy Abramson, Boston, MA (USA)

16:00 ‐17:30 Channel 4 Bayer

THE EVOLVING TREATMENT LANDSCAPE AND EMERGING NOVEL THERAPIES IN

INDOLENT NON‐HODGKIN’S LYMPHOMA (iNHL)

Chair: Martin Dreyling, Munich (Germany)

Despite the recent advances in the treatment of iNHL, many patients with advanced

disease experience relapse and resistance to ongoing therapies, underscoring the need

to identify novel treatment options and appropriate treatment combinations. In this

Bayer‐sponsored symposium, our esteemed faculty will explore the evolving treatment

landscape and promising therapies for iNHL, including various chemotherapy‐free

treatment options such as targeted therapies (eg, PI3K inhibitors), CAR‐T therapy, and

bispeciﬁc antibodies. Current and emerging treatment options for relapsed follicular

lymphoma (FL) and marginal zone lymphoma (MZL) will be discussed in detail, with a

490

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

focus on recent key clinical data and ongoing clinical trials. A live Q&A session will

provide an opportunity for participants to interact with the faculty experts.

Welcome and Opening Remarks

Martin Dreyling, Munich (Germany)

Current Treatment Landscape and Emerging Therapies in iNHL

Gilles Salles, New York, NY (USA)

The Evolving Therapeutic Options for Patients With Follicular Lymphoma After First

Relapse

Pier Luigi Zinzani, Bologna (Italy)

How to Treat Relapsed Marginal Zone Lymphoma? Challenges and Clinical Considerations

Christian Buske, Ulm (Germany)

Live Q&A live session

All panelists, led by Martin Dreyling, Munich (Germany)

18:00 – 19:30 Channel 1 Bristol Myers Squibb

ADVANCEMENTS OF CAR T CELL THERAPIES IN B‐CELL MALIGNANCIES

Chair: David Maloney, Seattle WA (USA)

Please join this Bristol Myers Squibb supported Satellite Symposium on the Advancements

of CAR T cell therapies in B‐cell malignancies at the 16th ICML Virtual Edition. During

the Symposium, Dr. Maloney and Prof. Mateos will present an overview of the latest

data on the use of CAR T cell therapy in DLBCL and Myeloma respectively; how use of

CAR T therapy could be optimized and could shape the treatment landscape in B‐cell

malignancies. Dr. Michael Hudecek will then share his translational insights, with a

speciﬁc focus on improving patient selection and optimizing outcome. Following the

presentations, there will be an opportunity to interact with the faculty at the live Q&A

session.

18:00 – 18:05 Welcome and Introduction

David Maloney, Seattle WA (USA)

18:05 – 18:25 Evolution of the CAR T treatment paradigm in DLBCL

David Maloney, Seattle WA (USA)

18:25 – 18:45 Prime time for CAR T cell therapy in multiple myeloma

Maria‐Victoria Mateos, Salamanca (Spain)

18:45 – 19:05 Understanding scientiﬁc advancements with CAR T cell therapy

Michael Hudecek, Wurzburg (Germany)

19:05 – 19:30 Q&A and discussion

All faculty, moderated by David Maloney, Seattle WA (USA)

Closing remarks

Davide Maloney, Seattle WA (USA)

18:00 – 19:30 Channel 2 F. Hoffmann‐La Roche

UNLOCKING THE FUTURE: SEARCHING FOR A CURE IN DLBCL

Chair: Georg Hess, Mainz (Germany)

In this forward‐looking symposium, a vision of how novel therapies, and future advances in

DLBCL may improve patient care in the next ﬁve years will be presented by an expert

panel. Interactive discussions, in the form of patient cases and knowledge exchange, will

revolve around current treatment pathways and challenges, and how future integrated

(Continues)

491

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

care solutions may help raise the bar to cure more patients with DLBCL. You will have

plenty of opportunities to vote on the cases, and interact with the renowned faculty on

the insights and clinical experiences they will share.

Where are we now?

Georg Hess, Mainz (Germany)

Improving outcomes in ﬁrst‐line DLBCL

Matthew Matasar, New York, NY (USA)

Treatment choices in R/R DLBCL: What, why and when?

Christopher Fox, Nottingham (UK)

Experts in conversation – Your questions answered

All faculty ‐Live panel discussion and Q&A session

Is a cure within reach? A ﬁve‐year countdown

Georg Hess, Mainz (Germany)

18:00 – 19:30 Channel 3 Lymphoma Hub

SEQUENCING OF THERAPIES IN HIGH‐RISK RELAPSED/REFRACTORY LYMPHOMA

AND CLL

Chair: Gilles Salles, New York, NY (USA)

The Lymphoma Hub Satellite Symposium, ‘Sequencing of therapies in high‐risk relapsed/

refractory lymphoma and CLL,’ will be presented by an international speaker panel

chaired by Gilles Salles. The aim of the virtual symposium is to inform participants of

the therapeutic options and the data available to help guide treatment selection for

difﬁcult‐totreat relapsed/refractory disease, using case examples of ibrutinib‐resistant

CLL, early‐relapsing FL, TP53‐mutated MCL, and primary refractory DLBCL. The

presentations will be followed by a live roundtable Q&A discussion with the chair and

speakers—Francesc Bosch, Loretta Nastoupil, Steven Le Gouill, and Andrew Davies.

Objectives and introductions

Gilles Salles, New York, NY (USA)

Treatment options for a patient with ibrutinib‐resistant CLL

Francesc Bosch, Barcelona (Spain)

How to treat early relapse in a patient with FL

Loretta J. Nastoupil, Houston, TX (USA)

Sequencing of therapy for a patient with TP53‐mutated MCL

Steven Le Gouill, Nantes (France)

Sequencing treatment options in primary refractory DLBCL

Andrew Davies, Southampton (UK)

Roundtable discussion

All faculty

18:00 – 19:30 Channel 4 Novartis

EXPERT PERSPECTIVES IN CAR‐T: IDENTIFICATION, REFERRAL AND MANAGEMENT

OF PATIENTS WITH LYMPHOMA

Chair: Anna Sureda, Barcelona (Spain)

This virtual symposium will discuss the current treatment landscape and unmet needs in

relapsed or refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) and follicular

lymphoma (FL), and future directions to optimize patient outcomes with CAR‐T cell

therapy. Key discussions will include expert guidance on patient identiﬁcation, timely

492

(Continued)

Friday, June 18

Time Channel Session Article/ abstract nr.

use of CAR‐T therapy earlier in the third‐line setting, overcoming barriers to timely

referrals to CAR‐T centers, and management of long‐term adverse events following

CAR‐T therapy. A review of the latest CAR‐T therapy trial data in R/R FL will also be

provided. There will be an opportunity for questions during the Live Q&A.

Introductions and opening remarks

Anna Sureda, Barcelona (Spain) and Natacha Bolaños, Madrid (Spain)

CAR‐T cell therapy for DLBCL: optimizing patient outcomes, and future directions

Paolo Corradini, Milan (Italy), Anna Sureda, Barcelona (Spain), Luca Arcaini, Pavia (Italy)

Expert panel discussion: Management of long‐term adverse events following CAR‐T cell

therapy

Anna Sureda, Barcelona (Spain), Pier Luigi Zinzani, Bologna (Italy) and Paolo Corradini,

Milan (Italy)

CAR‐T cell therapy in R/R FL: current landscape and future directions

Pier Luigi Zinzani, Bologna (Italy)

Live Q&A and closing remarks

Anna Sureda, Barcelona (Spain), Paolo Corradini, Milan (Italy), Luca Arcaini, Pavia (Italy),

Pier Luigi Zinzani, Bologna (Italy) and Natacha Bolaños, Madrid (Spain)

Monday, June 20

Time Channel Session Article/ abstract nr.

19:00 – 20:00 Oncology Institute of Southern Switzerland (IOSI)

(supported by an unrestricted educational grant from Gilead Sciences Europe, Ltd, who

provided funding)

THE BIG DEBATE ‐DLBCL: ONE DISEASE, ONE TREATMENT?

Chair: Emanuele Zucca, Bellinzona, Switzerland

DEBATE 1.

Are we ready to introduce genetic classiﬁcation in routine diagnostics?

YES. Treatment improvement will not be possible otherwise.

Björn Chapuy, Göttingen (Germany)

NO. This is not yet feasible in everyday community settings.

Leticia Quintanilla‐Fend, Tübingen (Germany)

DEBATE 2.

Is frontline R‐CHOP still the sole standard?

YES. R‐CHOP21 remains the standard of care.

Laurie Sehn, Vancouver, B.C., (Canada)

NO. We have already moved beyond R‐CHOP.

Grzegorz S. Nowakowski, Rochester, NJ (USA)

DEBATE 3.

Will targeted treatments soon inform frontline management?

YES. Precision medicine will allow patient‐tailored treatment.

Margaret Shipp, Boston, MA (USA)

NO. CART and agnostic immunotherapies will replace chemotherapy.

Stephen J. Schuster, Philadelphia, PA (USA)

493

DOI: 10.1002/hon.2883

SUPPLEMENT ABSTRACT

INDUSTRY PROGRAM ‐SATELLITE SYMPOSIUM ABSTRACT

IP01

Bayer‐Sponsored Satellite Symposium at ICML 2021:

The Evolving Treatment Landscape and Emerging Novel Thera-

pies in Indolent Non‐Hodgkin’s Lymphoma (iNHL)

Non‐Hodgkin’s lymphoma (NHL) is the most common hemato-

logic malignancy, comprising several heterogeneous subtypes,

characterized as aggressive or indolent.

1,2

Indolent NHL (iNHL)

accounts for nearly 40% of all NHLs.

3,4

Despite advances in the

treatment of iNHL with the use of combination immunotherapy,

patients often experience relapse and progressive resistance to

treatment, underscoring the need to identify novel treatment op-

tions and rational combinations.

2,3,5

In addition, there is no uniform

standard of care beyond ﬁrst‐line treatment for patients with iNHL,

including both follicular lymphoma (FL) and marginal zone lym-

phoma (MZL).

3,5

Current therapies for patients with relapsed FL include standard

chemoimmunotherapies, immune‐modulatory treatment, and various

targeted therapies, while treatment options for patients with MZL

are more limited and often extrapolated from the management of

FL.

Moreover, despite available treatment options, there is growing

interest in additional effective chemotherapy‐free treatments with

limited side effects.

7,8

PI3K signaling is key to the proliferation and survival of indolent

B‐cell lymphoma cells; its inhibition has emerged as a therapeutic

strategy for the treatment of iNHL.

9‐14

While a few PI3K

inhibitors (oral and intravenous) are approved as monotherapy in the

relapsed/refractory setting, several oral PI3K inhibitors have

demonstrated severe adverse events that have precluded their

combination with other agents in earlier treatment lines.

12,13,15,16

Copanlisib is an intravenously administered, pan–class I PI3K inhibitor

that can be safely combined with other therapies in patients with

relapsed iNHL.

11,17

Recent data from the randomized phase 3

CHRONOS‐3 study supports the combination of copanlisib with

rituximab in relapsed iNHL, including FL and MZL, making it a

promising treatment option in the second line.

18,19

In addition, many novel agents, including CAR T‐cells and

bispeciﬁc antibodies, show promise in patients with iNHL. The proper

treatment sequencing, dosing and scheduling, and rational combina-

tions warrant further investigation.

2,3,20

References

1. GLOBOCAN 2020 World Factsheet. Accessed February 24,

2020. https://gco.iarc.fr/today/data/factsheets/populations/

900‐world‐fact‐sheets.pdf

2. Juarez‐Salcedo LM, et al. Drugs Context. 2020;9:2019‐9‐3.

3. Chao MP. Cancer Manag Res. 2013;5:251‐269.

4. Lunning M, Vose JM. Blood Rev. 2012;26(6):279‐288.

5. Matasar MJ, et al. Oncologist. 2019;24(11):e1236‐e1250.

6. National Comprehensive Cancer Network. B‐Cell Lymphomas

V2.2021. Accessed March 14, 2021. https://www.nccn.org/pro-

fessionals/physician_gls/pdf/b‐cell.pdf

7. van Oers MHJ, et al. Blood. 2006;108(10):3295‐3301.

8. Leonard JP, et al. J Clin Oncol. 2019;37(14):1188‐1199.

9. Wiestner A. Haematologica. 2015;100:1495‐1507.

10. Pongas G, Cheson BD. Semin Oncol. 2016;43:647‐654.

11. Aliqopa. United States prescribing information. Bayer AG; 2017.

12. Zydelig. United States prescribing information. Gilead Sciences;

2014.

13. Copiktra. United States prescribing information. Verastem;

2018.

14. Ukoniq. United States prescribing information. TG Therapeutics;

2021.

15. Casulo C, et al. Blood. 2016;128(22):2979.

16. Zelenetz AD, et al. Lancet Oncol. 2018;18(3):297‐311.

17. Dreyling M, et al. Am J Hematol. 2020; doi: 10.1002/ajh.25711.

18. Matasar MJ, et al. Lancet Oncol. 2021. In press.

19. Matasar MJ, et al. Presented at: American Association of Cancer

Research (AACR) Annual Meeting 2021; April 9‐14, 2021. Ab-

stract CT001.

20. Freedman A, Jacobsen E. Am J Hematol. 2020;95(3):316‐327.

494

Hematological Oncology. 2021;39(S2):494. wileyonlinelibrary.com/journal/hon

DOI: 10.1002/hon.2884

AUTHOR INDEX

Abadi, U., 240

Abdo, A. N. R., 345

Abdulla, F., 213

Abouladzé, M., 366

Abraham, A., 168

Abramson, J. S., 067, 068, 072, 198, 371

Abrisqueta, P., 028, 135, 141, 179, 182, 243,

286

Ackermann, J., 082, 271

Adélaïde, J., 278

Adachi, N., 014

Adamis, H., 251

Addada, J., 174

Adhinaveni, R., 142

Advani, R. H., 94, 223

Aeppli, S., 201

Afonso, C., 172, 337, 339, 341, 350, 381

Aftab, B. T., 377

Agafonov, R. V., 233

Agarwal, A., 272

Agarwal, R., 081

Agarwal, S., 374

Agrawal, P., 157

Agrippino, R., 356, 382

Ahearne, M., 286 bis

Ahle, G., 161

Ahmadi, T., 365

Ahmed, S., 265

Ahn, J. R., 063, 310

Ai, W., 177

Aiken, L., 194

Aissat, A., 90

Akay, O. M., 164

Aktar, S., 116

Al Essa, W., 142

Al Moosawi, M., 290

Al Sawaf, O., 034

Al Tabaa, Y., 245

Al‐Sawaf, O., 030, 031, 137, 139, 249

Albano, D., 204

Alcantara, M., 162

Alcoceba, M., 103, 115

Alderuccio, J. P., 177

Alduaij, W., 065, 290

Aleksik, O., 395

Alencar, A., 156

Alessandria, B., 059

Alessi, A., 277

Alfayate, A., 141

Alhaj Moustafa, M., 222

Ali, S., 373

Alig, S., 006, 023, 025, 046

Alinari, L., 180, 231

Aliste Santos, C., 167

Alizadeh, A. A., 006, 025, 046, 139

Alizadeh, A., 023

Alkodsi, A., 92

Alkorta Eizagirre, A., 387

Allan, J. N., 032

Allen, A., 99

Allen, P., 014

Allione, B., 181

Allocati, E., 392

Alonso‐Álvarez, S., 115

Alonso‐Alonso, R., 98, 226, 228, 229, 300

Alonso‐Prieto, C., 286

Alonso, C., 117

Alonso, R., 141, 292

Alperovich, A., 120

Althaus, B., 253

Altmüller, J., 155

Altuna Mongelos, A., 353, 387

Alvarez, I., 173

Alves, A., 355

Alves, D., 304

Alves, L. B. d. O., 313

Amaador, K., 294

Amador, C., 064, 065, 101

Ambarkhane, S., 028, 178

Ambati, S. R., 94

Ambrosoni, C., 358

Amdiev, A., 354

Amengual, J. E., 148

Amigó de Quesada, M., 302

Amorin, S., 189

Anastasia, A., 119

Anderson, J. K., 148

Ando, J., 209

Ando, K., 209, 210

Andorno, A., 142

Andorsky, D. J., 063, 310

André, M., 028, 237, 246, 307

Andre, M., 071, 203, 244

Andreadis, C., 085, 266

Andreou, E., 318

Andreu, R., 122, 135, 141, 182

Andriani, A., 319

Andrievskikh, M., 354

Angelillo, P., 154, 181

Angelopoulou, M., 164

Angrilli, F., 049, 079, 351

Anguita Velasco, J., 268

Annechini, G., 119, 356, 382

Annetta, I., 348

Annibali, O., 352

Annunziata, M. A., 392

Annunziata, S., 070

Anota, A., 379

Ansell, S. M., 003,041, 066, 074, 075, 171,

185, 186

Antelo Rodríguez, B., 167

Antier, C., 050

Antoine‐Poirel, H., 283, 344

Anyaegbu, G., 208

Arambarri Oyarzabal, A., 353, 387

Arat, M., 053

Arcaini, L., 043, 049, 077, 080, 119, 154,

312

Arcari, A., 173, 183, 204, 218, 352

Ardavan, A., 247

Ardeshna, K. M., 177, 197, 264

Ardeshna, K., 087, 194

Argirofﬁ, G., 277

Argnani, L., 127, 191, 205, 276

Armand, P., 074, 198

Armengol, M., 241

Arribas, A., 043

Arriola, J., 348

Artemyeva, A., 343

Arthur, C., 111

Ascani, S., 207

Asch, A. S., 113

Ashraf, K. K., 254

Hematological Oncology. 2021;39(S2):495–520. wileyonlinelibrary.com/journal/hon

495

Ashykhmin, A., 357

Asnaﬁ, V., 152

Assanto, G. M., 119, 356, 382

Assouline, S., 109

Atalar, A. C., 164

Attarbaschi, A., 036

Attinger, A., 244

Auer, R., 174

Aurer, I., 071, 078, 203

Autore, F., 029, 133

Avigdor, A., 240, 270, 279

Avram, A., 346

Aymerich, M., 060

Ayuk, F., 082, 274

Azim Jr, H. A., 054

Bárcena, C., 228

Bárez, A., 141

Bæch, J., 89

Böhmer, L. H., 217

Böttcher, S., 031, 034, 062

Bücklein, V., 082, 271

Bühler, M. M., 058

Babali, V., 318

Babu, S., 240

Babuin, E., 298

Bachanova, V., 148, 157

Bachier, C., 273

Bachy, E., 015, 082, 084, 085, 107, 110, 145,

225, 238, 245, 266, 376

Badarau, A., 373

Baech, J., 147

Baez‐Duran, E., 300

Bagnardi, V., 178

Bagnato, G., 191

Bagot, M., 054

Bai, B., 215

Bai, O., 052

Baidoun, F., 222

Bailén, R., 268

Baile, M., 122, 141, 179, 286

Baillet, C., 245

Bailly, C., 245

Bailly, S., 050

Baiocchi, R. A., 180, 231

Bairey, O., 136

Baker, R., 112

Bakiri, M., 318

Bal, E., 004

Balagué, O., 069

Balague, O., 103

Balaguer Rosello, A., 122

Balari, A. S., 016, 250

Balbas, M., 129

Baldini, L., 079

Baldomero, H., 188

Baldus, C., 274

Balke‐Want, H., 155

Ballerini, F., 121, 218

Ballester, C., 135

Baltadakis, I., 318

Baltasar, P., 135, 141

Balzarotti, M., 047, 048, 049, 173, 183, 255

Bamigbola, O., 140

Banchs, J., 265

Banerjee, L., 243

Bannerji, R., 032, 94, 111

Bao Pérez, L., 167

Bao, H., 216

Baptista, M. J., 043

Barbolini, E., 352

Barbui, A. M., 275

Barcena, C., 103, 229

Bardet, A., 278

Bargetzi, M., 201

Bari, A., 080, 352, 392

Barlow, B., 334

Barman, P., 041

Barnes, J. A., 198

Barnes, L., 232

Barone, M., 205

Barr, P. M., 032, 051, 136

Barraclough, A., 081

Barrans, S. L., 100

Barrans, S., 040

Barreau, S., 386

Barrington, S. F., 073

Barrington, S., 049, 071, 203, 247

Barrons, S., 99

Barros Lima, C., 172, 337, 339, 381

Barta, S. K., 148, 331

Bartlett, N. L., 038, 067, 068, 072, 075, 254

Baryakh, E., 354

Basso, K., 004, 042

Bassolli, L., 345

Bast, M., 148

Bastidas, G., 043

Bastie, J. N., 005

Bastos Oreiro, M., 126

Bastos‐Oreiro, M., 115, 117, 144, 243, 268,

286

Bastos, M., 179, 227

Batchelor, T., 156

Bates, A., 286 bis

Batlevi, C. L., 109, 120, 175

Batlevi, C., 375

Battistini, R., 019, 319

Baud, V., 017, 166

Baumann, T., 103

Baysal, B., 370

Beà, S., 058, 103

Bea, S., 043

Beauvais, D., 084

Beauverd, Y., 346

Bech‐Serra, J. J., 241

Becker, S., 005, 050, 176

Becnel, M., 265

Beelen, D. W., 274

Beer, P., 040

Behan, S., 197

Beider, K., 279, 027, 064, 065, 101

Belén Vidriales, M., 135

Belada, D., 220, 237, 285, 330

Bellesso, M., 165, 345

Bello López, J. L., 167

Bello, C. M., 198

Bellosillo, B., 125

Belot, Aurél., 184

Belousov, A., 015

Ben‐Neriah, S., 024, 064, 065, 101

Benedetti, F., 059, 218

Benesova, K., 220, 330

Benet, C., 122

Bengston, E. M., 198

Benjamin, R., 083

Benmaad, I., 90

Bento, L., 125, 144

Beraldo, J. I., 345

Berg, S., 157

Berger, C., 082

Bergesio, F., 019

Bergua Burgues, J. M., 227, 237

Bernard, S., 050

Berneman, Z., 307

Bernuzzi, P., 119

Berriolo‐Riedinger, A., 050

Bertolazzi, G., 96

Bertoni, F., 043, 059, 079

Besley, C., 087

Besser, M. J., 279

Besser, M., 270

Besson, C., 050, 278, 280

Besutti, G., 204

Betancor, I., 228

Bethge, W., 082, 274

Bethony, J., 067, 068

Beverstock, S. L., 335

Beygi, S., 006

Beylot‐barry, M., 054

496

AUTHOR INDEX

Bhagat, G., 043

Bhella, S., 123, 158

Bhuller, K., 197

Bianchi, M. P., 319

Binder, M., 047

Biondi, A., 088

Bird, R., 076

Birnbaum, D., 278

Bishton, M., 212

Bisig, B., 044, 045, 225

Bittolo, T., 029

Björkholm, M., 92

Blaedel, J., 365

Blaise, D., 053

Blaker, Y. N., 92

Blanc‐Durand, P., 90

Blanco Nuñez, O., 227

Blazevic, D., 333, 360

Blecua, P., 241

Bleul, S., 046

Block, A., 370

Bloehdorn, J., 030

Blonski, M., 162

Blouin, W., 056

Blumenberg, V., 082, 271

Bobillo, S., 114, 115

Boccomini, C., 062, 080, 119

Bodine, C. D., 334

Boegeholz, J., 023

Boellaard, R., 021, 190

Bogart, J. A., 072

Bohers, E., 91

Boldorini, R. L., 142

Boldorini, R., 043

Bolis, S., 019, 119, 121

Bollu, V., 266, 272

Bologna, S., 005, 044

Bommier, C., 314

Bond, D. A., 180

Bond, D. B., 157

Bond, D., 061, 147, 148

Bondarenko, I., 112

Bonﬁglio, F., 043

Boni, J., 238

Bonifazi, F., 276

Bonnet, C., 005, 044, 050, 199, 225, 263

Bonomini, L., 043, 048

Bonzheim, I., 069

Boot, J., 156

Booth, S., 197, 214, 247

Borchmann, P., 155, 195, 267

Borchmann, S., 155

Borel, C., 189, 199

Bories, P., 084, 317

Borko Jovanovic, B., 055

Borregón, J., 228, 229

Borregon, J., 226, 300

Borsatti, E., 070

Borte, M., 305

Bosch, F., 135, 141, 241

Bosch, J., 103

Bosly, A., 150, 184

Bossard, C., 044, 225

Botin, T., 317

Bottelli, C., 173, 183

Botto, B., 048, 049, 121, 173, 352

Bouabdallah, K., 112, 176, 199, 225, 280

Bouabdallah, R., 91

Bouchard, S., 389

Boucher, L., 94

Boumendil, A., 053

Bounaix, L., 084

Bourgeois, H., 389

Bouscary, D., 189, 386

Boussen, I., 160

Bouzani, M., 318

Bowen, J., 067, 068

Boyer, M., 138

Boyle, M., 024

Bröckelmann, P. J., 074, 195

Brüggemann, M., 034

Brülisauer, D. M. A., 201

Brackertz, B., 237

Bradvica, V., 358

Bramanti, S., 275

Brammer, J., 180

Branagan, A., 373

Branco, B., 317

Brandão, A. A. G. S., 345

Breij, E., 365

Brescini, M., 382

Bret, C., 366

Brice, P., 051, 189, 190, 197, 199

Briere, J., 005

Brigidi, P., 205

Brink, M., 217

Broccoli, A., 043, 127, 191

Brodtkorb, M., 027

Bron, D., 307

Broom, A., 174

Brotelle, T., 044

Broussais, F., 084

Brousset, P., 008

Brouwer‐Visser, J., 94

Browett, P., 107

Brown, F., 231

Brown, P. d. N., 027

Brown, P., 89, 239

Brueggemann, M., 151

Brugger, W., 237

Bruna, R., 218

Bruneau, J., 225

Bruno, A., 022

Bruno, R., 077

Bruscaggin, A., 029, 043, 070, 133,

142

Bryan, A. C., 067

Bryan, A., 068

Bryan, L. J., 238

Buño, I., 126, 268

Buccheri, V., 193

Buchholz, T. A., 118

Buchholz, T. J., 376

Budde, E., 242

Buege, M. J., 147, 175, 281

Buie, L. W., 175

Bulian, P., 070, 133

Bullinger, L., 106

Burbelo, P. D., 284

Burda, D., 343

Burger, E., 047

Burger, J. A., 136

Burke, J. M., 130, 237

Burkhardt, B., 036

Burroni, B., 152, 189

Burton, C., 040, 99, 100, 174, 194, 247

Burton, K., 194

Busco, S., 391

Buske, C., 373

Butler, J., 085, 266

Buvat, I., 020

Buzzoni, C., 391

Byrd, J. C., 033

C Jin, M., 006

C Oliveira, A., 141

Córdoba, R., 98, 117, 135, 226, 227, 228,

229

Cañeque, T., 366

Caballero Barrigón, M. D., 182

Caballero, D., 115, 228, 229

Caballero, M. D., 144

Cabarrou, B., 317

Cabero, A., 117

Cabezudo, E., 227

Cabral, R., 342

AUTHOR INDEX

497

Cabras, G., 154, 173

Cabras, M. G., 047, 049, 079

Cabrejo, M., 196

Cabrera, M. E., 078

Caccavari, V., 392

Cacciapuoti, M. T., 102

Caddy, J., 100

Cai, A. R., 378

Cai, C., 282, 394

Cai, G., 052

Cai, J., 157

Cai, Q., 215

Cai, Y., 234, 362

Caimi, P. B., 148

Caimi, P. F., 075, 177

Cairoli, A., 044, 062

Cairoli, R., 128

Calay, F., 283

Calcinotto, A., 043

Caldarella, A., 391

Califano, C., 079, 080

Calimeri, T., 154, 156

Callanan, M., 152

Calvo, R., 146, 252

Calzada, O., 148

Camalori, M., 204

Cambalia, A., 054

Campana, F., 037

Campbell, N., 286 bis

Campbell, P. J., 040

Campbell, P., 109

Campo, E., 043, 058, 060, 064, 065, 069,

101, 103

Campostrini, G., 187

Campoy, F., 141

Campr, V., 220

Camus, V., 050, 184

Canales, M. A., 118

Cancelli, V., 284

Canioni, D., 152

Cannata‐Ortiz, J., 286

Cantò, C., 351

Cantonetti, M., 019, 319, 352

Canzonieri, V., 043

Cao, A., 112

Cao, J., 057, 364

Capochiani, E., 079

Capra, M., 112

Carbonell, D., 126, 268

Carda, J. P., 339

Carda, J., 172, 337, 341, 381

Carda, J.P., 350

Carella, M., 191

Carlile, D., 015

Carlo‐Stella, C., 015, 070, 075, 177, 238,

251, 264

Carniti, C., 218, 275, 277

Caron, P. C., 120

Carpenter, B., 039

Carpio, C., 376

Carr, R., 039, 208

Carrabba, M., 275

Carrancio, S., 232, 376

Carreiro, M., 317

Carrozzi, G., 391

Carter, J., 157

Cartron, G., 079, 084, 91, 110, 145, 176,

189, 245, 261, 297, 366

Carty, S., 061

Caruso, L., 316

Casadei, B., 191, 205, 275, 276

Casado, L. F., 135

Casanova, M., 060

Casaroli, I., 059

Casas‐del Pozo, E. M., 300

Casasnovas, O., 017, 079, 110, 146, 166,

176, 184, 189, 199, 245

Casasnovas, R.‐O., 025

Casasnovas, R., 91

Casasnovas, René‐O., 084

Cascavilla, N., 328

Cascione, L., 018, 022, 043, 059

Casella, C., 391

Caspar, C., 201

Casper, C., 067, 068

Cassiordor0, G., 332

Castagna, L., 053

Castellino, A., 154, 255

Castellino, C., 059, 218

Castillo‐llanos, R., 363

Castillo, J. J., 373

Castrejon‐de‐Anta, N., 069

Castro, B., 342

Castro, F., 168

Catalani, O., 253

Cathcart, E., 056

Catovsky, D., 127

Cattaneo, C., 181, 284

Cavalieri, D., 044, 189, 225

Cavalli, F., 029, 043, 047, 049, 070, 079, 133

Cavalli, M., 119

Cavallo, F., 079, 107, 173, 183, 187, 218

Cavallo, R., 391

Cavallo, T., 385

Celades, C., 122

Celico, C., 047

Cen, H., 216

Cencini, E., 119, 173

Cenfra, N., 119

Cereceda, L., 98, 226, 228, 229

Cerhan, J. R., 041, 185, 186

Cerhan, J., 066

Ceriani, L., 018, 022, 043, 049, 070

Ceribelli, M., 011

Cernauskiene, S., 321

Cerroni, L., 226

Cerutti, A., 196

Chabay, P., 295

Chabon, J. J., 025

Chaganti, S., 087, 156, 258

Chahal, M., 200

Chai‐Adisaksopha, C., 322

Chaidos, A., 109

Chalandon, Y., 188

Challenor, S., 174

Chamizo, C., 226, 300

Chamuleau, M. E.D., 016

Chan, E., 96, 97, 235

Chan, H., 107

Chan, J. Y., 235

Chan, K., 116

Chan, M., 200

Chan, W. C., 064, 065, 101

Chan, W., 231

Chanan‐Khan, A., 033

Chang, S.‐T., 97

Chang, V., 354

Chang, Y., 269, 396

Chaoui, D., 199

Chapuis, N., 386

Chapuy, B., 106

Chartier, L., 017, 91, 152, 166

Chaturvedi, P., 233

Chatzidimitriou, C., 164

Chauchet, A., 050, 94, 189, 130

Chauvie, S., 019, 022, 070, 121, 246

Chavez, J. C., 085, 266

Chavez, J., 148, 242, 376

Cheah, C. Y., 236, 372

Cheah, D. M. Z., 235

Chebanov, D. K., 369

Chee, Y. L., 96, 97, 235

Cheminant, M., 152

Chen Liang, T., 122

Chen‐Kiang, S., 231

Chen, D. Y., 130

Chen, D., 269

Chen, H., 364

Chen, J.‐M., 052

498

AUTHOR INDEX

Chen, J.‐Y., 052

Chen, K.‐M., 016

Chen, Q., 325

Chen, R., 336

Chen, S.‐J., 052

Chen, Y., 215, 269

Cheng, S., 026, 052

Cherel, L., 379

Cherkasova, E., 343

Cherrill, L. R., 214

Cherry, M., 273

Cheson, B. D., 072

Cheung, L. W.‐K., 143

Cheung, M., 116, 259

Cheung, S., 236

Chiappella, A., 048, 218, 255, 275, 277

Chiaravalloti, A., 356, 382

Chiarenza, A., 316

Chiattone, C. S., 223

Chicano, M., 126

Childs, B. H., 112

Chimienti, E., 077, 173

Chin, V., 327

Chin, Y. S., 108, 349

Chin, Y., 327

Ching, K., 393

Ching, T., 031

Chiu, C. W., 365

Chiusolo, P., 275

Chng, W. J., 96

Chng, W.‐J., 235

Chng, Wee‐J., 97

Choi, H., 97

Choi, I., 209, 210

Choi, J. W., 011

Chong, E. A., 331

Chong, G., 081

Choquet, S., 050, 084, 160, 162, 258

Chow, E. K., 235

Christian, B., 180

Chuan, J., 377

Chuang, S.‐S., 97

Chudinovskikh, Y., 343

Chung, J., 231

Chung, M., 251

Churilov, L., 081

Churnetski, M., 148

Chyla, B., 138

Ciabatti, E., 119

Ciammella, P., 204

Ciancia, R., 218

Cibien, F., 134

Ciccone, G., 049, 218, 255

Cicinelli, E., 359

Cid López, M., 167

Cimminiello, M., 352, 385

Ciolli, S., 134

Ciotti, G., 356, 382

Cipriano, A., 172, 337, 339, 341, 350, 381

Cittone, M. G., 043, 133

Cittone, M., 070

Civallero, M., 223

Clément‐Filliatre, L., 044

Clark, E., 015

Class, B., 233

Clausen, M. R., 016, 250

Claussen, C., 265

Clement, L., 189

Clerc, J., 386

Cleveland, J., 157

Clifton‐Hadley, L., 071, 073, 203,

247

Climent, F., 103, 104, 227, 228, 229

Clot, G., 058

Co Ting Keh, L., 025

Co, M., 107

Cocito, F., 154

Cogliatti, S., 043

Cohen, A., 130

Cohen, J. B., 074

Cohen, J. I., 284

Cohen, J., 148

Coleman, A., 99

Coleman, H., 286 bis

Coleman, M., 063, 107, 310

Colin, F., 379

Collinge, B. J., 065, 101

Collinge, B., 024, 064

Collins, G. P., 038, 074, 075, 194, 197, 214,

247

Collins, G., 087, 286 bis

Colloca, G., 204

Colomo, L., 104, 125

Colton, M. D., 378

Columbié Molina, A., 302

Conconi, A., 048, 078, 079, 080

Condoluci, A., 029, 043, 070, 133

Connors, J., 200

Contreras, J., 122

Cook, J. R., 064, 065, 101

Cooke, S., 040

Cool, C., 393

Coombs, C. C., 129

Copie Bergman, C., 280

Copie‐Bergman, C., 90

Copin, M. C., 044

Coppola, A., 204

Coppola, P. E., 191

Coralluzzo, G., 385

Corcoran, S., 011

Cordoba, R., 179

Corradini, P., 053, 111, 119, 218, 275, 277

Correa, J., 141

Cortés‐Romera, M., 060

Cortés, M., 286

Cortelazzo, S., 059

Cortes Gomez, E., 102

Cortes, M., 122

Coscia, M., 128, 134

Cosman, G., 327

Coso, D., 005

Costa, M. J., 304

Costello, Rég., 107

Cottereau, A. Ségolèn., 020

Cottereau, A. S., 189

Cottereau, A.‐S., 017, 166, 386

Cottereau, A., 91

Counsell, N., 071, 203

Courreges, V., 348

Courtright, J., 273

Coutinho, J., 342

Coutinho, R., 342

Coutre, S. E., 136

Cowley, A., 174

Cox, M. C., 173, 183, 187

Cozens, K., 047, 049

Craig, A. F. M., 025

Craig, A., 023

Craig, J. W., 024

Craig, J., 290

Cramer, P., 034

Cranco, S., 298

Creasey, T., 197

Crocetti, E., 391

Croft, B., 111, 243

Crosbie, N., 147, 156

Cross, D., 076

Cross, M., 127

Crosswell, H. E., 038

Crouch, S., 040

Crump, M., 015, 123, 158, 201, 384

Cruz, H. G., 075

Crystal, A. S., 233

Cuadrado, M., 083

Cucco, F., 99, 100

Cuesta, A., 141

Cui, G.‐H., 052

Cultrera, J. L., 130

Cuneo, A., 134

AUTHOR INDEX

499

Cunningham, D., 016, 051, 262

Custidiano, M. R., 298

Cwynarski, K., 047, 049, 154, 156, 197,

214

Cygan, K. J., 94

Czerw, T., 311

D Phelan, J., 011

D'Addona, M., 390

d'Amore, F., 239

D'Elia, G. M., 356, 382

Díaz Arias, J. Án., 167

Díaz Crespo, F., 126, 268

Díez‐Martín, J. L., 268

Döhner, H., 030

Dörr, H., 155

Dührsen, U., 023, 025

Długosz‐Danecka, M., 236

Da Silva, M. G., 043

Dabrowska Iwanicka, A., 049

Dai, S., 136

Dai, V., 238, 264

Dal Maso, L., 391

Dalla‐Favera, R., 004, 042

Dalle, S., 054

Dalmasso, F., 022

Daly, K., 149, 153

Damaj, G. L., 005

Damaj, G.‐L., 050

Damaj, G., 044, 91, 110, 145, 146, 225

Damiano, S., 358

Daneels, W., 344

Daniel, A., 044

Daniele, A., 392

Danilov, A., 061

Dantin, C., 188

Danylesko, I., 270, 279

Dao, P. H., 281

Darmani, I., 318

Darrall, A., 370

Dartigues, P., 278

Darzentas, N., 151

Davey, T., 056, 211

David, K. A., 157

Davies, A. J., 286 bis

Davies, A., 039, 049, 99, 100, 146, 154, 214

Davies, E., 174

Davies, J., 100

De Abreu Lima, L. B., 037

De Almeida, J. M., 355

De Beleyr, B., 307

De Boer, J. P., 074

de Boer, R., 294

De Bonis, C., 338

de Castro, N. S., 223

de Guibert, S., 238, 379

de Jong, B., 365

de Jong, D., 190

de la Cruz, F., 060, 104, 182

De la Fuente Burguera, A., 060

de la Fuente, A., 117, 182

de la Fuente, C., 329

De la Serna, J., 135

De la Torre, A., 158

De la Torre, C., 241

de Leval, L., 043, 044, 045, 225

de Long, L. M., 076

De Lorenzo, S., 312

De Luca, M. L., 356, 382

De Matteo, E., 295

De Mel, S., 96, 97, 235

De Novi, L. A., 119

de Oliveira, J. S. R., 193

De Paoli, L., 029, 142

de Ramon Ortiz, C., 346

De Renzis, B., 079

De Sanctis, V., 392

De Santis, G., 328

De Souza, C. A., 223

de Vet, H. C. W., 021

de Wilde, V., 044

De Wind, R., 044

Deambrogi, C., 029, 133

Dean, J. P., 032, 136

DeAnda, F., 143

Dearden, C., 127

Deau‐Fischer, B., 386

Deau, B., 189

Decazes, P., 050

Dechmi, A., 386

Deckert, M., 047

Deering, R. P., 94

Degeyndt, A., 344

Deighton, K., 114

del Campo, R., 117, 286

Del Giudice, I., 080, 119, 382

Delabie, J., 064, 065, 101, 384

Delarue, R., 184, 261

Delfau Larue, M.‐H., 90

Delfau‐Larue, M., 91

Delfau, M.‐H., 151, 152

Delgado Trillo, I., 169, 170, 292

Delgado, J., 135

Della Gala, G., 276

Della Starza, I., 119

Dellatola, M., 318

Delmer, A., 199

Delwail, V., 238

DeMarco, D., 016

DeMarco, J., 370

Deng, L., 192

Deng, X., 057

Denis, F., 389

Denolf, P., 283

Deodato, M., 128, 133

Depaus, J., 238, 264

Derenzini, E., 043

Dereure, O., 054

Desai, S. H., 066

Desai, S., 171

Deschamps, P., 189, 386

Descroocq, J., 386

Deswal, A., 265

Deux, J.‐F., 017, 166

Devata, S., 061

Devereux, S., 136

Devin, J., 366

Devizzi, L., 043, 079

Dewhurst, F., 380

Dey, D., 178

Dhami, K., 143

Dhanik, A., 94

Di Blasi, R., 084

Di Molfetta, S., 392

Di Nicola, M., 351

Di Raimondo, F., 316

Di Rocco, A., 173, 255, 275, 319

Di Russo, A., 392

di Trani, M., 070

Diamanti, I., 301

Diaz Couselo, F., 298

Diaz Velez, N., 348

Dickinson, M. J., 015

Dickinson, M., 085, 109, 168, 193, 266

Dickson, S., 327

Diefenbach, C., 148, 242, 243

Diehn, M., 006, 023, 025, 046

Diepstra, A., 190

Dietrich, J., 156

Dietrich, S., 043, 053

Diez Martín, J. L., 126

Diez‐Feijoo Varela, R., 125

DiLiberto, M., 231

Dimitraki, E.‐K., 318

Dimopoulos, M., 373

Dimou, M., 154, 305

500

AUTHOR INDEX

Dinaro, Y. M., 391

Dinavahi, R., 258

Ding, C., 336

Ding, K., 131

Ding, M., 362

Dirnberger‐Hertweck, M., 028

Dirnhofer, S., 018, 022, 043, 062, 105

Dlouhá, L., 285

Dlouha, J., 220

Dlugosz‐Danecka, M., 146

Do Nascimiento, J., 141

Dobbs, K., 284

Dockter, T., 072

Dodero, A., 077, 218, 275, 277

Dogan, A., 056, 120

Dolnik, A., 106

Domingo Domenech, E., 333, 347, 360

Dominguez, M., 104

Donato, E., 106

Dondi, A., 119

Dong, C., 038

Dong, H., 114

Donovan, A., 148

Doorduijn, J. K., 146

Dorado, N., 268

Dorritie, K. A., 086

Dorritie, K., 242

Dotson, E., 180

Dreger, P., 034, 053, 274

Dren, N., 140

Dreval, K., 024, 067, 068

Dreyling, M., 028, 062, 082, 085, 150, 151,

266

Driessen, C., 062

Driessen, J., 021, 190

Drieux, F., 044,225

Drill, E., 056, 175, 281

Drott, K., 027

Drullinsky, P., 375

Dryer, M., 068

Du, G., 012

Du, M. Q., 99

Du, M., 100

Du, T., 192, 256

Du, Y., 267

Duarte, S., 172, 337, 339, 341, 350, 381

Dubois, J., 138

Dubovsky, J., 377

Duell, J., 028, 94

Dufﬂes Amarante, G. B., 313

Dufﬂes, G., 345

Dunne, B., 340

Dupont, E., 044

Dupuis, J., 146

Duran‐Ferrer, M., 058

Duran, A., 313, 345

Duras, J., 220, 330

Durmo, R., 020, 121

Durot, E., 050

Duval, R., 042

Duvall, A., 393

Duyster, J., 046

Dyer, M., 067

Dymkowska, M., 244

E Busse, C., 106

Ebbesen, L. H., 89

Ebinger, M., 036

Ebnöther, M., 201

Eckert, K., 260

Eckhardt, K., 062

Eek, R., 146

Eertink, J. J., 021

Efremov, D., 029

Eichhorst, B., 030, 031, 034, 137, 138, 139,

249

Ekwede, I., 93

El Yamani, A., 044

El‐Galaly, T. C., 89

El‐Galaly, T., 147

El‐Gkotmi, N., 318

El‐Sharkawi, D., 174

Eldering, E., 294

Elemary, M., 259

Elemento, O., 95, 231

Eleta, M., 202

Elia, A. R., 043

Elliot, B., 365

Elliott, B., 016

Ellonen, P., 92

Else, M., 127

Emelina, E., 308, 309

Emmons, R., 111

Encuentra, M., 333, 347, 360

Endakova, A., 354

Engert, A., 074, 195

Enrico, A., 196

Eom, H. S., 209

Eom, H.‐S., 057

Epelman, S., 037

Epperla, N., 148, 157, 180

Eradat, H., 240

Erbella, F., 181

Ernst, M., 397

Eron, S. J., 233

Ervin‐Haynes, A., 238

Escoda, L., 286, 329, 333, 347, 360

Esfahani, M. S., 006, 046, 139

Espadana, A. I., 339, 350

Espadana, A., 172, 337, 341, 381

Espinet, B., 104, 125

Esposito, F., 022, 048, 049, 079

Essell, J., 273

Estcourt, L., 398

Esteller, M., 241

Esteve, A., 227

Esteves, G., 304

Etherington, A., 194

Evangelista, A., 059, 218

Evens, A. M., 157

Evens, A., 148

Eyre, T. A., 129

F García, J., 229

F Herrera, A., 053

F Seymour, J., 033

Fürstenau, M., 034

Fabbri, A., 047, 173, 183, 352

Fabiani, B., 005

Fabio, L., 385

Facchetti, F., 043, 181

Facco, M., 134

Fadeeva, N., 354

Faderl, M. R., 133

Faderl, M., 029, 043, 070

Fagerli, U. M., 239

Fagerli, Unn‐M., 027

Fagioli, F., 037

Fahrni, G., 133

Falautano, M., 047

Falchi, L., 056, 120, 175

Falcini, F., 391

Falconer, J., 286 bis

Falini, B., 080, 121, 207

Falini, L., 207

Fallanca, F., 121

Fan, L., 336

Fan, S., 96, 97

Fanale, M. A., 038

Fanale, M., 051

Fancourt, T., 081

Fanelli, F., 319

Fanetti, A. C., 391

AUTHOR INDEX

501

Fang, S., 056

Fang, X., 362

Fanning, S. R., 063

Fanning, S., 273

Fanti, S., 276

Farina, K. A., 175

Farina, L., 080, 121

Farinha, P., 024, 064, 065, 97, 101

Farolﬁ, A., 276

Farooq, U., 066, 185, 186

Fataccioli, V., 044, 225

Fathoala, D., 194

Faul, C., 082

Faust, S. N., 286 bis

Favero, F., 89

Favini, C., 059, 142

Favre Juilland, Mél., 045

Favre, C., 037

Fe', A., 385

Fedeli, U., 391

Federico, M., 071, 078, 080, 121, 203, 223,

395

Fehr, M., 062, 201

Fehse, B., 082

Feingold, J., 177

Feldman, A. L., 064, 065, 101

Feldman, A., 066

Feldman, T., 376

Fend, F., 069

Feng, C., 393

Feng, J., 112

Feng, L., 265

Feng, R., 215

Feng, S., 130

Feng, X., 361, 368

Fenske, T. S., 148

Fenton, K., 038

Ferguson, G., 194

Ferhanoglu, B., 164

Fernández de la Mata, M., 135

Fernández González, M., 122

Fernández‐Ibarrondo, L., 125

Fernández‐Miranda, I., 228, 229

Fernández‐Rodríguez, C., 125

Fernandez‐Miranda, I., 104

Fernandez‐Serrano, M., 241

Fernandez, I., 196

Ferrà, C., 135

Ferra, C., 144

Ferranti, A., 047

Ferrara, F., 154

Ferrara, I., 332, 390

Ferrari, A., 173

Ferrari, L., 196

Ferrari, S., 238, 376

Ferrario, A., 154

Ferreiro Ferro, R., 167

Ferreiro Martinez, J. J., 387

Ferrer, A., 125

Ferreri, A. J. M., 047, 154, 156, 181, 266

Ferreri, A. J., 119

Ferreri, A., 019

Ferreri, Andrés J. M., 077, 078, 048, 049

Ferrero, S., 059, 062, 080, 119, 173

Ferretti, S., 391

Ferri, V., 142

Feugier, P., 005, 079, 91, 110, 145, 176, 199

Fiaccadori, V., 071, 203

Fiad, L., 196, 202, 223

Fiaschi, N., 94

Ficola, U., 019

Fidalgo, J., 039, 208

Figuera, A., 316

Filatova, L., 343

Filippi, A., 246

Filonenko, K., 395

Finel, H., 053

Fink, A. M., 034

Fink, A.‐M., 030, 031, 137, 249

Finke, Jür., 047

Finke, J., 046

Fior, R., 162

Fioroni, F., 020

Fischer, K., 030, 031, 034, 137, 139, 249

Fischer, N., 201

Fisher, D. C., 056

Fisher, S. L., 233

Flavin, R., 340

Fleck, E., 044

Fleming, M., 180

Flenghi, L., 173, 218

Fleury, I., 267

Flink, D. M., 94

Flinn, I., 130, 248

Flospergher, E., 181

Flowers, C., 111

Fluge, Ø., 027

Flynn, C., 340

Foà, R., 119, 134

Fogliatto, L. M., 118

Follows, G. A., 197

Fomintseva, M., 388

Foncuberta, M. C., 298

Fontán, L., 012

Fontana, R., 332, 390

Fontanillo, C., 232

Foppoli, M., 154, 181

Forestieri, G., 029, 043, 070, 133, 142

Fornecker, L. M., 189

Fornecker, L.‐M., 161

Fornecker, Luc‐M., 199

Fortpied, C., 071, 203

Fosså, A., 049

Foss, F. M., 014

Fouquet, G., 386

Fowler, N. H., 085, 266

Fox, C. P., 156, 174, 212, 214, 250, 261

Fox, C., 047, 286 bis

Fox, L., 329

Frölich, L., 082, 271

Fraga Rodríguez, M. F., 167

Franceschetti, S., 392

Franceschetto, A., 121

Franceschi, S., 391

Franch‐Sarto, M., 179

Franch, M., 286, 333

Franchi, P., 189, 386

Francis, S., 051

Frank, M., 023

Franklin, A. R. K., 037

Frauenfeld, L., 069

Freeman, B., 130

Freeman, C. L., 150

Freeman, C., 024, 200

Fresa, A., 134

Fried, S., 270

Friedberg, J. W., 073

Friedman, J. D., 248

Frigola, G., 103

Fruchart, C., 184

Frustaci, A. M., 029, 128, 133

Frutos, L., 122

Fu, K., 064, 065, 101, 296

Fu, R. X., 324

Fu, X., 269, 323, 361, 396

Fuchs, M., 195

Fuente, M. L., 298

Furman, R. R., 033

Furtado, M., 197

Fusco, M., 391

Fylaktou, A., 301

Gámez Pérez, E., 302

Gómez‐Fernández, I., 268

Gómez‐Roncero, M. I., 286

Gómez‐Roncero, M

I., 141

502

AUTHOR INDEX

Gödel, P., 155

Güsewell, S., 201

Gac, A. C., 199

Gadacha, O., 366

Gadient, S., 062

Gafter‐Gvili, A., 164

Gaidano, G., 025, 028, 029, 043, 048, 059,

070, 078, 128, 133, 142

Gainaru, G., 164

Galasso, N., 056, 211

Galimberti, S., 059, 080, 119, 352

Galiulin, R., 112

Gallamini, A., 019, 246

Galli, G. R., 395

Gallop‐Evans, E., 194, 247

Gambardella, L.M., 007

Gamelin, L., 258

Gan, Y., 224

Gandhi, M. D., 251

Gandhi, M. K., 076

Ganeev, I.I., 306

Ganesan, N., 056, 211

Ganzel, C., 164

Gao, F., 323

Gao, S., 131

Gao, Y., 215, 361, 367, 368, 372

García Belmonte, D., 117

García Marco, J. A., 170

García Vela, J. A., 169, 170, 292

García‐Cosío Piqueras, M., 170

García‐Cosio, M., 228, 229

García‐Díaz, N., 98

García‐Malo, M

D., 141

García‐Marco, J. A., 135

García‐Pintos, M., 141

García‐Sanz, R., 060

García, J. F., 98, 125, 228

Garcia de Paco, E., 366

Garcia‐Arroyo, F. R., 104

Garcia‐Calduch, O., 179

Garcia‐Cosio, M., 104

Garcia‐Ibanez, L., 042

Garcia‐Marco, J. A., 033

Garcia, D., 179

Garcia, J. F., 043

Gardeli, D., 318

Garg, V., 373

Garofalo, A., 006

Garrido Castro, P., 365

Garthe, A.‐K., 036

Garzon, F., 373

Gasiorowski, R., 193

Gaspard, M.‐H., 317

Gasparotti, C., 391

Gastier‐Foster, J. M., 067, 068

Gastinne, T., 084, 189, 190, 199

Gat, E., 084, 297

Gato, L., 227

Gattei, V., 029, 070, 080, 119, 133

Gaudio, F., 359

Gaulard, P., 044, 90, 225

Gauthier, M., 050

Gauthier, N., 162

Gavarotti, P., 019

Ge, J., 396

Ge, R. J., 324

Geissler, K., 112

Geller, S., 211

Gendlin, G., 308, 309

Genta, S., 018

Gentile, M., 134

Gentilini, M., 191

Gerardi, C., 392

Gerber, B., 029, 043, 070, 133

Gerhard, D. S., 067, 068

Gerrie, A. S., 024, 147, 148, 150

Gerrie, A., 200

Gerson, J. N., 148, 331

Geyer, J. T., 043

Ghanzin, M., 343

Gharibo, M., 063, 310

Ghenim, L., 317

Ghesquières, H., 184

Ghesquieres, H., 005, 079, 114, 189, 199

Ghia, P., 029, 032, 033, 043, 133, 136

Ghiggi, C., 121, 218

Ghilardi, G., 018, 043, 201

Ghione, P., 102, 114, 370

Ghobadi, A., 374

Ghosh, M., 085, 266

Ghosh, N., 242

Giannopoulos, K., 236, 240

Giatra, C., 318

Gibert, J., 125

Giebel, S., 311

Giezek, H., 193

Gigantes, S., 318

Gilbertson, M., 081, 326

Gille, R., 189

Gillenwater, H. H., 086

Gillessen Sommer, S., 070

Gillessen, S., 029, 133, 195

Gillings, M., 209, 210

Gimeno, E., 125, 141

Giné, E., 058, 060, 103, 115, 182

Gini, G., 019, 079, 080, 173, 183, 352, 392

Gioula, G., 301

Giovanella, L., 018, 022

Giudice, V., 390

Giuliani, F., 196

Giza, A., 034

Gkasiamis, A., 261

Glaisner, S., 044

Glantz, M., 157

Glass, B., 053

Glenn, M., 148

Glover, P., 040

Godwin, J. E., 273

Goh, J., 235

Goh, X., 235

Goldblatt, D., 286 bis

Goldkuhle, M., 397

Goldlust, S., 157

Golenkov, A.K., 306

Gomes, M., 172, 337, 339, 341, 350, 381

Gomez‐Espuch, J., 144

Gomez, S., 104

Gong, L., 086

Gong, T., 394

González Barca, E. M., 286

González Madruga, T., 302

González Pérez, M. S., 167

González Rodríguez, A., 169

González‐Barca, E., 028, 060, 135, 227, 329,

333

González‐González, B., 338

González‐López, T. J., 060

González, M., 135

Gonzalez Barca, E. M., 347

Gonzalez Barca, E., 360

Gonzalez de Villambrosia, S., 117

Gonzalez‐Barca, E., 103, 179, 243

Gonzalez‐Menendez, I., 106

Gonzalez‐Rincon, J., 104

Gonzalez, C. M., 196

Gonzalez, S., 179

Good, A., 233

Gopal, A. K., 263

Gorbach, O., 357

Gorbatchevsky, I., 113, 262

Goswami, B., 178

Goswami, R., 259

Gottardi, D., 019

Goy, A., 146

Goyal, G., 334

Grønbæk, K., 89

Graber, J., 157

Gracia Medina, E., 302

Grainge, M. J., 212

AUTHOR INDEX

503

Gramegna, D., 204

Grande, B. M., 064, 067, 068

Grande, B. M/c., 024

Grande, C., 182

Grandjean, B., 188

Grant, C., 340

Grapulin, L., 119

Grau, M., 103

Gravelle, P., 297

Gray, N., 012

Greco, A., 328

Gregor, M., 029, 133

Gregory, G. P., 253, 326

Greiner, T. C., 064, 065, 101

Greiner, T., 067

Gressin, R., 079, 110, 152, 245

Gribben, J., 114

Gricourt, G., 90

Grieve, C., 375

Grifﬁths, G., 99

Grigg, A. P., 038

Grigg, A., 081

Grigoriadou, G. I., 301

Grigoropoulos, N. F., 96, 97

Grimaldi, D., 059, 187

Griner, N. B., 067, 068

Griskevicius, L., 321

Gritti, G., 022, 043, 051, 111, 312

Groman, A., 370

Grommes, C., 156

Groocock, L., 232

Gros, François‐X., 084

Grosicki, S., 136

Gross, T. G., 067, 068

Grudeva‐Popova, Z., 244

Gu, J., 102

Guadagnuolo, S., 205, 276

Gualberto, A., 228

Guan, Q., 296

Guanchiale, L., 196

Guarda, L., 391

Guardalben, E., 312

Guariglia, R., 332, 390

Guarini, A., 119, 392

Guarinos, C., 376

Guerra, L., 019, 121

Guezennec, C., 073

Guidetti, A., 043, 275, 277

Guidetti, F., 043

Guidez, S., 110, 145, 245

Guillén‐García, H., 286

Guille, A., 278

Gumpel, C., 196

Gunawardana, J., 076

Gupta, S. A., 108, 349

Gupta, S., 327

Gurion, R., 164

Gurung, B., 315

Gussetti, D., 133

Gustavo, T., 103

Guthrie, T. H., 130

Gutiérrez Aleaga, Z., 302

Gutiérrez, A., 182

Gutierrez, A., 117, 125, 144

Gutierrez, Antonio‐M., 179

Gutierrez, C., 265

Gutierrez, G., 144

Gutwein, O., 164

Guzman‐Becerra, N., 258

Gyan, E., 079, 110, 245

H Walker, D., 013

Hájková, B., 285

Häupl, Björ., 011

Hübel, K., 118, 263

Hübschmann, D., 106

Hüttmann, A., 023, 025, 049

Haastrup, E. K., 89

Habermann, T. M., 041, 171, 185, 186

Habermann, T., 066

Habib, A., 157

Hadaya, K., 346

Hadigol, M., 004

Hagenbeek, A., 190

Haioun, C., 005, 015, 050, 079, 90, 91, 110,

184, 280

Hallek, M., 001, 030, 031, 034, 137, 139,

249

Halliday, S.‐J., 076

Halligan, S., 212

Hamadani, M., 053, 075, 177, 251

Hamed, A., 112

Hamilton, A., 120

Hamlin, P. A., 120

Hamlin, P., 375

Hammoud, M., 189

Hamon, M., 278

Hamon, S., 94

Hanáčková, V., 285

Han, X., 267

Han, Y., 234, 289, 291

Hanackova, V., 330

Hancock, H., 056, 211

Handorf, E., 148

Hansen, J., 232

Hantrakool, S., 322

Harigae, H., 085, 266

Harris, N. L., 067, 068

Hart, A. A., 233

Harvey, T., 340

Harwin, W. N., 254

Hatcher, J., 012

Hatic, H., 334

Hatzimichael, E., 164

Havenith, K., 238

Haverkos, B., 378

Hawkes, E. A., 081, 223

Hawking, J., 081

Hayden, A., 200

Hayoz, S., 018, 022

He, S., 177

He, X., 238

Hebart, H., 132

Heger, J.‐M., 155

Heiland, D. H., 046

Helmig‐Mason, J., 231

Hemmaway, C., 047

Henderson, C., 233

Henderson, J. A., 233

Henry, L., 194

Herbaux, C., 110, 145, 245, 297

Heredia Manzano, L., 302

Hermann, C., 305

Hermine, O., 150, 151, 152

Hernández‐García, M. T., 338

Hernández‐Mohedo, F., 286

Hernández‐Rivas, J. Án., 135

Hernández‐Rivas, J. A., 141

Hernández‐Rodríguez, I., 141

Hernández‐Sánchez, E., 141

Hernandez‐Ilizaliturri, F., 102, 370

Hernandez, A., 076

Hernani, R., 144

Herrera, A. F., 075

Herrera, A., 061

Herrera, F., 169, 170, 292

Herrera, P., 144, 292

Hertenstein, B., 047

Hertzberg, M., 253

Hess, B. T., 264

Hess, B., 177

Hess, G., 047, 062

Hess, N., 317

Hidaka, M., 209

Hiemeyer, F., 112

Hiemstra, I. H., 365

504

AUTHOR INDEX

Higgins, K., 033

Hildebrandt, M., 271

Hilger, J., 372

Hill, B. T., 222

Hill, B., 148

Hillmen, P., 033, 136, 138

Hilton, L. K., 024, 064, 065, 067, 068

Hinterschied, C., 231

Hirata, J., 111, 243

Hirsch, C., 287, 397, 398

Hitz, F., 043, 201

Ho, L., 248

Ho, P. J., 266

Hoang Xuan, K., 156

Hoang‐Xuan, K., 161

Hoang, P. M., 97

Hoaus, S., 319

Hoda, D., 273

Hodgson, D., 049, 158, 201

Hodson, D. J., 040

Hoechstetter, M., 249

Hoekstra, O. S., 021

Hohaus, S., 070, 173

Holmes, A. B., 042

Holmes, A., 004

Holmes, H., 240

Holte, H., 027, 064, 065, 92, 101, 239

Holtick, U., 274

Hong, A., 179

Hong, Y., 296

Hopkins, L., 214

Hoppe, M. M., 96, 97

Hopper, M. A., 041

Horowitz, N., 164, 240

Horwitz, S. M., 056, 120, 219, 281

Horwitz, S., 014, 211, 371

Hossain, N., 157

Hoster, E., 082, 150, 151, 271

Hou, M., 052

Houdyk, K., 081

Houillier, C., 161, 162

Houot, R., 050, 079, 084, 110, 145, 245, 379

Hristopoulos, M., 242

Hsi, E. D., 072

Hu, B., 107

Hu, D., 364

Hu, J.‐D., 052

Hu, J., 131, 325, 234, 362, 289, 291, 303,

052, 131

Huang, D. W., 011

Huang, D., 178, 235

Huang, H.‐Y., 052

Huang, H., 215

Huang, J., 107, 130, 372

Huang, L., 052

Huang, W., 262

Huang, X.‐B., 052

Huang, X., 057, 143

Huang, Y., 180

Hubareva, A., 395

Hue, S. S.‐S., 97

Huelsenbeck, J., 132

Hughes, M. E., 331

Huguet, M., 115

Huls, G. A., 217

Humpe, A., 271

Humphrey, K., 015

Husainova, G., 354

Husby, S., 89

Huscher, D., 305

Hutchings, M., 015, 016, 190

Hutson, A., 370

Huw, Ling‐Y., 242

Hwang, I., 231

I Gordon, L., 055

Iacoboni, G., 015

Iacovacci, S., 391

Iannitto, E., 154

Idoine, A., 130

Ielmini, N., 047, 049, 079

Ikonopoulou, D., 318

Ilariucci, F., 047, 218

Illerhaus, G., 046, 047

Illes, A., 033

Illidge, T., 071, 203

Ilyin, N., 388

Imaizumi, Y., 014, 210

Infante, M. S., 227

Infante, M., 117, 286

Inghirami, G., 043, 064, 065, 101, 102

Inwards, D. J., 148, 185, 186

Inwards, D., 171

Ionescu, C., 049

Ionova, T., 354

Iorio, J., 202

Irigoin, V., 358

Iriondo Alzola, J., 353, 387

Irvin, J. D., 067, 068

Isasa, M., 233

Isenberg, G., 164

Ishikawa, T., 118

Ishitsuka, K., 014, 209

Ishizawa, K., 209

Ishmatova, I., 343

Isuﬁ, I., 111

Itchaki, G., 156

Itti, E., 90

Ivanov, V., 354

Iyengar, S., 087, 107, 197

Izutsu, K., 014, 118, 209, 210, 252

Izuzquiza, M., 286

J Davies, A., 174

J Frank, M., 006

J Hernandez‐Ilizaliturri, F., 148

J Luck, T., 106

Jäger, U., 249

Jørgensen, G. Ø., 89

Jørgensen, J., 027, 92, 239

Jackson, S., 032

Jacobs, R., 032

Jacobsen Pulczynski, E., 047

Jacobsen, E. D., 014, 056

Jacobsen, E., 054, 146, 198

Jacoby, E., 270, 279

Jacque, N., 162

Jaeger, U., 074, 267

Jaffe, E. S., 064, 065, 101

Jaffe, E., 067, 068

Jagadeesh, D., 113, 219, 222, 244

Jahan, R., 042

Jain, M. D., 384

Jain, M., 082

Jain, P., 146

Jain, S., 076

Jais, J. P., 225

Jakob, T., 398

Jallades, L., 082

Janíková, A., 285

Janakiram, M., 238

Janardhanan, P., 232

Jani Sait, S., 370

Janikova, A., 049, 078, 220, 330

Jankeel, D., 232

Jankovic, V., 94

Janssen, P. M., 217

Janssens, A., 307

Janus, A., 127

Jardin, F., 050, 91, 235, 280

Jaynes, P., 96, 97

Jehng, T., 377

Jenner, R., 247

AUTHOR INDEX

505

Jentzsch, L., 082

Jeong, S., 94

Jeréz Cayuela, A., 122

Jerkeman, M., 049, 92

Jesús Peñarrubia, M., 286

Jeyasekharan, A. D., 96, 97, 235

Ji, C., 131, 299

Ji, D., 057

Jiang, A., 147, 200

Jiang, L., 151

Jiang, X.‐F., 052

Jiang, Y.‐J., 052

Jiang, Y., 030, 031, 137, 138, 362

Jiménez Galainena, J. J., 302

Jiménez Ubieto, A., 060

Jiménez‐Ubieto, A., 115, 182, 286

Jimenez‐Unieto, A., 117

Jimenez, O., 295

Jin, J., 057, 107, 112, 216

Jin, M. C., 025, 046

Jin, M., 368

Jindra, P., 285

Jing, H., 057

Jo, T., 210

Jodon, G., 378

Joffe, E., 120, 257

Johansson, P., 249

John, L., 287

Johnson, M., 286 bis, 370

Johnson, N. A., 051, 193

Johnson, N., 259

Johnson, P. W., 047, 073, 286 bis

Johnson, P., 016, 049, 99, 100, 247

Johnston, P. B., 171, 185, 186

Jones, C., 087

Jones, S. G., 197

Joris, M., 084

José Kersten, M., 085, 266

José Lis, M

., 141

José Terol, M., 135, 182

Josefsson, Pär L., 89

Joseph‐Pietras, D., 286 bis

Joseph, A., 375

Joubert, Clém., 184

Jozami, A. C., 348

Judet, A., 017, 166

Julião, M. J., 172, 339, 350, 381

Julião, M., 337

Junior, W. F. S., 345

Jurczak, W., 028, 033, 109, 112, 129, 236,

240, 244, 260, 262

Jure‐Kunkel, M., 365

Juskevicius, D., 018, 105

Jyrkkiö, S., 027

K Hilton, L., 101

Kühnle, I., 036

Kaźmierczak, M., 109

Kabíčková, E., 036

Kader, A., 370

Kadnikova, T., 395

Kahl, B. S., 177

Kahl, B., 157, 252, 315

Kalpadakis, C., 164

Kaltenbach, S., 152

Kamdar, M., 242, 378

Kaminski, M., 061

Kanellias, N., 164

Kanellis, G., 318

Kanoun, S., 189, 245, 114, 315

Kaouranis, K., 318

Kaplan, J. B., 148

Kaplanov, K., 354

Kara, M., 347

Karakasis, D., 318

Karakatsanis, S., 164

Karaolidou, F., 318

Karban, J., 330

Karianakis, G., 164

Karihtala, K., 027, 206

Karim, R., 174

Karimi, Y., 061

Karimzad, K., 265

Karjalainen‐Lindsberg, M‐L., 027

Karjalainen‐Lindsberg, M.‐L., 206

Karlen, J., 377

Karmali, R., 055, 148, 157

Karmiris, T., 164, 318

Karnabeda, O., 357

Karnik, R., 013

Karpha, I., 174

Karpova, O., 357

Karschnia, P., 082

Kasibhatla, S., 376

Kaskel, P., 195

Kataeva, E.V., 306

Kater, A. P., 033, 138, 146, 294

Kato, K., 014, 085, 210, 266

Katodritou, E., 164, 301

Kaverina, O., 354

Kawamata, T., 014

Kay, N., 033

Kaynar, L., 164

Ke, X., 107

Keane, C., 076, 081

Keating, M. M., 259

Kehden, B., 151

Kelleger, N., 333

Kelleher, N., 103, 329, 347, 360

Keller, U., 047

Kenkre, V. P., 113

Kennedy, H., 380

Kersten, M. J., 021, 190, 217, 272, 294

Kesanakurthy, V., 261

Kessler, L., 228

Khan, N., 211

Khan, S., 041

Kharabi, B., 393

Kharfan‐Dabaja, M., 053, 185, 186

Kheterpal, M., 211

Khiabanian, H., 004, 029, 043

Khodadoust, M. S., 006, 056, 211

Khoury, J. D., 97

Kim, E., 211

Kim, J. S., 107, 209

Kim, M. S., 157

Kim, S. Y., 030, 250

Kim, S.‐H., 157

Kim, S., 031, 137

Kim, W. S., 209

Kim, W.‐S., 057

Kim, Y. H., 056, 211

Kim, Y., 054

Kimball, A., 374

Kindrakevych, O., 357

King, R. L., 041

King, R., 066, 171

Kingsley, E., 130, 264

Kipps, T. J., 032, 136

Kipps, T., 138

Kirby, R. J., 233

Kirkwood, A. A., 073, 087, 194

Kirkwood, A., 247

Kiseleva, M., 354

Klöpfer, P., 237

Klapper, W., 035, 036, 150

Klaus, C., 013

Klein, A., 148

Kline, J., 051, 075

Klingbiel, D., 118

Klitochenko, T., 354

Kluin‐Nelemans, H., 151

Kmetyuk, Y., 357

Knörr, F., 036

Kneba, M., 034

Knopp, M. V., 073

506

AUTHOR INDEX

Knowles, S., 219

Kořen, J., 285

Kobayashi, R., 037

Koch, R., 029, 043, 070, 133

Koenecke, C., 274

Koeppel, L., 195

Kogarko, B.S., 306

Kogarko, I., 306

Koh, L. P., 235

Koh, Y., 057, 209

Koldej, R., 081

Kolla, B., 148

Kollar, P., 358

Kolstad, A., 085, 266

Konstantinidou, P., 301

Kopeckova, K., 237

Korin, L., 298

Kosmas, P., 318

Kostakoglu, L., 072

Kostrewa, J., 370

Kothari, S., 148

Kotrova, M., 151

Koumarianou, A., 164

Koutroumpakis, E., 265

Kovach, A. E., 148

Kovalchuk, S., 173

Koviazin, A., 343

Kozlov, V., 357

Krčméryová, M., 285

Krampera, M., 047

Krasniqi, F., 201

Krause, S., 047

Kreger, B. T., 233

Kreuz, M., 106

Kreuzer, K. A., 034

Kreuzer, K.‐A., 030, 031, 137, 249

Kriachok, I., 357, 395

Kridel, R., 123, 158, 201, 384

Krug, L. T., 93

Krull, J., 041

Kryachok, I., 049, 223

Ku, M., 253

Ku, N. C., 129

Kugathasan, L., 147

Kuhnl, A., 083, 087, 174

Kuittinen, O., 383

Kuitunen, H., 383

Kukreti, V., 123, 158, 201, 384

Kulis, M., 058

Kumar, A., 056, 120, 147, 149, 153, 175,

375

Kumar, P., 157

Kumar, R., 004

Kunz, W., 271

Kurakin, V., 354

Kurgansky, N., 196

Kurlapski, M., 070

Kuroda, J., 209

Kurosawa, M., 209, 210, 025, 046, 139

Kurtz, D. M., 006

Kurtz, D., 023

Kuruvilla, J., 051, 074, 123, 158, 193, 201,

259, 374, 376, 384

Kushchevyi, Y., 395

Kuss, B., 032

Kusumoto, S., 014, 210

Kutsch, N., 155

Kuzan, D., 272

Kwak, J.‐Y., 057

Kweekel, C., 365

Kwon, M., 126, 268

L Mackall, C., 006

L Ortiz‐Romero, P., 054

L Shaffer III, A., 011

López Jiménez, F. J., 169, 170

López Jiménez, J., 060, 122

López‐García, A., 141

López‐García, P., 338

López‐Guillermo, A., 060, 103, 115

López‐Jiménez, J., 141

López‐Rubio, M., 141

López, C., 058, 103, 169, 170, 292

La Rosée, P., 047

La Rosa, E., 328

Labrador, J., 141

LaCasce, A. S., 038, 072, 198

Lacerda, J. F., 304

Lacy, S., 040

Laddaga, F. E., 359

Ladetto, M., 043, 059, 080, 119, 312

Lafuente, M., 125

Lage, L. A. P. C., 345

Lahiry, A., 237

Lai, A. C., 172, 350, 381

Lai, A., 337, 339, 341

Laister, R. C., 384

Laister, R., 259

Lakhwani, S., 338

Lamadrid García, J., 302

Lamanna, N., 129

Lamb, M., 039

Lambert, J., 314

Lamy, T., 146, 199, 379

Landau, D.A., 009

Landoni, A. I., 358

Landsburg, D. J., 148, 331

Lang, N., 158, 201

Langer, P., 287

Langerak, A. W., 138

Langerbeins, P., 034

Lansigan, F., 063, 148, 198, 310

Lapalombella, R., 231

Lapietra, G., 356, 382

Laplant, B., 171

Laraque, L., 375

Lares, A., 211

Laribi, K., 050

Larionova, O., 354

Larouche, J. F., 259

Larsen, T. S., 027, 89, 239

Larson, M. C., 041

Lasica, M., 236

Latif, A.‐L., 087

Laubach, C., 073

Lauer, E. M., 046

Laurenge, A., 156

Laurent Damaj, G., 109

Laurent, C., 110, 145, 152, 278, 297, 317

Laurenti, L., 029, 133, 134

Lauritzsen, G. F., 239

Lavaud, A., 160

Law, P., 076

Law, Soi‐C., 076

Lawrence, M., 99

Lawrie, E., 247

Lazareva, D., 354

Lazaroiu, M., 112

Lazarovici, J., 050, 189, 199

le Blanc, M., 073

Le Bras, F., 084, 199

Le Bris, Y., 152

Le Cann, M., 162

Le Dû, K., 389

Le Dieu, R., 194

Le Du, K., 050

Le Garff‐Tavernier, M., 162

Le Garff, M., 160

Le Goff, E., 90

Le Goff, M., 389

Le Gouill, S., 079, 084, 110, 145, 146, 152,

245, 280

Leal, F., 067, 068

Lebel, E., 384

Leblond, v., 160

Lebras, L., 005, 050

AUTHOR INDEX

507

Lech‐Maranda, E., 129

Ledoux‐Pilon, A., 044

Lee, C. Y., 221

Lee, H. G., 209

Lee, H. J., 074, 248

Lee, J. H., 209

Lee, J.‐S., 057

Lee, J., 96, 97, 235

Lee, S. T., 081

Lee, W. S., 209

Lee, W.‐S., 057

Lefebure, M., 138

Leitch, H., 290

Leivonen, S.‐K., 206, 239

Lema, V., 358

Lemmonier, F., 044

Lemonnier, F., 90, 225

Lengerke, C., 274

Lentz, G., 252

Leonard, E. J., 037

Leonard, J. P., 072

Leonidopoulou, T., 164

Lepik, K., 354

Lepistö, M., 92

Leppä, S., 027, 92, 206, 239

Lepretre, S., 033

Lequesne, J., 050

Leslie, L., 257

Letailleur, V., 044

Leveneur, Y., 317

Levi, I., 240

LeVoir, A., 281

Levy, M. Y., 130, 244

Lewis, D. J., 016

Lewis, D., 129, 147, 214

Lewis, K. L., 236

Lhomme, F., 044

Li, B., 052

Li, D., 263

Li, F., 052, 216

Li, H., 073, 368

Li, J., 057, 063, 113, 131, 136, 215, 261, 269,

310, 336

Li, L., 269, 293, 296, 323, 361, 396

Li, M., 364

Li, S., 97, 148, 376

Li, W., 112, 215, 293

Li, X., 269, 323, 361, 396

Li, Y., 131, 296

Li, Z.‐F., 052

Li, Z., 215, 216, 269, 368, 396

Liao, M. Z., 031

Liardo, E. V., 187

Liberati, A. M., 028, 079, 107, 119

Liberatore, C., 181

Liestøl, K., 239

Ligdi, L., 318

Lim, S. T., 96, 97, 235

Lim, S.H., 286 bis

Lima, C. B., 341, 350

Limbrick‐Oldﬁeld, E. H., 114, 315

Limongello, R., 207

Lin, J., 260

Lin, N., 192, 256

Lin, T., 112

Lin, Y.‐L., 366

Lin, Y., 157

Linhares, Y., 251

Link, B. K., 041, 185, 186

Linton, K. M., 047

Linton, K., 016, 107, 214

Litovich, C., 053

Liu, C. L., 006, 025, 046

Liu, J., 052, 234, 282, 362, 394

Liu, L., 052, 131

Liu, M., 303

Liu, N., 116

Liu, R. D., 190

Liu, T., 131

Liu, W., 192, 282, 364, 394

Liu, X., 96, 97, 215, 235, 293, 296

Liu, Y.‐H., 052

Liu, Y.‐Y., 052

Liu, Y., 168

Llamas Gutierrez, F., 044

Llanos, M., 104

Lleshi, A., 173, 181

Llorin‐Sangalang, J., 113

Lo, A., 200

Lobetti Bodoni, C., 078

Locatelli, F., 037

Locke, F., 082

Loh, J. W., 029

Lohrmann, E., 237

Loi, Hoi‐Y., 235

Lolli, G., 191

Lome‐Maldonado, C., 363

Long, M., 231

Lopes, C., 304

Lopez‐Girona, A., 232

Lopez‐Godino, O., 144

Lopez‐Guillermo, A., 043, 078, 243

Lopez, A., 179

Lorente, S., 286

Lorenzano, F., 316

Lorenzoni, A., 277

Lorne, B., 379

Loscertales, J., 141

Losem, C., 132

Loseto, G., 392

Lossos, I. S., 242

Loutsidi, A., 318

Lown, R., 286 bis

Lowy, I., 94

Loyaux, R., 90

Lu, F., 299

Lu, T., 031, 362

Lucchini, E., 043

Luchetta, P., 348

Luciani, S., 351

Lucioni, M., 043

Lue, J. K., 148

Lugtenburg, P. J., 190

Lugtenburg, P., 016, 239, 250

Luisi, F. A. V., 037

Luizaga, L., 103, 115

Luminari, S., 020, 077, 078, 079, 080, 119,

121, 173, 183, 223, 263, 352

Lund, I., 370

Lundberg, L., 015

Lunning, M., 257

Luponio, S., 332, 390

Lurain, K., 93

Luther, S., 371

Luzardo Henriquez, H. D., 227

Luzardo, H. D., 179

Luzardo, H., 286

Lv, F., 112

Lymboussakis, A., 223

Lymp, J., 273

Lysenko, I., 354

Müller, H., 195

Müller, N., 271

Vale, A., 141

Ma, J., 282, 394

Ma, L., 114

Ma, X.‐J., 052

Macaulay, C. W., 046

Macaulay, C., 023

Maccaro, C., 056

Mach, N., 062

Machan, S., 226

Maciel, F. V. R., 345

Macintyre, E., 151, 152

Mackensen, A., 082

508

AUTHOR INDEX

MacManus, M. P., 326

Macon, W., 171

Macq, G., 344

Maddocks, K. J., 028, 072, 148

Maddocks, K., 061, 075, 180

Maecker‐Kolhoff, B., 036

Maerevoet, M., 176

Magnano, L., 103, 115

Mahajan, N., 375

Mahler, M., 233

Maier, S., 373

Maierhofer, B., 373

Maiolo, E., 319

Maiorana, A., 043

Maisonneuve, H., 050

Maitre, E., 127

Major, A., 157

Majzner, R., 006

Makita, S., 014, 210

Malak, S., 280

Malecek, M.‐K., 157

Maliske, S., 185, 186

Malizia, C., 276

Malkowski, B., 049

Malladi, R., 266

Maloisel, F., 389

Maly, J., 238

Mammi, C., 173, 183, 018, 022

Mancino, S., 385

Mancuso, S., 183

Mangone, L., 391

Mangusan, R., 93

Manicone, M., 204

Manji, F., 123

Mankel, B., 069

Mannarella, C., 119

Manni, M., 080, 121, 223, 395

Mannina, D., 080, 119, 187, 352

Mannisto, S., 027, 239

Manos, K., 081

Manske, M. K., 041

Manso‐Alonso, R., 228

Manso, R., 226, 229, 300

Mantoan, B., 119

Manzke, O., 263

Mapar, P., 92

María Arguiñano, J., 286

María Rodríguez‐Pinilla, S., 226

Marín Niebla, A., 060

Maradei, J., 196

Marasca, R., 043, 107

Marcheselli, L., 077, 080, 121, 173, 183,

187, 204, 352

Marchetti, M., 134, 134

Marcial Martínez, W., 302

Marcus, R., 107

Margiotta Casaluci, G., 142

Maria Arguinano Perez, J., 243

Mariani, S., 319

Mariano, R., 196

Marinello, P., 195

Marino, D., 079, 173

Maris, M., 273

Marks, R., 274

Marlton, P., 111

Marouf, A., 189

Marques, B., 172, 337, 339, 341, 350, 381

Marquet Palomanes, J., 169, 170

Marquet, J., 122, 292

Marquez, M., 348

Marra, A., 207

Marra, M. A., 024, 067, 068

Martín García‐Sancho, A., 060, 182, 227,

286

Martín Moro, F., 169, 170, 292

Martín Rojas, R., 126

Martín Rubio, I., 292

Martín Santos, T., 122

Martín‐Martitegui, X., 286

Martín‐Subero, J. I., 058

Martín, A., 122

Martín, R., 117

Martín, S., 333

Martínez Lorca, A., 170

Martínez‐Laperche, C., 126, 268

Martínez, A.‐B., 122

Martelli, M. P., 207

Martelli, M., 049, 356

Martens, A. W. J., 294

Martignetti, R., 198

Martin García‐Sancho, A., 103

Martin‐Acosta, P., 104, 228, 229

Martin, A., 179

Martin, C., 144

Martin, J. P., 067

Martin, J.‐P., 068

Martin, M.‐R., 067, 068

Martin, P., 149, 153, 157, 261

Martin, S., 103, 329

Martines, C., 029

Martinez‐Calle, N., 194, 197, 212

Martinez‐Lopez, J., 085, 266

Martinez‐Prieto, M., 267, 272

Martinez, E., 257

Martinez, G., 313

Martinez, X., 213

Martino, M., 275

Martins, C., 304

Martorelli, C., 332, 390

Martus, P., 274

Martynchyk, A., 395

Maruyama, D., 014

Masciopinto, P., 359

Masood, A., 266

Masouridi‐Levrat, S., 188

Massaro, F., 352

Mata, A. V., 304

Matasar, M. J., 112, 120, 281

Matasar, M., 168, 252, 371, 375

Mateos Mazón, J. J., 141

Mato, A. R., 129

Mato, A., 033

Matous, J., 373

Mattar, B., 273

Mattarucchi, R., 133

Mattioli, V., 391

Mattlener, J., 155

Matturro, A., 385

Matutes, E., 043

Maurer, M. J., 041, 147, 185

Maurer, M., 066

Mauro, F. R., 134

Mavis, C., 102, 370

Mayer, A., 069

Maynard, B., 286 bis

Mayo, M., 013

Mayo, S., 259

Maziarz, R. T., 272

Mazzoleni, G., 391

Mazzucchelli, L., 043, 078

Mazzucco, W., 391

MBoumbae, D. L., 90

Mbulaiteye, S. M., 067, 068

McCarthy, H., 136

McCarthy, M., 340

McCord, R., 240

McCulloch, R., 147

McDonald, A., 013, 193

McGuirk, J. P., 266, 267

McKay, P., 99, 107, 109, 174, 194, 197

McKinney, M., 240

McMillan, A. K., 197

McMillan, A., 087, 243

McNally, D. R., 95

McWhite, K., 370

Mead, M. D., 257, 374

Medeiros, J., 304

Mederios, J., 148

Medina, A., 060

AUTHOR INDEX

509

Medinger, M., 188

Meeuwes, F. O., 217

Megalakaki, E., 164

Mehra, A., 112

Mehta‐Shah, N., 051, 056

Mehta, A., 148, 242, 334

Meignan, M., 017, 020, 91, 166, 189, 199,

246

Meignin, V., 043

Meissner, B., 024

Melear, J. M., 063

Mell, T., 100

Mellink, C., 138

Mellios, Z., 164, 318

Melnichenko, V., 354

Melnick, A., 012, 95

Melo, R. B., 345

Menárguez, J., 126

Menarguez, J., 268

Mendibil Esquisabel, B., 353, 387

Mendy, D., 232

Menendez, P., 241

Meng, H., 269

Meng, L., 384

Menna, P., 239

Menne, T. F., 197

Menne, T., 028, 083, 087, 380

Menter, T., 062, 105

Mercadal, S., 104, 115

Mercer, K., 99, 100

Meriranta, L., 92

Merli, F., 020, 048, 049, 079, 173, 183, 187,

204, 352

Merli, M., 029, 043, 077, 079, 080, 121, 133,

173

Mescam, L., 278

Mesquita, I. P., 304

Messmer, M., 148

Metser, U., 049

Mettivier, L., 332, 390

Metz, C., 162

Metzler, S. R., 198

Mey, U. J., 201

Mey, U., 062

Meyer, P., 239

Mi, H., 336

Mi, L., 192, 282, 364, 394

Mi, X., 055

Miall, F., 99, 194, 243

Mian, M., 059, 078

Miao, H. H., 038

Micallef, I. N., 185, 186

Micallef, I., 171

Micallef, S., 244

Miceli, R., 275

Michieli, M., 187

Michot, J.‐M., 376

Michot, Jean‐M., 184

Mier‐Hicks, A., 157

Mikhaeel, G., 049

Mikhailova, N., 354

Mikhaylova, I. N., 369

Miklos, D. M., 006

Miklos, D., 023

Milan, L., 022

Miles, D., 031

Miller, J. H., 326

Milner, S. G., 207

Minami, H., 209

Mingrone, W., 201

Minguez, P. A., 300

Minoia, C., 223, 392

Minotti, G., 239

Minullina, R., 354

Mirás, F., 141

Mironov, O., 354

Miskin, H. P., 236

Miskin, H., 241

Misleh, J., 130

Missiaglia, E., 045

Missiglia, E., 044

Misyurina, E., 354

Mitschke, J., 046

Miyagi, T., 210

Miyata‐Takata, T., 064, 065

Mo, Z., 232

Moatti, H., 199

Moccia, A., 043, 048, 070, 201, 246

Mochkin, N., 354

Mociková, H., 107

Mocikova, H., 220, 330

Mohr, A., 370

Mohty, M., 084

Moia, R., 029, 059, 070, 133, 142

Moignet, A., 379

Moja, L., 397

Moles‐Moreau, Marie‐P., 050

Moles, M.‐P., 161, 389

Molica, S., 134

Molina, T. J., 184

Molinari, A. L., 079, 119, 218

Molinari, A., 111, 173

Mollejo, M., 043, 104, 228, 229

Moluçon‐Chabrot, C., 161

Mondéjar, R., 228

Mondoulet, L., 366

Monegier, A., 314

Mongay Soler, L., 112

Monjanel, H., 044, 050

Monsalvo, S., 268

Montalbán, C., 179

Montalban, C., 043

Monter, A., 227

Montes‐Moreno, S., 182

Montillo, M., 029, 128

Montoro, J., 144

Montoto, S., 053, 078

Moore, S. G., 310

Mora, R. F., 174

Moreaux, J., 366

Morel, P., 044

Morel, V., 160, 162

Moreno Jiménez, G., 169

Moreno, C., 032, 135, 136

Moreno, M., 179

Morgan, R., 378

Morigi, A., 191

Morillo, D., 376

Morin, R. D., 024, 064, 065, 067, 068, 101

Morin, R., 259

Morineau, N., 110, 145, 245

Morishima, S., 014

Morisse, M. C., 085

Morland, C., 214

Morschhauser, F., 005, 015, 079, 084, 91,

109, 110, 145, 146, 176, 190, 245, 261

Mortier, L., 054

Moskowitz, A. J., 021, 051, 056, 120, 221

Moskowitz, A., 211

Moskowitz, C. H., 021

Mosquera Orgueira, A., 167

Motalkina, M., 343

Motta, G., 316

Motta, M., 077, 128

Mottok, A., 97

Mougiakakos, D., 082, 274

Mounier, N., 280

Mous, R., 016

Mozas, P., 103, 115

Mozos, A., 227

Muñiz, P., 126

Muñoz, C., 268

Mucientes, J., 122

Muiña, B., 141

Mulè, A., 352

Mulholland, N., 083

Muller, D., 286 bis

Mullighan, C. G., 067, 068

Mundy, C., 286 bis

510

AUTHOR INDEX

Mungall, A. J., 064, 065, 067, 068, 101

Mungall, K., 067, 068

Munksgaard, L., 027

Munoz, J., 086

Munson, D., 377

Muntañola, A., 103, 115, 141, 286

Muntanola Prat, A., 060

Murphy, A. J., 94

Murru, R., 134

Musick, L., 111, 243

Musolino, A., 391

Musso, M., 352

Musto, P., 359

Musulen, E., 241

Musuraca, G., 079, 080, 119, 121, 173, 187,

218

Mutsaers, P. G.N.J., 217

Mutter, J. A., 046

Muxi, P., 358

Muzi, C., 154, 204

Mwangi, R., 066

Mykhalska, L., 357

Myskowski, P., 056, 211

Nørgaard, P., 027

Nabergoj, M., 188

Nadeu, F., 058, 103

Nagai, H., 209

Nagler, A., 270, 279

Nagumantry, S. K., 197

Nagy, E., 214

Nahar, A., 193

Naik, S., 157

Nair, B. C., 129

Nair, R., 223

Nakamura, H., 259

Namirembe, C., 067, 068

Nan, F. F., 324

Nan, F., 269, 396

Nanni, L., 191

Narayana Rao Gari, S., 148

Nardelli, C., 359

Narkhede, M., 334

Narla, R. K., 232

Narni, F., 059

Nassi, L., 119, 173, 392

Nasta, S. D., 331

Nasta, S., 244

Nastoupil, L. J., 266

Nastoupil, L., 265, 376

Nasveschuk, C. G., 233

Nath, K., 076

Natkunam, Y., 006

Nauwelaerts, H., 244

Navarro, A., 058

Navarro, B., 104, 117

Navarro, J.‐L., 122

Navarro, W., 258

Nazario Dolz, M., 302

Neelapu, S., 265

Negievich, Y., 075

Negri, F., 196

Negri, P., 196

Negricea, R., 242

Neidert, N. N., 046

Neuenburg, J. K., 260

Neven, A., 071, 203

Neves, D. S., 341

Neves, D., 172, 337, 339, 350, 381

Ney, D., 157

Ng, S.‐B., 97

Ng, Siok‐B., 96, 235

Ngoya, M., 053

Nguyen‐Quoc, S., 162

Nichols, J., 370

Nicolas Virelizier, E., 110, 245

Nicolas‐Virelizier, E., 91

Nicoletti, A., 385

Nielsen, A. F., 89

Nielsen, C., 89

Nielsen, L., 307

Niemann, C. U., 249

Nijland, M., 190, 217

Nikitin, I., 308, 309

Nikitina, T., 354

Nikolaenko, L., 371

Ninomoto, J., 032

Nioche, C., 020

Nistal, S., 286

Niu, T., 052

Noël, R., 044

Noesslinger, T., 132

Nogueira, F. L., 154

Nonis, A., 047

Noor, S., 211

Norasetthada, L., 322

Norman, J., 087

Normant, E., 236, 241

Norol, F., 162

Norris, R. E., 037

Northend, M., 174, 194, 247

Nosaka, K., 014

Notarangelo, L. D., 284

Novak, A. J., 041

Novak, J. P., 041

Novak, U., 043, 062, 201

Novelli, S., 144, 286

Novikov, M., 357

Novo, M., 255

Novoa, A., 298

Novosad, O., 357, 395

Nowakowski, G. N., 066

Nowakowski, G. S., 063, 171, 178, 185, 186,

237, 254, 261, 310

Nowakowski, G., 078, 257

Noy, A., 056, 067, 068, 120, 175, 371

Nuccorini, R., 385

Nunn, L., 99

Nyamutswa, L., 393

O'Brien, S., 033

O'Callaghan, A., 286 bis

O'Connor, O. A., 236

O'Hear, C., 240, 242

O'Mahony, D., 197

O'Reilly, M., 087

Oña, R., 117, 227

Oak, J., 006

Oarbeascoa, G., 268

Oberic, L., 146, 152, 184, 317

Obr, A., 028, 330

Occhini, U., 079

Ocheni, S., 398

Ochoa, P., 298

Odone‐Filho, V., 037

Oellerich, T., 011

Offner, F. C., 015

Offner, F., 136, 266, 307, 344

Ogasawara, K., 086

Ogna, A., 284

Ogwang, M. D., 067, 068

Ohtsuka, E., 210

Oki, Y., 168, 242

Okwali, M., 120

Oleinik, Y., 343

Oliinichenko, O., 357

Oliva, S., 392

Oliveira, A. C., 333, 347

Oliveira, A., 360

Oliver, A. C., 358

Oliver, R., 194

Oliveri, R. S., 365

Olivier, P., 005

AUTHOR INDEX

511

Ollila, T., 157

Olsen, M., 006, 046

Olszewski, A. J., 240

Ondarra Segurola, L., 353

Ong, C. K., 96, 97, 235

Onofrillo, D., 154

Onogi, H., 209, 210

Oostvogels, R., 217

Opat, S. S., 326

Opat, S., 032, 107, 109, 372

Oppi, S., 019

Orem, J., 067, 068

Orme, J., 185

Orsucci, L., 047, 048, 077, 079, 218

Ortiz Romero, P., 98

Ortuño, F., 122

Osborne, W., 083, 087, 99, 174, 194, 197,

380

Oschlies, I., 036

Oscier, D. G., 043

Osipov, Y., 354

Osorio, S., 141

Osovská, M., 285

Östman, A., 206

Özcan, M., 112

Ostrovsky, O., 279

Ott, G., 064, 065, 101

Otto, F., 069

Ouyang, B., 052

Owen, C., 136, 138

Owen, M., 194

Owens, C., 120, 371

Ozcan, M., 193

Ozgur, M., 164

Pérez Buira, S., 226

Pérez Ceballos, E., 122

Pérez Corral, A., 268

Pérez Encinas, M. M., 167

Pérez Persona, E., 237

Pérez‐Fernández, I., 141

Pérez‐Simón, J. A., 258

Pérez, N., 300

Pérez, S., 141

Paccagnella, A., 276

Pagani, C., 181, 183, 187, 284

Pagel, J., 113

Paget, J., 280

Paik, J., 231

Painter, D., 040

Pak, T., 281

Palaskas, N., 265

Palassopoulou, M., 164

Pallasch, C., 249

Palmer, B., 055

Palmer, J., 213

Palomba, L. M., 120

Palomba, M. L., 114, 175

Palombi, F., 079, 319

Paludo, J., 147, 186

Pan, G., 269

Panchal, A., 031, 137

Paneesha, S., 263

Pang, W. L., 235

Pang, Y., 299

Pangalis, G. A., 078

Panizo, C., 146, 243

Panse, J., 047

Panzarella, T., 384

Paolani, G., 276

Papa, E., 319

Papageorgiou, S. G., 154

Papageorgiou, S., 164

Papavasiliou, F N., 106

Parameswaran, V., 310

Pardee, T. S., 371

Parisi, L., 149, 153

Parody, R., 144, 329

Parreira, J., 118

Parrens, M., 044, 225, 278

Partesotti, G., 119

Pasanen, A., 027, 92

Pascale, S. P., 385

Pasero, P., 366

Pasqualucci, L., 004, 042

Passamonti, F., 029, 043, 133

Passweg, J., 029, 133, 188

Pastano, R., 053

Pastushenko, I., 357

Pastushenko, Y., 395

Paszkiewicz‐Kozik, E., 193, 311

Patah, P., 261, 376

Patel, A. R., 114, 315

Patel, A., 087

Patel, P., 033

Patmore, R., 040

Patriarca, A., 142

Patten, P. E. M., 266

Patten, P., 083

Patterson, V., 198

Patti, C., 019, 218, 312, 352

Paulli, M., 043, 077

Paunescu, A.‐C., 280

Pavlovsky, A., 196, 202, 223

Pavlovsky, S., 196

Pavone, V., 059, 328, 352

Pavoni, C., 019

Paydas, S., 164

Peñalver, F. J., 286

Peñalver, F.‐J., 179

Peñarrubia, M., 182

Peano, S., 121

Pecciarini, L., 181

Pedrosa, C. L., 342

Pedrosa, L., 104

Peggs, K., 247

Peixeiro, R. P., 342

Peleteiro Raindo, A., 167

Pellegrini, C., 191

Pelliccia, S., 187, 319

Pellinen, T., 206

Penack, O., 274

Peng, C., 336

Peng, S., 232

Peng, Y. Y., 174

Peng, Y., 96, 97

Pennese, E., 047, 173, 312, 351

Peraza Bordao, J., 302

Perbellini, O., 077

Pereira, J., 165, 223, 313, 345

Pereyra, P., 223

Perez de Oteyza, J., 117

Perez‐Callejo, D., 015

Perez, A., 082, 144

Perez, L., 056, 211

Perini, G. F., 193

Perino, S., 233

Peron, M., 389

Perrone, T., 080, 119

Peterson, T. J., 281

Petrello, H., 067, 068

Petrides, G., 083

Petrova, T., 354

Petrucci, L., 154, 319

Pettirossi, V., 207

Petzer, A., 266

Peyrade, F., 005

Peyre, M., 152

Pezzullo, L., 332, 390

Pham, S., 242

Phillips, B., 247

Phillips, E. H., 174, 203

Phillips, E., 071, 194

Phillips, N., 174

Phillips, T. J., 061, 238

Phillips, T., 109, 111

512

AUTHOR INDEX

Piñana, J. L., 144

Pianovski, M. A., 037

Piazza, F., 043, 077, 134

Piccione, E., 015

Pichler, P., 237

Pickles, T., 200

Piechotta, V., 287, 397, 398

Pietrantuono, G., 079, 121, 352

Pietrasanta, D., 128, 134

Piffaretti, D., 029, 043, 070, 133

Piffer, S., 391

Pike, L. C., 073

Pike, L., 247

Pileckyte, R., 321

Pileri, S. A., 043, 218

Pilz, V., 195

Pimentel, A., 141

Ping, L., 192

Pini, K., 029, 043, 070, 133

Pinilla‐Ibarz, J., 033

Pinna, P., 391

Pinnix, C., 265

Pinto, A., 070, 121, 218, 312, 376

Pinyol, M., 069

Pinzón, S., 125

Piparo, C., 312

Piperidou, A., 164

Piras, D., 391

Piris Pinilla, M. Án., 98

Piris Villaespesa, M., 170

Piris, M. Án., 043, 226, 228

Piris, M. A., 104, 227, 229, 300

Piriyakhuntorn, P., 322

Pirosa, M. C., 043, 070, 079, 133

Pisani, F., 047

Pitkänen, E., 92

Pittaluga, S., 064, 065, 101

Pittrow, D., 305

Pizzamiglio, s., 277

Pizzolitto, S., 043

Pizzolo, G., 134

Plates, V., 202

Plattel, W. J., 190

Pokala, S., 118

Poliatskin, I., 343

Politi, L. S., 047

Pollock, R. M., 233

Polo, B., 304

Ponzoni, M., 043, 047, 154, 181

Poon, D., 073

Poon, L., 96, 97, 235

Popplewell, L. L., 374

Popplewell, L., 061, 085, 266

Porcu, P., 014, 054

Porﬁrieva, N., 354

Porrata, L. F., 171, 185, 186

Porro Lura, M., 030

Portell, C., 107

Porter, R., 130

Portugues, C., 91

Pott, C., 151

Potter, V., 083

Pottinger, B., 99

Poullot, E., 044, 90

Pourdehnad, M., 376

Pourpe, S., 94

Prates, V., 196

Pravato, S., 134

Preau, M., 280

Preciado, M. V., 295

Prete, E., 328, 352

Prica, A., 116, 123, 158, 201, 384

Prince, H. M., 223

Prinz, M., 046

Pro, B., 055, 078

Prochazka, V., 220, 330

Proﬁtos‐Peleja, N., 241

Proia, D. A., 233

Prouty, A., 231

Provencio, M., 074, 104

Przespolewski, E., 370

Publicover, A., 380

Pucciarini, A., 207

Puccini, B., 173, 183

Pukrop, T., 047

Pulsoni, A., 077, 079, 080, 119, 121, 352,

356, 382

Pupo, L., 319

Puzzovivo, A., 392

Pylypenko, H., 244

Pytlik, R., 220

Qayum, N., 240

Qi, F., 364

Qi, K., 149, 153

Qian, L., 224

Qian, W.‐B., 052

Qian, Z., 293, 296

Qiao, Q., 012

Qin, Y., 177

Qiu, J., 336

Qiu, L., 216, 293, 296

Quaglia, F. M., 134

Quaresima, V., 284

Quartara, A., 196

Queizán, J.‐A., 179

Queizan, J. A., 227

Querfeld, C. S., 213

Queru, K., 044

Quintanilla‐Martinez, L., 069, 106

Qureshi, I., 174

R Thompson, S., 108

Ríos, E., 135, 141

Röth, A., 047

Rütti, M., 201

Radford, J. R., 109

Radford, J., 071, 075, 114, 177, 203

Raemaekers, J., 071, 203

Raess, P. W., 064, 065, 101

Rafferty, J., 99

Rai, S., 209

Rajakumar, P., 157

Rajamäki, A., 383

Rajarethinam, A., 109

Rajguru, S., 148

Ramírez Páyer, Án., 135

Ramírez‐Ibarguen, A. F., 363

Ramírez‐Páyer, Án., 182

Ramírez‐Payer, Á., 286

Ramírez‐Payer, A., 141

Ramírez, M., 182

Ramadan, S., 062

Ramakrishnan, P., 154

Ramaswami, R., 93

Rambaldi, A., 019, 022, 246

Ramchandren, R., 193, 257

Ramirez, A., 078

Ramis‐Zaldivar, J. E., 069

Ramos, R., 125

Rao, S. S., 130

Raposo, J., 304

Rashid, M. B. M. A., 235

Rasi, S., 029, 142

Rattanathammethee, T., 322

Rattarittamrong, E., 322

Rattotti, S., 077, 119

Rau, R., 393

Raus, N., 189

Raut, M., 193, 195

Ravichandran, H., 95

Raya, J.M., 338

Re, A., 173, 181, 183, 187, 218

AUTHOR INDEX

513

Re, F., 059, 077, 079, 080, 119, 173, 187,

218

Rebaud, L., 020

Rebmann Chigrinova, E., 188

Rechavi‐Robinson, D., 244

Reda, G., 134

Redd, R., 198

Reddy, N., 113, 148, 157

Rees, G., 214

Regadas, L., 342

Reguilón Gallego, L., 122

Reinacher, P. C., 046

Reinhardt, H. C., 155

Rejeski, K., 082, 271

Relander, T., 239

Relf, J., 015

Remaggi, G., 196

Remedi, A., 358

Ren, M., 106

Ren, S., 234

Renaud, L., 91

Reneau, J., 180

Renner, C., 062

Renzi, D., 119

Requena, L., 226

Restuccia, F., 351

Rey Búa, B., 182, 286

Reyes‐Garau, D., 241

Reyes, C. D., 338

Reynolds, C. M., 310

Reynolds, S. J., 067, 068

Riaza, R., 141

Ribeiro, M. L., 241

Ribera, J. M., 329, 333, 347, 360

Riberio, M. T., 114

Ribrag, V., 005, 91, 109, 151, 152, 262, 280

Ricardi, U., 049, 119

Ricart, A. D., 236

Ricciuti, G., 351

Richter, P., 201

Riddick, M., 196, 202

Riedell, P. A., 085, 266, 267

Rietveld, J. M., 294

Rigacci, L., 173

Rigolin, G. M., 134

Rimsza, L. M., 064, 065, 101

Rimsza, L., 041

Rimza, L., 069

Rinaldi, A., 059

Ringeleviciute, U., 321

Ristow, K., 148

Ritchie, D., 081

Ritgen, M., 031, 137, 249

Ritter, K., 188

Rivas‐Delgado, A., 103, 115

Rivas, A., 179

Rivero, A., 103, 115

Robak, T., 033, 127, 136, 146

Robe, C., 90

Robinson, K. W., 331

Robrecht, S., 030, 031, 034, 137, 249

Rocha, V. G., 313

Rocha, V., 165, 345

Rocquet, M., 189

Rodari, M., 070

Roddie, C., 174

Rodin, D., 158, 201

Rodríguez Martín, E., 170

Rodríguez‐Fernández, A., 141

Rodríguez‐Peralto, J. L., 226

Rodríguez‐Pinilla, S. M., 228

Rodríguez‐Salazar, M.J., 338

Rodríguez, M., 228, 329

Rodriguez‐Gonzalez, F. G., 89

Rodriguez‐Luaces, M., 360

Rodriguez‐Peralto, J. L., 98

Rodriguez‐Pinilla, S. M., 98, 229, 300

Rodriguez‐Rivera, I., 120, 371

Rodriguez‐Sevilla, J. J., 125

Rodriguez, G., 144

Rodriguez, M.‐J., 179

Rodriguez, M., 98, 226, 227, 229, 300, 333

Rodriguez, R., 366

Roig, M., 227

Rois Pego, N. F., 353, 387

Rojo, F., 300

Roldán Santiago, E., 170

Roldán‐Pérez, A., 286

Roman, E., 040

Romano Gargarella, L., 134

Romano, A., 019, 316

Romanowicz, G., 070

Romejko‐Jarosińska, J., 311

Romero, P., 141

Ronan, R., 373

Rontogianni, D., 318

Roos‐Weil, D., 160, 162

Roque, A., 172, 339, 341, 350, 381

Rosamilio, R., 332

Roschewski, M., 025

Rosen, S. T., 213

Rosenberg, E., 279

Rosenthal, A. C., 185, 186

Rosenthal, A., 257, 064, 065, 101

Roshan, R., 93

Rossi, A., 352

Rossi, C., 050, 246, 025, 029, 043, 059, 070,

079, 128, 132, 133, 142, 246

Rossi, F. G., 218

Rossi, G., 181, 183, 187, 284

Rosskamp, M., 344

Rosso, S., 391

Rotger, A., 060

Rotolo, F., 054

Roue, G., 241

Rouits, E., 244

Roulin, L., 90

Roumelioti, A., 318

Roveri, E., 196

Rovira, J., 115, 329, 333, 347, 360

Rovo, A., 188

Ruan, J., 055

Rubenstein, J., 157

Rubio, L., 201

Rubio, M. T., 189

Rubio, M.‐T., 162

Rubio, Marie‐Thérès., 084

Rudge, J. F., 197

Rudiuk, T., 357

Rudoy, S., 196

Ruf, S., 036

Rufﬁni, A., 020

Ruggiu, M., 314

Ruiz‐Camps, I., 141

Ruiz, C., 122

Ruiz, F., 377

Ruiz, M

E., 141

Rukavitsyn, O., 354

Rule, S., 146, 147

Rummel, M. J., 047,063, 310

Rumpold, G., 280

Ruppert, A., 072

Rusconi, C., 049

Rushton, C. K., 024, 065, 101

Russell, K., 032

Russo, A. G., 391

Russo, F., 077

Ruzicka, M., 271

Ruzickova, L., 172, 337, 339, 341, 350, 381

Ryan, G., 078

Ryu, S., 056, 211

Sánchez Blanco, J. J., 182, 227

Sánchez Blanco, J.‐J., 122

Sánchez‐Beato, M., 228, 229

Sánchez‐González, B., 286

514

AUTHOR INDEX

Sánchez‐Ramírez, M., 141

Sánchez, M

J., 141

Sønderskov Gørløv, J., 047

Sørensen, B., 89

Saadoon, E., 344

Sabattini, E., 043

Sabdia, M. B., 076

Sabell, S., 268

Sacchetti, G. M., 070

Sacchi, M., 074

Sackman, F., 196

Sadullah, S., 174

Saﬁn, R., 354

Sagiraju, S., 142

Saha, S., 111, 243

Sahaf, B., 006

Sakellariou, K., 318

Salanoubat, C., 162

Salar, A., 104, 117, 122, 125, 179, 263

Salas, Q., 144

Salaverria, I., 069

Sale, B., 99

Salles, G., 028, 043, 082, 91, 109, 120, 149,

153, 175, 178

Salman, H., 113

Salman, S., 157

Salmerón‐Villalobos, J., 069

Salvador Chalup, M. M. B., 154

Salvino, M. A., 037

Samii, K., 346

Samoylova, A., 354

Sampol, A., 144

Sanchez Avalos, J. C., 298

Sanchez‐Beato, M., 104

Sanchez‐Gonzalez, B., 125

Sancho Cia, J. M., 360

Sancho, J. M., 103, 115, 117, 286, 329, 333,

347

Sancho, J.‐M., 179

Sander, S., 106

Sanderson, R., 083, 087

Santambrogio, E., 043

Santarosa, A., 211

Santarsieri, A., 197

Santi, A., 207

Santiago, R., 141

Santoro, A., 051, 074, 077, 193, 275

Santoro, M., 276

Santos, J. C., 241

Santuccio, G., 316

Sanz‐Pamplona, R., 227

Sanz‐Villanueva, L., 126

Sapunarova, K., 112

Sarangi, V., 041

Saretsky, T., 193

Sarouei, K., 240

Sartori, R., 173, 183

Sasaki, O., 210

Sasser, A.K., 365

Sassone, M. C., 156, 181

Sauter, C., 053

Savage, K. J., 024, 038, 064, 065, 074, 075,

101, 150

Savage, K., 200

Sawalha, Y., 148, 180

Sawicki, W., 311

Sayas, M. J., 227

Saydam, G., 112

Scalzulli, P. R., 154, 328, 352

Scarfò, L., 029, 128, 133, 134

Scarfó, L., 043

Schär, S., 018, 022, 062

Schöberl, F., 271

Schöder, H., 021, 072, 073

Schachter, J., 279

Schanz, U., 188

Scheich, S., 011

Scheid, C., 287

Scherer, F., 025, 046

Scherle, P., 231

Schetelig, J., 034

Scheubeck, G., 062

Schiano de Colella, J. M., 110, 145, 245

Schiano De Colella, J.‐M., 278

Schiavoni, G., 207

Schiavotto, C., 019

Schilhabel, A., 034, 139, 151

Schipani, M., 059, 142

Schmidt Jespersen, J., 89

Schmidt, A., 201

Schmidt, B., 132

Schmidt, C., 082, 271

Schmitt, A., 109, 389

Schmitt, M., 274

Schmitt, T., 274

Schmitz, N., 053

Schmoll, H. J., 047

Schneider, C., 030, 034

Schoder, H., 120

Schoen, F., 151

Scholz, C. W., 263

Scholz, C., 228

Schorb, E., 046, 047

Schroers‐Martin, J., 006

Schroers, R., 274

Schultz, A., 025

Schuster, S. J., 085, 266, 272, 331

Schuurhuis, D., 365

Schwaner, I., 132

Schwieterman, J., 056

Sciabolacci, S., 207

Scott, D. W., 024, 064, 065, 067, 068, 95, 97,

101, 150, 259

Scott, D., 012, 200

Scott, F. M., 335

Seguy, F., 263

Sehgal, L., 231

Sehn, L. H., 024, 064, 065, 150, 252, 263

Sehn, L., 200

Sekiguchi, N., 193

Sellam, G., 240

Selleri, C., 332, 390

Semiglazova, T., 343

Septans, A.‐L., 389

Sequero, S., 104

Serbest, G., 014

Seregni, E., 277

Seri, C., 141

Serio, B., 332, 390

Serraino, D., 391

Serres, M. R., 041

Seshadri, M. R., 012

Seshan, V. E., 120

Sesques, P., 050, 082, 084

Setoain, X., 060

Sevastoudi, A., 301

Seyffert, S., 373

Seymour, E., 243

Seymour, J. F., 111, 138

Sha, F., 120

Sha, Y., 336

Shadman, M., 130

Shah, B., 146, 148, 198

Shah, N. N., 129

Shah, N., 174, 197, 237

Shalaev, S., 343

Shanavas, M., 076

Shang, G., 109

Shao, S. H., 310

Sharma, K., 013

Sharman, J. P., 063, 130, 310

Sharman, J., 273

Shaughnessy, P., 273

Shaw, J., 380

Shcolnik, R., 345

Shelekhova, T., 354

Shem‐Tov, N., 270

Shen, W., 364

Shenderova, I., 388

AUTHOR INDEX

515

Sherstnev, D., 354

Sheybani, N., 006

Shi, C., 367

Shi, Y., 112

Shiano del colella, J. M., 199

Shibayama, H., 209, 210

Shimoda, K., 210

Shimoni, A., 270, 279

Shin, H.‐J., 057

Shindo, T., 209

Shipp, M. A., 074

Shotton, R., 194

Shouval, R., 270

Shpall, E., 265

Shrubsole, C., 194

Shu, S., 364

Shu, Y., 216

Shudrak, N., 395

Shukla, N., 006

Siakantaris, M., 164

Sibon, D., 005, 044, 110, 184, 189, 225, 280

Sicard, G., 189

Siddiqi, T., 032, 086

Sidi, Y., 037

Sidiropoulou, E., 106

Siebert, R., 106

Sieg, A., 157

Sieg, N., 155

Silva, P., 268

Silva, W. F., 165

Simón, J. A. P., 266

Sim, H. W., 174

Simashova, P., 354

Simko, S., 253

Simpson, D., 136, 372

Sims, R. B., 254

Singer, S., 157

Singh, A., 029

Singh, V., 174

Siqueira, S. A. C., 345

Sirulnik, A., 94

Siyu, Q., 399

Skoetz, N., 287, 397, 398

Skrypets, T., 223, 392, 395

Slack, G. W., 024, 064, 065, 101

Slade, D., 214

Sloan, S., 231

Smet, A., 307

Smirnova, E., 354

Smith, A. G., 040

Smith, C. D., 349

Smith, C., 081, 108

Smith, J., 047

Smith, S. D., 146

Smith, S. M., 157

Snauwaert, S., 307

Snijdewint‐Nkairi, R., 365

Soares, I. C., 345

Sobieraj‐Teague, M., 107

Soehlbrand, A., 151

Soh, T. G., 235

Sohail, S., 211

Sohoni, S., 033

Sokol, L., 198

Solé‐Rodríguez, M., 286

Soler, J. A., 141

Solh, M., 177

Solomon, S., 086

Solorzano, S., 160

Somasundaram, N., 235

Song, J. Y., 064, 065, 101

Song, W., 367, 368

Song, Y.‐P., 052

Song, Y., 057, 131, 192, 256, 282, 364

Song, Z., 293

Soo, J., 025

Sopena Novales, P., 122

Sorasio, R., 019

Sorigue, M., 383

Sorio, M., 352

Sotttini, A., 284

Souchet, L., 162

Soumerai, J. D., 113

Souravla, K., 318

Soussain, C., 156, 161, 162

Speletas, M., 305

Spina, M., 077, 079, 173, 181, 183, 255

Spina, V., 029, 043, 070, 133, 142

Spindler, T., 377

Sportoletti, P., 134, 207

Spurgeon, S., 157

Sreevatsan, P., 012

Stüssi, G., 029, 043, 070, 133

Staber, P., 249

Stafford, G., 197

Stakia, P., 188

Stamatoullas, A., 189, 199

Stanton, l., 99, 100

Stasia, A., 070

Stathis, A., 043, 070, 079, 113, 177

Staudt, L. M., 011, 064, 065, 067, 068, 101

Stefani, P. M., 059, 080, 121, 352

Steffanoni, S., 156

Stefoni, V., 191, 218

Steidl, C., 024, 064, 065, 95, 101

Steimle, T., 152

Steiner, R., 265, 371

Steinerová, K., 285

Steinerova, K., 220, 330

Steinhilber, J., 069

Stelitano, C., 059, 119

Stelljes, M., 274

Stenner, F., 201

Stenson, C., 380

Stepanishyna, Y., 395

Stephens, D. M., 086

Stern, A., 188

Sternberg, A., 197

Stevens, D. A., 273

Stevens, K., 208

Stieglmaier, J., 374

Stilgenbauer, S., 030, 031, 033, 034, 047,

137, 139, 249

Stocker, R., 380

Storozhenko, L., 388

Storti, S., 183

Stracci, F., 391

Strati, P., 265

Straus, D. J., 038, 175

Straus, D., 056, 120, 371, 375

Streich, S., 069

Strigari, L., 276

Strolin, S., 276

Strouse, C., 157

Stumpf, J., 249

Sturgess, K., 197

Suárez‐González, J., 126

Suarez, M., 122

Subklewe, M., 082, 271, 374

Sudhindra, A., 114, 315

Sujobert, P., 278

Sukor, S., 340

Suleman, A., 116

Sun, C. Z., 324

Sun, C., 143

Sun, M., 107

Sun, X., 303

Sun, Y., 258

Sun, Z., 269, 323, 361, 396

Sundaram, S., 102, 157, 370

Sunela, K., 383

Sureda, A., 015, 053, 179, 246, 329, 333,

347, 360

Svoboda, J., 331

Svobodová, E., 285

Swanink, R., 074

Swaroop, A., 055

Swerdlow, S. H., 067, 068

Sworder, B., 006, 023

516

AUTHOR INDEX

Sykorova, A., 220, 330

Symeonidis, A., 164

Syrykh, C., 278, 297

Szablewski, V., 176

Szafer‐Glusman, E., 032, 365

Szlauer‐Stefańska, A. T., 311

Szoke, A., 136

Szomor, Á., 112

Szor, R. S., 313

Szymczyk, M., 150

Tabbo', F., 102

Tadmor, T., 164

Tafuri, A., 319, 352

Tagliabue, G., 391

Taguchi, J., 210

Takamatsu, Y., 210

Takano, K., 210

Takvorian, T., 198

Talaulikar, D., 076, 107

Talotta, D., 142

Tam, C. S. L., 032

Tam, C. S., 236, 372

Tam, C., 260

Tam, W., 95

Tamayo, P., 122

Tamburini, J., 189

Tambuyzer, T., 283

Tan, D., 235

Tan, L. K., 235

Tan, S.‐Y., 97

Tandon, M., 030, 031, 137

Tang, J.‐P., 236

Tang, T., 96, 97, 235

Tang, W., 272, 373

Tang, Y., 192, 256

Tani, M., 048, 079, 119, 121, 154, 173, 187,

218, 238

Tansley‐Hancock, O., 99

Tantiworawit, A., 322

Tao, L., 146, 252

Tapia, G., 043

Tarantini, G., 173, 328

Tarantino, V., 121, 154

Tardy, M., 050

Tartas, N., 298

Tarte, K., 110, 145, 297

Tasakis, R. N., 106

Tasselli, L., 207

Tatevosova, N. S., 369

Tausch, E., 030, 031, 034, 137, 139, 249

Taveras, A., 373

Tchernonog, E., 044

Tedeschi, A., 029, 032, 107, 128, 133, 136

Teihman, S., 270

Templeton, A. J., 201

Tempra, P., 298

ten Hagen, W., 365

Terdi Di Bergamo, L., 142

Terol, M. J., 060

Terol, M.‐J., 122

Terol, M

J., 141

Teruel, A.‐I., 122

Terzi di Bergamo, L., 029, 043, 070

Terzi‐di‐Bergamo, L., 133

Tesei, C., 319

Teshima, T., 266

Tessoulin, B., 199

Thadani‐Mulero, M., 138

Thanarajasingam, G., 147

Theurich, S., 398

Thieblemont, C., 005, 017, 043, 079, 084,

085, 91, 107, 110, 145, 152, 166, 176,

184, 250, 266, 314

Tholouli, E., 087

Thomas, C., 011

Thomas, N., 067, 068

Thomas, R.‐N., 370

Thomas, S., 274, 373

Thome Miazza, M., 045

Thompson, C. A., 185

Thompson, C., 066

Thompson, M. C., 129

Thompson, S. R., 349

Thompson, S., 327

Thornton Snider, J., 114, 315

Thorpe, J., 086

Thorsgaard, M., 89

Thota, V., 377

Thurner, L., 047

Thurston, G., 94

Tiacci, E., 207

Tian, Z., 289, 291

Tilly, H., 005, 017, 050, 079, 91, 109, 110,

145, 166, 176, 184, 245

Timothy, G., 068

Tisi, M. C., 154, 275

Tissino, E., 029

Tiwari, R., 266

To, I., 242

Tobin, J. W., 076

Tobinai, K., 014, 209, 210

Toffanin, S., 244

Toffolutti, F., 391

Toldbod, H., 239

Tomás Navarro, J., 122

Tomás‐Roca, L., 98, 228

Tomás, L., 227

Tomas‐Roca, L., 229

Tomei, G., 319

Tomiczek, M., 118

Tomlinson, E., 398

Tomuleasa, C., 223

Tong, Y., 052

Tonialini, L., 328

Tonino, S. H., 190, 294

Tonnelet, D., 050

Tonseth, P., 259

Tooze, R., 040, 100

Topp, M. S., 94

Topp, M., 274

Torka, P., 102, 157, 370

Torres, A., 141

Tosti, M. E., 119

Touat, M., 156

Tounta, G., 318

Tournilhac, O., 044, 225

Tousseyn, T., 043

Townsend, W., 174

Traverse Glehen, A., 199

Traverse‐Glehen, A., 043, 050, 067, 068

Trede, N. S., 273

Trenina, N., 354

Trentim, L., 134

Trentin, L., 019, 032

Treon, S., 373

Triantafyllou, T., 301

Trichelair, P., 010

Tripodo, C., 96, 97

Trněný, M., 285

Trneny, M., 074, 078, 220, 244, 263, 330

Trotman, J., 076, 107

Troussard, X., 127

Trumpp, A., 106

Tsai, D. E., 129

Tsai, N.‐C., 213

Tsang, H., 076

Tsang, M., 157

Tsang, R., 078, 158, 201

Tsinaris, Z., 301

Tsirigotis, P., 164

Tsirogianni, M., 164

Tsirou, K., 301

Tsonis, I., 318

Tsukamoto, N., 209

Tsukasaki, K., 014, 209, 210

AUTHOR INDEX

517

Tu, G., 364

Tu, M., 192

Tucci, A., 043, 047, 048, 049, 080, 154, 173,

183, 187, 204, 284

Tudesq, J. J., 084

Tuglular, T., 164

Tuglus, C., 374

Tulstrup, M. R., 89

Tumino, R., 391

Tun, A. M., 185, 186

Tun, H. W., 222, 257

Turba, E., 198

Turner, G., 214

Turroni, S., 205

Tytorenko, I., 395

Tzankov, A., 018, 043, 105

Tzenou, T., 318

Uña, J., 122

Uchida, T., 112, 209

Uldrick, T. S., 93

Ultimo, S., 207

Umyarova, E., 148

Ungar, D., 177, 251, 264

Unterhalt, M., 150

Us, I., 012

Usai, S. V., 080, 173, 218

Utsunomiya, A., 014, 210

Uttenthal, B. J., 197

Uttenthal, B., 039

Uzunov, M., 160, 162

Vaca, R., 157

Vacca, M. P., 359

Vaccarella, S., 391

Vacková, B., 285

Vaddi, K., 231

Vaillant, W., 317

Vallisa, D., 077, 187, 044, 045

Van Bogaert, C., 307

van de Brug, T., 021

van den Berg, A., 190

van der Kevie‐Kersemaekers, A., 138

van der Poel, M. W.M., 217

Van Eycken, L., 283

van Hoppe, M., 100

van Hoppe, S., 040

Vanazzi, A., 048

Vander Borght, T., 005

Vannata, B., 078

Vanquaethem, H., 389

VanSchoiack, A., 96

Vaqué, J. P., 98

Varda‐Bloom, N., 270

Vardhana, S. A., 221

Varela, A., 196

Varela, J. C., 273

Varela, M. R., 144

Varettoni, M., 218

Varvarà, M., 391

Vasiliev, E., 354

Vasilieva, A., 388

Vassilakopoulos, T. P., 154

Vassilakopoulos, T., 164

Vega, F., 265

Vela, V., 105

Velasques, R. D., 165, 345

Velasquez, C. A., 141

Venanzi, A., 207

Vendiola, J. A., 157

Venegas, M. B., 298

Venugopal, P., 157

Vercellino, L., 017, 91, 166

Verderio, P., 277

Verdesoto, S., 360

Verga, L., 181

Vermaat, J. S.P., 217

Verner, E., 372

Verrou, E., 301

Versari, A., 020, 049, 080, 121

Veyrune, J.‐L., 366

Viailly, P., 91

Viardot, A., 266

Vicent, A., 329

Vidal, M

J., 141

Vidrine, J., 380

Viennot, M., 91

Vignon, M., 386

Viguria Alegria, M. C., 227

Viguria, M. C., 144

Viguria, M., 182

Vijnovich Baron, A., 298

Villa, D., 024, 147, 148, 150, 200, 259

Villacampa, G., 141

Villaescusa, T., 228, 229

Villalón, L., 141

Villamor, N., 103

Villarese, P., 151

Villarreal, J. A., 333

Villarroel, J., 329

Villarrubia Espinosa, J., 169

Villasboas, J. C., 186

Villemagne, B., 044

Vindelov, S. D., 250

Vinogradova, Y., 388

Vinyoles, M., 241

Visco, C., 043, 077, 078, 147, 167

Visentin, A., 134, 352

Visnadi, H., 345

Visser, L., 190

Visser, O., 217

Viswanathan, H., 393

Vitale, C., 128, 134

Vitolo, U., 043, 048, 255

Vitriu, A., 298

Viviani, S., 019, 246, 392

Vlasevska, S., 042

Vodička, P., 285

Vodicka, P., 330

Voegeli, M., 062, 201

Voevoda‐Dimenshtein, V., 279

Volchenkov, S., 343

Volodicheva, E., 354

Volpetti, S., 218

von Baumgarten, L., 271

von Bergwelt‐Baildon, M., 082

von Bergwelt, M., 271

von Bonin, M., 274

von Keudell, G., 074, 120

von Roemeling, R., 257

von Tresckow, B., 155, 195, 266, 274

Vorozheikina, E., 118

Vos, J. M. I., 294

Vose, J. M., 148

Vrakidou, E., 164

Vucinic, V., 274

W Macauley, C., 006

W Wright, G., 011

Wößmann, W., 036

Wade, S. W., 114

Wade, S., 393

Wagner‐Drouet, E. M., 274

Wagner‐Johnston, N. D., 072

Wagner‐Johnston, N., 238

Wagner‐Johntson, N., 148

Wahlin, B. E., 263

Walewski, J., 236, 246

Waller, E. K., 267

Wan, W., 396

518

AUTHOR INDEX

Wang, A., 377

Wang, B., 011

Wang, C.‐F., 052

Wang, D., 129, 364

Wang, J., 102

Wang, L.‐Q., 052

Wang, L., 026, 052, 075, 264, 282, 394

Wang, M. L., 260

Wang, M.‐C., 112

Wang, M., 057, 146, 148, 149, 153, 265, 269

Wang, S., 131

Wang, T., 131, 261

Wang, W., 159, 224

Wang, X., 052, 131, 192, 215, 234, 256, 269,

282, 289, 291, 293, 296, 303, 323, 325,

361, 362, 364, 396

Wang, Y., 066, 171, 185, 186, 269, 269, 320

Wang, Z., 216, 336

Wapenaar, R., 307

Warbey, V., 247

Wartski, M., 386

Warwick, L., 140

Waultier Rascalou, A., 162

Waultier, A., 161

Webster, N., 040

Wehrle, J., 046

Weiß, A., 151

Wei, J.‐Y., 052

Weigert, O., 082

Weinreich, D. M., 94

Weinstock, D., 056

Weirather, J., 028

Weischenfeldt, J. L., 89

Weisenburger, D. D., 064, 065, 101

Weiss, J., 155, 384

Weiss, M., 013

Wendtner, C. M., 034

Wendtner, C., 031, 137, 249

Wenzl, K., 041

Westhead, D., 100

Westin, J. R., 025

Westin, J., 265

Wetherall, N., 286 bis

Whitby, D., 93

Wickham, N., 236

Widell, A., 93

Wielgos‐Bonvallet, M., 365

Wierda, W. G., 032, 086, 129

Wiesinger, A., 315

Wilcox, R., 061

Willaume, A., 050

Willems, L., 161, 162, 386

Willenbacher, W., 074

Williams, C., 174

Willimott, V., 286 bis

Wills Sanin, B., 221

Wilson, W. H., 025, 067, 068

Wilson, W., 174

Winderlich, M., 178

Winkelmann, M., 271

Winter, J., 055

Wirth, A., 326

Witzig, T. E., 066, 171, 185, 186

Woei‐A‐Jin, F. J. S. H., 244

Woei‐A‐Jin, S., 217

Wold, B., 027

Wolff, D., 274

Wolff, T., 132

Wondergem, Mariël., 217

Wong, J., 065, 067, 101, 370

Wood, S., 232

Worel, N., 258, 267

Woszczyk, D., 240

Woyach, J., 129

Wróbel, T., 236

Wrench, D., 174

Wu, C.‐Y., 052

Wu, D.‐P., 052

Wu, F., 376

Wu, H., 012, 215

Wu, J. Q., 138

Wu, J., 323, 361

Wu, M., 192

Wu, T., 216

Wu, W., 029, 043, 336

Wu, X., 213, 215, 396

Wuerthner, J., 075

Wulf, G., 274

Wynn, T., 286 bis

Xerri, L., 044, 278, 297

Xia, M., 012

Xia, Y., 396

Xia, Z., 131

Xian, D., 261

Xiang, S., 269

Xiao, R., 052

Xiao, Y., 215

Xie, Y., 192, 240, 256

Xiong, J., 052

Xu‐Monette, Z., 167

Xu, B., 052, 131

Xu, D., 396

Xu, H., 269

Xu, J.‐Y., 052

Xu, P.‐P., 052

Xu, P., 026

Xu, W., 131, 215, 336

Xu, X., 216

Xu, Z., 216

Xudong, Z., 399

Xue, H., 320

Y Spiegel, J., 006

Yáñez, L., 135, 141

Yañez, E., 112

Yañez, L., 144

Yacoub, A., 063, 310

Yahalom, J., 120

Yallop, D., 083

Yamauchi, N., 014

Yan‐Li, L., 288

Yan, F., 052

Yan, J., 269, 396

Yan, X., 364

Yancopoulos, G. D., 94

Yang, D. H., 209

Yang, H., 057, 216, 272

Yang, J., 234

Yang, L., 086, 269

Yang, S., 131

Yang, X., 195

Yang, Y., 011, 114, 336

Yang, Z., 041, 057

Yanguas, N., 104

Yannakou, C. K., 236

Yap, C., 214

Yarchoan, R., 93

Yasenchak, C. A., 254

Yavrom, S., 262

Ye, J., 299

Ye, Y., 364

Yedwabnick, M., 377

Yenerel, M. N., 033

Yerushalmi, R., 270

Yi, H.‐M., 052

Yimer, H. A., 130

Yimer, H., 273

Yin, M., 129

Yin, Z., 303

Ying, Z., 192, 256, 364

Yoffe, L., 102

Yokoyama, M., 209

AUTHOR INDEX

519

Yonekura, K., 210

Yoon, D. H., 209

Yoon, D.‐H., 057

Yoshida, S., 209, 210

Yosifov, D., 030

You, F., 269

Younes, A., 120

Young, J., 171

Young, K., 167

Youssef, M., 273

Youssef, Y., 231

Ysebaert, L., 110, 145, 245, 317, 379

Yu, H., 269, 364, 396

Yu, J., 293

Yu, L., 052

Yu, X., 011

Yuen, S., 111

Yuen, Y. C., 235

Yun, X., 303

Zabaljauregui, S., 196

Zabalza, A., 141

Zaccaria, G. M., 059

Zafar, S. F., 130

Zain, J. M., 055

Zain, J., 213

Zaja, F., 080

Zamprogna, G., 128

Zanabilli, J., 144

Zanatta, A., 133

Zander, T., 062, 201

Zangrilli, I., 070

Zanni, M., 047, 059, 079, 119, 173, 187, 218

Zaucha, J. M., 070, 246

Zayac, A., 157

Zeberio Etxetxipia, I., 182, 353, 387

Zeberio, I., 286

Zecca, M., 037

Zektser, M., 164

Zelenetz, A. D., 113, 120, 175

Zelenetz, A., 375

Zenz, T., 043, 128

Zhang, B., 131, 269

Zhang, C., 030, 031, 137, 139, 192

Zhang, H., 052, 131, 293, 296, 303

Zhang, J., 266, 272

Zhang, L., 163, 215, 269, 323, 361, 396

Zhang, M., 026, 269, 269, 323, 324, 325,

361, 368, 396

Zhang, Mei‐f., 163

Zhang, Q., 112

Zhang, S., 293

Zhang, T., 293

Zhang, W., 94, 131, 159, 163, 224, 364

Zhang, X. Y., 235

Zhang, X., 052, 130, 163, 289, 291, 303, 323,

325

Zhang, Y., 159, 163, 224, 231, 289, 291, 303

Zhao, D., 159, 282

Zhao, J., 293

Zhao, R., 131

Zhao, W.‐L., 052

Zhao, W., 026, 049, 252

Zhao, Y., 234, 299

Zhelyazkova, A., 99

Zheng, W., 192

Zheng, X.‐Y., 052

Zhong, H.‐J., 052

Zhou, C., 032

Zhou, D., 159, 163, 224

Zhou, J., 131

Zhou, K., 107, 216

Zhou, S., 293, 296

Zhou, W., 107

Zhou, X., 052, 234, 362

Zhou, Z., 269, 396

Zhu, A., 149, 153

Zhu, E. Y., 129

Zhu, H., 336

Zhu, J., 057, 192, 256, 282, 364

Zhu, Z., 131

Zhu, Zun‐M., 052

Zia, A., 085

Ziegelbauer, J. M., 93

Zignego, A. L., 077

Zijlstra, J. M., 021, 190

Zikos, P., 164

Zilioli, V. R., 049, 119, 173, 183, 187, 204,

218, 352

Zimmermann, M., 036

Zinger, M., 389

Zinzani, P. L., 038, 043, 051, 054, 074, 075,

107, 112, 127, 128, 146, 154, 177, 191,

193, 205, 238, 250, 252, 262, 264, 266,

276, 312

Zinzani, P., 275

Zmajkovicova, K., 373

Zoppegno, L., 196

Zorzi, M., 391

Zou, Dong‐m., 163

Zucca, E., 018, 022, 029, 043, 047, 048, 049,

062, 070, 078, 079, 133, 246,

314

Zuccaro, V., 077

Zucchetto, A., 029

Zucenka, A., 321

Zukotynski, K., 259

Zumalde Murua, A., 353, 387

Zverkova, A., 343

Zwezerijnen, G. J. C., 021

Zwezerijnen, G. J., 190

Zyuzgin, I., 343

520

AUTHOR INDEX